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Pancreatic adenocarcinoma (PDAC) is the fourth leading cause of cancer death in 
Western countries. The PDAC tumour microenvironment (TME) is characterized 
by a dense stromal reaction, consisting of many cell types including fibroblasts and 
immune cells.  
The chemokine receptor, CX3CR1 forms a high-affinity axis with its unique ligand 
CX3CL1 and is expressed on monocytes, macrophages and T cells. CX3CR1 is also 
present on pancreatic malignant cells, where it has been associated with metastasis 
formation. 
The aim of my project is to investigate the role of CX3CR1 in the progression and 
development of pancreatic cancer in a genetically engineered mouse model of 
PDAC, the CX3CR1GFP/GFPLSL-KRASG12D/+LSL-Trp53R172H/+Pdx1-Cre (CKPC) mouse. 
In these mice, the CX3CR1 protein is not functional but they express GFP.  
I have found that the absence of CX3CR1 in KPC mice has no effect in their lifespan 
and response to chemotherapy. Comparison of the immune infiltrate of the 
tumours revealed that the lack of CX3CR1 causes a significant decrease in T cells 
and a possible increase in myeloid cells in CKPC mice compared to KPC mice. 
Expression analysis of several inflammatory cytokines in the TME showed a 
significant difference in IL-10 between KPC and CKPC mice. There was also a 
significant increase in levels of, CX3CL1, both locally and in the plasma. 
Finally, we performed RNA-seq on KPC and CKPC tumours. My analysis revealed 
607 differentially-expressed genes, some of which encoded other chemokines or 
protein regulating the immune system. In particular, I observed the upregulation 
of Cxcl10 and Cxcl12, and the downregulation of Gata3 and S100a4, which could 
explain the decrease in T cells in the TME of CKPC mice. 
In conclusion, although the lack of CX3CR1 modifies the TME in this genetic model 
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1.1 Pancreatic cancer   
1.1.1 The pancreas 
The pancreas is an organ of the digestive system and the endocrine system. It is 
localised in the abdominal cavity behind the stomach. The pancreas performs 
endocrine and exocrine functions. The endocrine pancreas consists of cell clusters 
named islets of Langerhans; these islets are essential for the regulation of blood 
glucose levels and glucose metabolism and are composed by four primary types of 
cell: α cells secreting glucagon, β cells secreting insulin, δ delta cells secreting 
somatostatin and PP cells, or γ cells, secreting pancreatic polypeptide (Mastracci 
and Sussel 2012). 
 
Exocrine functions of the pancreas involve the release of enzymes, such as lipases, 
amylases and proteases, which help in the digestion of food. These enzymes are 
contained within the pancreatic fluid, which is released into the duodenum 
(Cleveland, Sawyer et al. 2012). 
 
1.1.2 Pancreatic tumours  
Pancreatic cancer can develop from either the endocrine or exocrine pancreas. 
Pancreatic neuroendocrine tumours (pNETs) are rare endocrine tumours, 
representing 1-2% of all pancreatic tumours, but the incidence of these tumours 
has increased in the past 20 years (Zhou, Zhang et al. 2012, McKenna and Edil 
2014). pNETs have different clinical characteristics and are grouped into 
'functioning' and 'non-functioning' types, based on the amount of hormones 
produced (Burns and Edil 2012). The functioning type tumours secrete large 
quantities of hormones, such as insulin and glucagon into the bloodstream, which 
induces symptoms including low blood sugar, favouring relatively early detection. 
The most common functioning pNETs are insulinomas and gastrinomas, named 
after the hormones they secrete (McKenna and Edil 2014). The non-functioning 
type of pancreatic cancer lacks the capability to secrete enough hormones to give 
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rise to overt clinical symptoms. For this reason, non-functioning pNETs are often 
diagnosed when they have already metastasised (McKenna and Edil 2014).  
 
Pancreatic exocrine tumours represent the majority of all pancreatic cancers, 
accounting for the 95% of all pancreatic tumours (Pancreatic-Cancer-UK 2016). 
The most common exocrine tumour is adenocarcinoma, accounting for 85% of all 
pancreatic tumours. Beside adenocarcinoma, the other exocrine pancreatic 
tumours are constituted of rare tumour types, such as mucinous tumours which 
constitute about 2-5% of all pancreatic tumours (H Chen 2015), and acinar cell 
carcinoma of the pancreas, which consists of 1-2% of all pancreatic tumours (La 
Rosa, Sessa et al. 2015).  
 
1.1.3 Pancreatic ductal-adenocarcinoma  
Pancreatic ductal-adenocarcinoma (PDAC) is the most common pancreatic tumour. 
PDAC is one of the most malignant types of solid tumours and it is one of the major 
causes of cancer death in the western world (Ryan, Hong et al. 2014). PDAC is the 
fourth most common cause of cancer in the USA (Ryan, Hong et al. 2014) and it is 
the eleventh in the UK (cancer-research-UK 2014). The median survival of patients 
from diagnosis is about 18-24 months with a 5-year survival rate of approximately 
5% (Reznik, Hendifar et al. 2014). It was predicted that in 2014 more than 46000 
new patients would have been diagnosed with PDAC (Ryan, Hong et al. 2014). 
 
Pancreatic cancer incidence is linked to a number of risk factors, such as old age, 
smoking, diabetes and chronic pancreatitis (Kamisawa, Wood et al. 2016). 
However, among these evidence for a causative association has only been reported 
for cigarette smoking, which doubles the risk of developing pancreatic cancer 
(Iodice, Gandini et al. 2008, Kamisawa, Wood et al. 2016). In some studies alcohol 
consumption, obesity and a western diet have been proposed as additional risk 
factors (Ryan, Hong et al. 2014). Individuals with family history of PDAC have 
increased risk of developing the disease; 10% of pancreatic cancer cases have a 
familial basis (Kamisawa, Wood et al. 2016).  
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Pancreatic cancer mainly occurs in people aged between 60 and 80 years, with a 
mean of 71 years (Ryan, Hong et al. 2014, Kamisawa, Wood et al. 2016). Moreover, 
cancer incidence is different between sexes, men have 50% greater incidence of 
the disease compared to women (Kamisawa, Wood et al. 2016).  
The poor survival of patients diagnosed with PDAC may be due to the fact that at 
the time of diagnosis approximately 85% of patients have advanced stage disease 
with local invasion or metastasis and cannot be submitted to surgery with curative 
intent (Vincent, Herman et al. 2011, Ryan, Hong et al. 2014).  
 
1.1.4 Pathophysiology of PDAC 
PDAC tumours are primarily located in the head of the pancreas (65%), then in the 
body (15%) and tail (10%) of the organ (Corbo, Tortora et al. 2012). On the basis 
of their degree of differentiation, PDACs are divided into three grades: well, 
moderately, and poorly differentiated (Kamisawa, Wood et al. 2016). 
 
PDAC arises from non-invasive, histologically distinct precursor lesions known as 
pancreatic intraepithelial neoplasia (PanIN), which is the most frequent (Figure 
1.1), intra-ductal papillary mucinous neoplasms (IPMN) and mucinous cystic 
neoplasms (MCN) (Corbo, Tortora et al. 2012).  
 
Depending on the grade of cellular and tissue degeneration, PanINs are 
traditionally sub-classified into PanIN-1, PanIN-2 and PanIN-3 (Figure 1.1). 
PanINs-1 are characterized by cells with a columnar shape, basally oriented, 
uniform and with round nuclei. In PanIN-2 lesions the tall columnar cells can 
exhibit flat or papillary shape. Additionally, they exhibit nuclear abnormality, such 
as loss of nuclear polarity, change in nuclear size, and nuclear pseudostratification. 
PanIN-3 lesions display the highest degree of dysplasia. These lesions are formed 
by papillae and cribriform structures. Moreover, the nuclei in PanIN-3 lesions are 
enlarged, and poorly oriented (Hruban, Maitra et al. 2008).   
 
IPMNs are constituted by cysts, which are more than 1 cm in size, and are 
characterised by the production of a mucinous liquid (Kamisawa, Wood et al. 
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2016). MCNs, instead, occur exclusively in women, and are composed of columnar, 
mucin-producing epithelium and supported by ovarian-type stroma. Moreover, 




Figure 1.1 Progression model for pancreatic cancer 
Progression from histologically normal epithelium to PDAC, through low-grade and high-
grade PanIN stages (PanIN1-3). Each step is associated with the accumulation of specific 
genetic alterations (Hruban, Wilentz et al. 2000). 
 
1.1.5 Genetics of PDAC  
PDAC, from the genetic point of view, can be explained by the accumulation of 
acquired mutations. The mutated genes, found in most of the tumours, belong 
mostly to one of these two categories: oncogenes (such as Kras) or tumour-
suppressor genes (such as p16 and TP53) (Table 1.1). The different mutations 
occurring during pancreatic carcinogenesis correlate with PDAC pathological and 
physiological characteristics. In fact, molecular analysis of PanINs demonstrated 
that the majority of genomic alterations appear at a specific PanIN stage (Figure 
1.1) (Bardeesy and DePinho 2002).  
KRAS (Kirsten rat sarcoma viral oncogene homolog) is the most mutated gene in 
PDAC, with KRAS mutations found in more than 90% of cases. The KRAS gene 
 24 
encodes for a small GTPase that mediates cellular signalling downstream of growth 
factor receptors. In PDAC, KRAS is mutated at codon 12 and this constitutively 
activates gene expression. KRAS mutations are typically found in the earliest 
PanIN-1 lesions (Hezel, Kimmelman et al. 2006, Kamisawa, Wood et al. 2016). 
 
CDKN2A is the most frequently mutated tumour suppressor gene, with loss of 
function present in more than 90% of all PDAC. CDKN2A encodes for the p16 
protein, member of the INK4 family of cyclin Dependent kinase (CDK) inhibitors. 
p16 is an essential cell-cycle regulator, controlling the cell cycle progression at the 
G1/S checkpoint: the loss of p16 activity results in uncontrolled cell growth. 
Mutations in CDKN2A gene are found in late stages of tumour progression 
(Bardeesy and DePinho 2002, Reznik, Hendifar et al. 2014, Kamisawa, Wood et al. 
2016).  
 
TP53 (tumour protein p53) is the second most commonly mutated suppressor 
gene in PDAC. TP53 encodes for a 53 kDa transcription factor, responsible for 
regulating the expression of several genes involved in cell cycle regulation/arrest, 
apoptosis, differentiation, DNA surveillance and repair. TP53 loss of function is due 
to missense alterations in the DNA-binding domain. TP53 is mutated in more than 
75% of pancreatic tumours and is detected in late-stage PanINs and invasive 
carcinomas (Hezel, Kimmelman et al. 2006, Kamisawa, Wood et al. 2016).  
 
Another common mutation in PDAC is in the SMAD4 gene. SMAD4 encodes for a 
transcriptional regulator, which plays a major role in the transforming growth 
factor beta (TGF-) signalling cascade. SMAD4 mutations are found in about 50% 
of tumours, and they arise in PanIN-3 and invasive carcinoma (Hezel, Kimmelman 







Gene Type Cellular function Mutated in 
PDAC 
KRAS Oncogene ERK-MAP kinase 
signalling 
>90% 
CDKN2A Tumour suppressor 
gene 
G1-S phase cell 
cycle inhibition  
>90% 
TP53 Tumour suppressor 
gene 
Cell-cycle arrest 75% 
CyclinD Oncogene Cell-cycle 
progression 
65% 





DNA damage repair 7-10% 









Table 1.1 Most commonly mutated genes in PDAC 
List of the most mutated gene in PDAC. For each mutated gene it is illustrated the type of 
gene, its cellular function and the percentages affected in PDAC. Table modified from 
(Ottenhof, de Wilde et al. 2011, Wood and Hruban 2015). 
 
In 2015, a whole genome analysis on 100 pancreatic tumour samples gave the most 
complete description of the genomic events of PDAC (Waddell, Pajic et al. 2015). 
This study confirmed the importance of KRAS, TP53, SMAD4 and CDKN2A 
mutations.  
This study also classified PDAC tumours in four subtypes by patterns in the 
variation of chromosomal structure. These identified subtypes were named stable, 
locally rearranged, scattered and unstable. The stable subtype accounted for 20% 
of all samples and it is characterised by less than 50 structural variation events and 
aneuploidy. The locally rearranged subtype, 30% of all samples, presented a 
significant focal event in up to two chromosomes. The scattered subtype, 
presented in 36% of all samples, exhibited a moderate range of non-random 
chromosomal damage and less than 200 structural variation events. Finally, the 
remaining 14% of all samples constituted the unstable subtype, which showed 
more than 200 structural variation events (Waddell, Pajic et al. 2015). 
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Pancreatic tumours have been also classified according to their gene expression 
profile. Analysis of the transcriptional profiles of primary PDAC samples from 
several studies allowed Collisson et al. to define three PDAC subtypes: classical, 
quasi-mesenchymal and exocrine-like. The classical subtype is characterised by 
high levels of adhesion-associated and epithelial genes, the quasi-mesenchymal 
subtype showed high expression of mesenchyme-associated genes, while the 
exocrine-like subtype exhibited relatively high expression of tumour cell–derived 
digestive enzyme genes (Collisson, Sadanandam et al. 2011). 
 
In 2016, Bailey et al. integrated genomic and transcriptomic analysis of PDAC 
samples (Bailey, Chang et al. 2016). The genomic analysis identified 32 recurrently 
mutated genes that aggregate into 10 pathways and confirmed KRAS, TP53, SMAD4 
and CDKN2A as the four most mutated genes in PDAC. The transcriptomic analysis 
allowed them to identify 4 PDAC subtypes: squamous, pancreatic progenitor, 
immunogenic and aberrantly differentiated endocrine exocrine (ADEX). Each of 
the four subtypes correlated with specific histopathological features. The 
squamous subtype correlated with adenosquamous carcinomas; the pancreatic 
progenitor and the immunogenic subtypes correlated with mucinous non-cystic 
adenocarcinomas and carcinomas arising from IPMN (mucinous); and the ADEX 
subtype correlated with rare acinar cell carcinomas (Bailey, Chang et al. 2016). 
Moreover, the immunogenic subtype is associated with evidence of a significant 
immune infiltrate. When they compared their classification with the one published 
by Collisson (Collisson, Sadanandam et al. 2011) they found that 3 of their subtypes 
(squamous, pancreatic progenitor and ADEX) correspond with the one identified 
in this study (Bailey, Chang et al. 2016).  
 
1.1.6 Symptoms and treatments 
PDAC patients, in almost all cases, are diagnosed in with advanced disease. This is 
caused by the lack of, or non-specific, symptoms in the early stage of cancer. In fact, 
most common symptoms of pancreatic cancer are weight loss, abdominal pain, 
nausea and vomiting, bloating, changes in bowel habit, dyspepsia, new-onset 
diabetes, pruritus, lethargy, back pain, shoulder pain, and jaundice (Keane, Horsfall 
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et al. 2014, Kamisawa, Wood et al. 2016). Therefore, in the majority of the cases 
PDAC is diagnosed when the tumour has already spread into the surrounding 
tissue and metastasised. At diagnosis less than 20% of patients are suitable for 
surgery (Ryan, Hong et al. 2014, Cid-Arregui and Juarez 2015). 
 
Due to the presence of micrometastases at diagnosis, 60-90% of patients who 
undergo surgical removal of their tumour developed tumour recurrence (Cid-
Arregui and Juarez 2015). The administration of either chemotherapy or 
radiotherapy after surgery (adjuvant therapy) improves survival rates 
significantly. In some cases, in order to shrink the tumour and to eliminate 
micrometastases chemotherapy or radiotherapy therapies can be applied before 
surgery (neoadjuvant therapy) (Cid-Arregui and Juarez 2015). .  
 
In the treatment of PDAC, gemcitabine and 5-Fluorouracil (5-FU) are the two drugs 
that have been shown to increase the survival in patients, as single agents. 5-FU is 
a uracil analogue, characterised by an extra fluorine in position five; it acts as an 
inhibitor of thymidylate synthase, an enzyme responsible for the conversion of 
deoxyuridine monophosphate (dUMP) into deoxythymidine monophosphate 
(dTMP), causing DNA damage (Longley, Harkin et al. 2003, Teague, Lim et al. 2015).  
 
Gemcitabine (2’,2’-difluorodeoxycytidine) is a pyrimidine analogue in which the 
hydrogen atoms on the 2' carbon of deoxycytidine are replaced by fluorine atoms. 
Gemcitabine, when converted in the triphosphate active form (dFdCTP), is 
incorporated into DNA, instead of cytidine (de Sousa Cavalcante and Monteiro 
2014, Teague, Lim et al. 2015). Gemcitabine has increased patient overall survival 
compared to 5-FU, with a median survival rate of 5.7–6.3 months. For this reason, 
gemcitabine is considered to be the single agent of choice in advanced pancreatic 
cancer (Snady, Bruckner et al. 2000, Cid-Arregui and Juarez 2015).  
 
Many clinical trials tried to improve the gemcitabine overall survival by adding 
different drugs, such as oxiplatinum, cetuximab and bevacizumab. Unfortunately, 
none of these combination therapies showed any beneficial effect on patient 
survival (Cid-Arregui and Juarez 2015, Teague, Lim et al. 2015).  An exception is 
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FOLFIRINOX, a combination of 4 different agents: leucovorin (folinic acid), 5-FU, 
irinotecan and oxaliplatin. Several studies showed that patients with metastatic 
pancreatic cancer treated with FOLFIRINOX have better median overall survival, 
progression-free survival, and objective responses compared to gemcitabine 
(Conroy, Desseigne et al. 2011, Marsh Rde, Talamonti et al. 2015). However, 
despite encouraging results, this regiment is associated with significant toxicities 
and the outlook for patients with pancreatic cancer remains poor. Subsequently 
gemcitabine combined with abraxane was also shown to significantly improve 
survival rates compared to gemcitabine (Von Hoff, Ervin et al. 2013).  
 
1.1.7 Mouse models of pancreatic cancer 
Genetically engineered mouse models (GEMMs) represent an invaluable tool in the 
study of cancer as they accurately mimic some of the pathophysiological and 
molecular features of human pancreatic tumours. They can also be used to test the 
efficacy of new therapeutic candidates (Herreros-Villanueva, Hijona et al. 2012). 
Although GEMMs are powerful tools in the study of cancer, they are limited by 
several factors. They are expensive and time-consuming to generate and maintain, 
and it is difficult to track tumour development. Most of the GEMM use 
recombinases, such as the Cre recombinases, to excise a specific DNA sequence, 
which is identified by short repeats called loxP sites. 
 
The most used mouse model, which recapitulates the critical gene lesions involved 
in the human pancreatic cancers, is the LoxP-Stop-LoxP-K-rasG12D/+; LSL-
Trp53R172H/+; Pdx-1-Cre mouse model (KPC model) (Hingorani, Wang et al. 2005). 
In these mice, Cre recombinase, under the control of the transcription factor 
pancreatic and duodenal homobox-1 (Pdx-1), remove the loxP-flanked sequence 
from the pancreas epithelium activating K-rasG12D and Trp53R172H mutation. The K-
rasG12D mutation causes the constitutive activation of Ras signaling whilst the 
TP53R172H is functionally equivalent to a null mutation (Hingorani, Wang et al. 
2005, Herreros-Villanueva, Hijona et al. 2012).  
The KPC mouse recapitulates the pathological, histological, genomic and clinical 
signatures of human pancreatic cancer (Hingorani, Wang et al. 2005). These mice 
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present with early PanIN lesions between four and six weeks of age. From 10 weeks 
old the animals manifest signs of the disease, developing cachexia, abdominal 
distension, and hemorrhagic ascites. Most of the mice also develop metastasis in 
the liver, diaphragm and adrenals. 
 
The median survival of these mice is approximately 5-6 months with a maximum 
survival of 12 months (Herreros-Villanueva, Hijona et al. 2012). However, these 
mice do not mimic perfectly human PDAC; for instance in the KPC mouse 
tumorigenesis occurs in multi-focal sites in the pancreas while in human tumours 
usually emerge as a single neoplastic focus (Guerra and Barbacid 2013). 
 
1.2 The tumour microenvironment   
Tumours do not only contain malignant cells. In fact, tumours also comprise of a 
variety of other cell types, regulatory proteins and other soluble factors as well as 
features such as hypoxia and acidosis: together these form the tumour 
microenvironment (TME) (Feig, Gopinathan et al. 2012, Turley, Cremasco et al. 
2015). Cancer cells interact with the other components of the TME, which influence 
tumour progression, metastasis formation and response to therapy (Turley, 
Cremasco et al. 2015).  
 
1.2.1 Pancreatic tumour microenvironment   
The PDAC TME is characterized by an abundant fibrotic tissue reaction referred to 
as the desmoplastic reaction. Approximately 80% of the tumour mass is made up 
of stroma, which is composed of extra-cellular matrix (ECM) proteins, new blood 
vessels, cancer associated fibroblast (CAF), mesenchymal cells (MSC), activated 
pancreatic stellate cells (PSC) and immune cells (Figure 1.1) (Lunardi, Muschel et 
al. 2014, Ryan, Hong et al. 2014). 
 
The TME is not a static entity but it is constantly changing in their composition 
especially during the progression from PanIN-1 to invasive PDAC. Early PanIN 
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lesions may be associated with small amounts of stroma surrounding the normal 
pancreatic ducts. On the other hand, in PanIN-3 lesions there is already an 
enhanced stroma formation, and the progression to invasive carcinoma is 
associated with a further increase in this component (Vincent, Herman et al. 2011, 
Feig, Gopinathan et al. 2012). 
 
Another characteristic of desmoplasia in pancreatic cancer is the poor and 
disorganized vascularization, which results in hypoxic conditions that contribute 
to tumour progression and metastasis (Quail and Joyce 2013). This lack of 
adequate vasculature, together with the abundant stroma, can prevent the effective 
delivery of chemotherapy to the tumour cells (Neesse, Michl et al. 2011).  
 
 
Figure 1.2 Schematic representation of the tumour microenvironment in pancreatic 
tumours 
Cancer cells in primary tumours are surrounded by a complex microenvironment rich in 
extracellular matrix that also includes pancreatic stellate cells (PSC), fibroblasts, mesenchymal cells 
and several types of immune cells including macrophages, myeloid-derived suppressor cells 
(MDSCs) T cells and neutrophils Adapted from (Evans and Costello 2012) 
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1.2.2 Acidosis and hypoxia  
Areas of acidosis, an increase in the acidity of the tissue, and hypoxia, an inadequate 
supply of oxygen within a tissue, can be found in almost every solid tumour (Bailey, 
Wojtkowiak et al. 2012, Feig, Gopinathan et al. 2012). The levels of acidosis and 
hypoxia fluctuate within the tumour and during tumour progression.  
 
The hypoxic environments in tumours are caused by an increase in oxygen 
consumption by tumour cells, and by an impaired vasculature, limiting the amount 
of available oxygen into the tumor tissue (Feig, Gopinathan et al. 2012). 
Consequences of the hypoxic environment include: alteration of cancer cell 
metabolism, remodeling of ECM, increasing the migratory and metastatic behavior 
of malignant cells, reducing the responsiveness to chemotherapy and radiotherapy 
treatments and inducing resistance (Yuen and Diaz 2014, Eales, Hollinshead et al. 
2016). 
 
Acidosis is the result of an increased excretion of lactic acid and the inability of the 
tumor vasculature to remove lactic acid waste from the TME. The presence of 
acidosis reduces the efficacy of chemotherapy and increases the metastatic 
potential of cancer cells (Bailey, Wojtkowiak et al. 2012).  
 
1.2.3 The extracellular matrix   
PDAC is characterized by the presence of an abundant ECM, which comprises 
collagens, hyaluronic acid, and other extracellular matrix component (Ryan, Hong 
et al. 2014). Type I and III collagen and fibronectin are the most abundant 
components present in the ECM of pancreatic cancer and are secreted 
predominantly by PSCs (Rasheed, Matsui et al. 2012, Lunardi, Muschel et al. 2014). 
ECM components, accumulated during carcinogenesis, alter the architecture of 
normal pancreatic tissue, causing the alteration of blood and lymphatic vessels 
distributions (Feig, Gopinathan et al. 2012). 
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The ECM provides a supporting structure for tumour growth (Mahadevan and Von 
Hoff 2007, Carr and Fernandez-Zapico 2016). For example, ECM proteins, such as 
laminin and fibronectin, promote survival and prevent death of pancreatic tumour 
cells (Pandol, Edderkaoui et al. 2009). In fact, the interaction between laminin and 
fibronectin with cancer cell integrin receptors leads to intracellular events that 
promote cancer cell survival and growth (Pandol, Edderkaoui et al. 2009). 
Moreover, the ECM can become a protective barrier against chemotherapy and 
radiotherapy (Whatcott, Posner et al. 2012, Schober, Jesenofsky et al. 2014). In 
particular, the tumour collagen content showed an inverse correlation with 
macromolecule penetration (Whatcott, Posner et al. 2012). 
 
1.2.4 Tumour vasculature 
Angiogenesis is essential for the growth of solid tumours and metastasis formation 
(Quail and Joyce 2013). As mentioned in the previous paragraph, the vasculature 
in PDAC is profoundly impaired by the massive presence of ECM (Ryan, Hong et al. 
2014). PDAC tissues have a low micro-vessel density compared to other solid 
malignancies (Feig, Gopinathan et al. 2012). Functional analysis of PDAC 
vasculature showed that vessels have variable diameters, abnormal multiple 
branching and disrupted inter-endothelial junctions. Additionally, the vessels are 
collapsed. This phenomenon is caused by high interstitial pressure and leads to a 
reduced delivery of small molecule drugs (Longo, Brunetti et al. 2016). Indeed, a 
consequence of PDAC poor vascularisation and high interstitial pressure is the 
decreased penetration of chemotherapy inside the tumours. Interestingly, it has 
been shown that the normalization of high interstitial pressure, by targeting 
hyaluronic acid, re-expands the microvasculature allowing chemotherapy to reach 
the tumour area (Provenzano, Cuevas et al. 2012).  
 
To promote angiogenesis cancer cells and other cells in the TME including 
macrophages and stellate cells, secrete angiogenic factors such as vascular 
endothelial growth factor (VEGF), fibroblast growth factor 2 (FGF-2), interleukin 6 
(IL-6), IL-8 and angiopoietins (Longo, Brunetti et al. 2016). VEGF is overexpressed 
in the majority of PDAC and correlates with a high microvessel density, disease 
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progression, increased risk of metastatic spread, and a poor prognosis (Whipple 
and Korc 2008). Since angiogenesis plays a major role in tumour growth and 
metastasis formation, it has been chosen as a possible therapeutic target in PDAC 
using VEGFR inhibitors or anti-VEGF-A antibodies (Whipple and Korc 2008). 
Therefore, several preclinical and clinical trials are taking place in PDAC using anti-
angiogenic therapies. Unfortunately, in a phase III clinical trial pancreatic tumour 
patients who received gemcitabine in combination with bevacizumab, an anti-
VEGF-A monoclonal antibody, did not show improvement in the overall survival 
(Longo, Brunetti et al. 2016). 
 
1.2.5 Cancer associated fibroblasts, CAFs, and mesenchymal 
stromal cells, MSCs 
CAFs are activated fibroblasts found in the tumour stroma. CAF morphology is 
similar to myofibroblasts, large spindle-shaped cells that are activated during the 
wound healing process (Tao, Huang et al. 2017) . Markers used to identify CAFs are 
α-smooth muscle actin (α-SMA), fibroblast activation protein (FAP) and platelet 
derived growth factor receptor-α and β (PDGFR α and β). CAFs promote tumour 
growth by the secretion of autocrine and/or paracrine cytokines, growth factors, 
such as EGF. Moreover, the soluble factors secreted by CAFs are involved in the 
recruitment of immune cells into the tumour, angiogenesis and metastasis (Tao, 
Huang et al. 2017).  
 
In transgenic mice the depletion of α-SMA+ myofibroblasts leads to 
undifferentiated tumors with enhanced hypoxia, epithelial-to-mesenchymal 
transition, cancer stem cells and ability to metastasize and with reduced animal 
survival (Bolm, Cigolla et al. 2017). In mice and PDAC patients, low CAFs in the TME 
correlate with reduced survival (Ozdemir, Pentcheva-Hoang et al. 2014). 
Moreover, clinical trials targeting stromal myofibroblasts resulted in accelerated 
disease progression and immunotherapy combined with loss of myofibroblasts 
prolongs survival in mice (Ozdemir, Pentcheva-Hoang et al. 2014). 
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MSCs constitute a population of multipotent and undifferentiated adult cells with 
extensive self-renewal properties and the ability to differentiate into a variety of 
mesenchymal lineage cells. MSCs have both an anti-inflammatory and an 
immunomodulatory activity on the immune system (Klimczak and Kozlowska 
2016). MSCs can be recruited by cancer cells and support tumour growth and 
progression. In particular, MSCs can induce cancer cells to evade the immune 
system, promote tumour angiogenesis, invasion and metastasis, epithelial-
mesenchymal transition (EMT) and induction of stem-like properties that allow 
cancer stem cells to increase their survivability through the circulation (Chang, 
Schwertschkow et al. 2015). 
  
1.2.6 Pancreatic stellate cells   
PCSs are found in the exocrine portion of the healthy pancreas, near the acinar cells 
and represent about 4% of the total cells (Vonlaufen, Joshi et al. 2008, Apte, Pirola 
et al. 2012). In the quiescent state they are characterised by a star-like morphology 
and have lipid droplets, containing vitamin A within their cytoplasm (Vonlaufen, 
Joshi et al. 2008). The quiescent PCSs have a low proliferative capacity and produce 
low amounts of ECM (Vonlaufen, Joshi et al. 2008).  
 
PSCs switch to an activate state after pancreatic injury, with morphological and 
functional changes (Apte, Pirola et al. 2012). Activated PSCs acquire a 
‘myofibroblast-like’ phenotype, and lipid droplets disappear from the cytoplasm 
(Bachem, Zhou et al. 2008). PSCs start to express cytoskeletal protein named alpha 
smooth muscle actin (α-SMA) and secrete large amounts of ECM proteins including 
collagens, fibronectin and laminin (Vonlaufen, Phillips et al. 2008, Apte, Pirola et al. 
2012). The activation of PSCs during pancreatic injury is caused by the presence of 
inflammatory cytokines such as IL-1, IL-6, and tumour necrosis factor alfa (TNF-α), 
growth factors like transforming growth factor β1 (TGF-β1), ethanol and its 
metabolites, and oxidative stress (Bachem, Zhou et al. 2008). 
 
PSCs are capable of sustaining their activated state through autocrine signalling. 
For instance, they secrete growth factors such as platelet-derived growth factor, 
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connective tissue growth factor and endothelin 1 this generate an autocrine loop 
that maintain PSCs activation and increased production of fibrous ECM (Phillips 
2012). PSCs also secrete inflammatory cytokines like TGF-β1, IL-1, IL-8 and IL-15 
(Apte, Pirola et al. 2012). 
 
In vitro studies of co-cultures of PCSs with pancreatic cancer cells showed that PSCs 
induced the proliferation of malignant cells, increased their migratory and invasion 
ability and reduced cancer cell apoptosis (Vonlaufen, Joshi et al. 2008, Apte, Pirola 
et al. 2012). Moreover, in vivo studies using an orthotopic mouse model, found that 
mice injected with cancer cells and PSCs developed larger tumours compared to 
mice injected only with cancer cells. Mice injected with both PSCs and cancer cells 
also developed distant metastases unlike mice injected with cancer cells alone 
(Vonlaufen, Joshi et al. 2008). PSCs are also able to stimulate angiogenesis by the 
secretion of VEGF and periostin (Erkan, Reiser-Erkan et al. 2009).  
 
1.2.7 Soluble factors 
There are many soluble mediators in the TME secreted by the malignant cells and 
other cell types. These soluble factors released in the TME include cytokines, 
chemokines, enzymes, such as cyclooxygenase-2 (COX-2) and metalloproteases 
(Farrow and Evers 2002). Cytokines such as TNF-α, interleukin IL-1α IL-1β, IL-6 
and IL-10, found in the pancreatic TME create an inflammatory environment 
(Farrow and Evers 2002, Colotta, Allavena et al. 2009, Steele, Jamieson et al. 2013). 
These cytokines initiate inflammatory responses and are secreted by infiltrating 
leukocytes and malignant cells (Smyth, Cretney et al. 2004, Colotta, Allavena et al. 
2009). 
 
The IL-1 family cytokines IL-1α, IL-1β interact with membrane-bound IL-1 
receptor type (IL-1R) I or II.  IL-1α and IL-1β are produced by cancer cells and also 
by cells of the TME. IL-1β is expressed in several different malignant cell types, 
including breast, gastric, pancreatic, prostate, head and neck, liver, lung, cervix, and 
biliary duct (Lewis, Varghese et al. 2006). IL-1α levels are increased in tumour 
tissue and correlated with the survival of PDAC patients (Wormann, Diakopoulos 
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et al. 2014). Multiple in vitro studies have demonstrated that IL-1 promotes tumour 
progression, invasion, migration, sustaining angiogenesis and inducing an 
immunosuppressive environment (Smyth, Cretney et al. 2004, Wormann, 
Diakopoulos et al. 2014). 
 
IL-6 is produced by tumour cells, fibroblasts and myeloid cells in the TME and after 
binding with its receptor, it activates signal transducer and activator of 
transcription 3 (STAT3) in both inflammatory cells and epithelial cells. IL-6 and 
STAT3 are constitutively active in tumours, leading to the up-regulation of genes 
involved in proliferation, survival, angiogenesis, migration, and inflammation, 
promoting tumour progression (Kumari, Dwarakanath et al. 2016). In PDAC 
patients, increased IL- 6 serum levels positively correlated with tumour stage and 
decreased survival (Wormann, Diakopoulos et al. 2014).  Studies have suggested 
that IL-6 promotes PDAC development by enhancing the pro-tumorigenic STAT3 
signalling (Wormann, Diakopoulos et al. 2014). For example, in a mouse model of 
PDAC IL-6, and STAT3 have been shown to be involved in pancreatic cancer 
initiation (Lesina, Kurkowski et al. 2011). In this study, the inactivation of IL-6 or 
STAT3 inhibited PanIN progression and reduced the progression of PDAC. 
Moreover, the aberrant activation of STAT3 accelerated tumour progression 
through PanIN stages and PDAC (Lesina, Kurkowski et al. 2011).  
  
IL-10 is produced by cancer cells and cells of the TME, such as macrophages. The 
role of IL-10 in tumour progression is extremely controversial. Indeed, some 
studies showed that IL-10 positively promotes tumour growth, whereas others 
suggested that IL-10 is involved in the suppression of angiogenesis and metastasis 
(Mannino, Zhu et al. 2015). In pancreatic cancer patients, tissue and serum levels 
of IL-10 are increased. The presence of IL-10 promotes an anti-inflammatory 
microenvironment, which reduces the function of effector cells, such as natural 
killer cells and dendritic cells, and induces a shift toward Th2 cytokines (Wormann, 
Diakopoulos et al. 2014). 
 
TNF-α is produced by cancer cells or by cells of the TME (Balkwill 2009). Several 
studies reported the increase of serum TNF-α concentration in different cancer 
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types, such as chronic lymphocytic leukaemia, Barrett's adenocarcinoma, prostate 
cancer, breast cancer, and cervical carcinoma. During carcinogenesis TNF-α is 
involved in tumour cell proliferation, angiogenesis, and metastasis (Wang and Lin 
2008). In PDAC, high expression of TNF-α is an independent prognostic marker of 
poor survival. Zhao et al 2016 found that in vivo treatments with an anti-TNF-α 
antibody reduced desmoplasia and the inflammatory TME in PDAC. Moreover, the 
combination of anti-TNF-α treatments with chemotherapy, partly overcome 
chemoresistance, increasing the survival of PDAC mouse model (Zhao, Fan et al. 
2016). 
 
1.2.8 The immune infiltrate in pancreatic cancer 
The cancer microenvironment has a diverse leukocyte population consisting of 
neutrophils, dendritic cells (DCs), macrophages, myeloid derived suppressor cells 
(MDSCs), monocytes, mast cells, natural killers (NK), eosinophils, B and T cells, 
(Figure 1.2 and Table 1.2) (Heinemann, Reni et al. 2014, Lunardi, Muschel et al. 
2014). Infiltrating immune cells in the tumour microenvironment supports tumour 
progression by releasing growth and survival factors, matrix remodelling factors, 
immunosuppressive molecules and inflammatory mediators. (Wachsmann, Pop et 
al. 2012, Lunardi, Muschel et al. 2014). 
 
Tumour cells have the ability to produce numerous chemotactic cytokines and 
chemokines that attract leukocytes. In addition, tumour cells influence components 
of the immune system in order to create an environment that promotes tumour 
growth and progression (Wormann, Diakopoulos et al. 2014). This may explain 
why most of the immune-infiltrated leukocytes have an immunosuppressive 
phenotype. This immunosuppressive population includes tumour-associated 
macrophages (TAMs), MDSCs and regulatory T cells (Tregs) (Cox and Olive 2012, 
Wormann, Diakopoulos et al. 2014). On the contrary, lymphocytes are mostly 




The most abundant leukocyte subset in PDAC is TAMs, which can be identified by 
the expression of F4/80 in mouse or CD68 in humans. TAMs cluster around 
neoplastic ducts from very early stages (Mielgo and Schmid 2013) and are 
recruited to tumour sites by chemoattractants, including chemokines CCL2, CCL3, 
CCL4, CCL5, and CCL8. In addition, TAMs can be recruited via stromal-derived 
factor 1 (SDF-1), also known as CXCL12, and thrombospondin-1 (TSP-1) (Mielgo 
and Schmid 2013). Once in the tumour and activated, macrophages secrete various 
growth factors and cytokines into the immediate microenvironment, indirectly 
contributing to an altered stromal environment and to an enhanced desmoplasia.  
 
TAMs can be broadly divided into two different population ns, the classical/M1-
activated macrophages, which in humans are CD68+, and the alternative/M2-
activated macrophages, CD163+. The M1-activated macrophages act against 
intracellular pathogens as well as tumour cells, providing an anti-tumorigenic 
response by secreting TNF-α (Ruffell, Affara et al. 2012, Mielgo and Schmid 2013). 
The M2-activated macrophages initiate a pro-tumorigenic response by promoting 
tumour growth, angiogenesis and invasion and suppressing the adaptive immunity 
(Ruffell, Affara et al. 2012) (Sica and Mantovani 2012). It is thought that the 
polarisation of TAMs from a tumour-suppressive M1 phenotype to a M2 phenotype 
is initiated by cytokines, including IL-10 and TGF-β received from T regulatory and 
tumour cells (Sica and Mantovani 2012). However, macrophages in vivo do not 
strictly adhere to the M1/M2 classification but instead they show a broad spectrum 
of phenotypes, in which M1 and M2 represent the two extremes of polarization. 
Moreover, in the TME, macrophages exhibit extraordinary plasticity, adapting their 
phenotype and effector functions in response to local stimuli (Sica and Mantovani 
2012). 
 
In PDAC macrophages are significantly increased compared to normal pancreatic 
tissue; TAMs with a M2 phenotype have been associated with a poor prognosis 




MDSCs represent a prominent population in many tumour types as well as in the 
spleens of cancer patients and in mouse models of cancer (Cox and Olive 2012, 
Wormann, Diakopoulos et al. 2014). MDSCs are characterized by the expression of 
Gr-1 on their surface and they are recruited into tumours by granulocyte-
macrophage colony-stimulating factor (GM-CSF), which is secreted by tumour cells 
(Bayne, Beatty et al. 2012). Within the tumour microenvironment the presence of 
MDSCs inversely correlates with that of cytotoxic T cells (CTL) (Clark, Hingorani et 
al. 2007). In vivo mouse model studies of PDAC have shown increased numbers of 
MDSCs in the TME. In particular, in a spontaneous mouse pancreatic carcinoma 
model, the increase of MDSCs was associated with their ability to suppress T-cell 
response (Wachsmann, Pop et al. 2012). In PDAC patients the levels of MDSCs in 
the circulation are increased when compared to healthy controls; and this is a poor 
prognostic factor (Sideras, Braat et al. 2014). 
 
Neutrophils  
The role of neutrophils in cancer is not fully understood although they have been 
implicated in several aspects of tumourigenesis such as tumour initiation, growth, 
proliferation, angiogenesis and metastatic spreading (Ocana, Nieto-Jimenez et al. 
2017). Neutrophils are attracted into the TME by CXCR2 ligands, CXCL1, CXCL2 and 
CXCL5. Neutrophils mediate pro-tumour mechanisms by the secretion of several 
soluble factors, such as reactive oxygen species (ROS), proteases, cytokines and 
chemokines (Sionov, Fridlender et al. 2015).  
Neutrophils are rarely found in PDAC biopsies although analysis of blood samples 
from PDAC patients revealed that elevated pre-operative neutrophil-lymphocyte 
ratio correlated with poorer prognosis (Evans and Costello 2012) . 
 
T Cells  
Few studies have addressed the role of tumour infiltrating lymphocytes, TILs in 
PDAC. The presence of CD3+ T cells has been reported both in human and mice 
tumours (Evans and Costello 2012). CD3+ T cells are mostly localized as aggregates 
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in the stroma while very few cells are reaching the tumour area (Wachsmann, Pop 
et al. 2012). The stroma has a large population of CD4+ T lymphocytes and 
macrophages with a small population of CD8+ T cells and B cells (Evans and 
Costello 2012). The role of both CD4+ T and CD8+ T lymphocytes and B cells in 
PDAC immunity is poorly understood (Wachsmann, Pop et al. 2012).  
 
Amongst TILs, the role of Tregs cells is better understood. Both circulating and 
tumour resident Tregs are significantly increased in patients with PDAC compared 
to healthy controls. Moreover, the presence of Tregs within the tumour correlates 
with the stage and progression of disease. Tregs display an immunosuppressive 
phenotype and mediate the immune evasion of cancer cells in PDAC, by the 
suppression of CD4+ T lymphocytes (Evans and Costello 2012). Interestingly, in 
vivo studies suggest that decreasing or depleting Tregs cells, in a mouse model of 
PDAC, results in the inhibition of tumour growth and the promotion of a tumour-
specific immune response (Viehl, Moore et al. 2006, Tan, Goedegebuure et al. 
2009). 
 
Cell type Activation stage in 
pancreatic cancer 
Roles in tumour progression 
NK Deactivated Unable to Induce tumour 
cytotoxicity  
CD8+ T cells  Deactivated Unable to kill tumour cells 
TAM (M1) Decreased Anti-tumorigenic  
TAM (M2) Increased Decrease survival, promote 
angiogenesis ad enhance 
metastasis 
MDSCs Increased Decrease survival, suppress T cell 
response 
Tregs  Increased Decrease survival, mediate 
immune evasion and suppress T 
cell response  
Table 1.2 Cells of the immune system in PDAC 
List of major immune cells present in PADC, their activation state and their effect during 
tumour progression. NK: natural killer cell; TAM: tumour associated macrophage; MDSC: 
myeloid derived suppressor cell; Tregs: regulatory T cells. 
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The study of the TME is becoming fundamental to better understand how tumours 
are formed, progress and metastasise (Feig, Gopinathan et al. 2012). Additionally, 
understanding the roles of TME components has revealed new possible 
therapeutic targets, such as anti-angiogenic drugs and immunotherapy (Cid-
Arregui and Juarez 2015). However, the study of the TME has revealed that there 
is huge variability in its composition. The dissimilarities in the TME are observed 
not only between tumours of different organs, but also within the same tumour 
type.  
 
In pancreatic cancer the TME represent the biggest part of the tumour mass. 
Several studies revealed that the reciprocal interactions between tumour cells and 
components of TME have an important role in tumour initiation, progression, 
metastasis and chemioresistance (Carr and Fernandez-Zapico 2016). Large-scale 
genomic and transcriptomic analysis can help to identify new pathways and 
molecular components with potential therapeutic relevance. For example, the 
Bailey’s study correlate the enrichment of expression patterns, that characterize 
specific immune cell populations, to better identify the molecular mechanisms that 
are active in the TME (Bailey, Chang et al. 2016). In the last years, several pre-
clinical and clinical trials targeting different molecules, pathways or cells of the 
TME have been conducted. In early phase clinical trials, promising results have 
been obtained using immunotherapy (Cid-Arregui and Juarez 2015).  
 
1.3 The chemokine superfamily 
Chemokines are chemotactic cytokines mainly known for their ability to direct 
migration of immune cells. The chemokine superfamily includes approximately 50 
chemotactic cytokines in humans and mice (Griffith, Sokol et al. 2014). Chemokines 
are involved in several biological processes, such as immune cell chemotaxis, 
embryogenesis, haematopoiesis, angiogenesis, wound healing, development and 
maintenance of immune tissues, and response to infection (Zlotnik and Yoshie 
2012, Anders, Romagnani et al. 2014). Chemokines have been classified into four 
subgroups: CXC, CC, CX3C, and XC, according to the number and the spacing 
between the first two conserved cysteine residues in the amino terminal part of the 
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protein. The sequence homology among the chemokines is variable, between 20-
90% (Anders, Romagnani et al. 2014). 
 
Chemokines are small proteins, approximately 8-12 kDa, with conserved sequence. 
The majority of chemokines are soluble proteins, with the exception of CX3CL1 and 
CXCL16 which have a membrane-bound form. Most human chemokines have 
orthologs in mice and vice versa. However, some chemokines, such as CCL13, 
CXCL8, CCL14 and CCL18, are expressed only in humans, while CCL12 and CXCL15 
are found only in mice (Zlotnik and Yoshie 2000). 
 
Chemokines can be broadly divided into two functional groups: homeostatic or 
inflammatory chemokines (Table 1.3 and Figure 1.3) (Zlotnik and Yoshie 2000, 
Griffith, Sokol et al. 2014). Homeostatic chemokines are constitutively expressed 
and produced, while inflammatory chemokines are induced by the presence of 
stimuli, such as during times of infection or injury (Griffith, Sokol et al. 2014). 
Homeostatic chemokines are constitutively expressed in the body and play a 
pivotal role in hematopoiesis and in the development and maintenance of the 
immune system (Zlotnik and Yoshie 2012). In particular, they regulate the 
development of primary and secondary lymphoid organs during embryogenesis, 
stem cell homing, leukocyte maturation, homing of leukocyte precursors during 
haematopoiesis, immune surveillance and maintaining homeostatic leukocyte 
traffic, (Anders, Romagnani et al. 2014, Griffith, Sokol et al. 2014). Furthermore, 
over the past decade it has become clear that the expression of chemokines and 
their respective receptors is not restricted to hematopoietic cells (Balkwill 2012).  
 
Inflammatory chemokines are induced by pro-inflammatory stimuli, such as TNF-
α and IL-1, in order to recruit effector leukocytes to sites of infection, inflammation, 
tissue injury and tumours. Most inflammatory chemokines display a wide range of 
functions, acting on cells of both the innate and the adaptive immune system 






Figure 1.3 Chemokines and chemokine receptors pairing 
The chemokine receptors belonging to XC, CC, CXC, and CX3C subfamilies are represented 
around the outer ring of the wheel, with their chemokine ligands shown along the wheel 
spokes. In green are shown the inflammatory chemokine in orange are shown the 
homeostatic chemokines and in purple are shown the atypical chemokines. Adapted from 
(White, Iqbal et al. 2013). 
 
1.3.1 Chemokine receptors 
Chemokines signal through seven transmembrane G protein coupled receptors 
(GPCR), referred to chemokine receptors. Approximately 20 different chemokine 
receptors have been characterized to date in humans and mice, and these are 
divided into four families depending on the type of chemokine they bind. They have 
been named according the chemokine subgroups, XC, CC, CXC, and CX3C followed 
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by “R” (for receptor) and a number indicating the order of their discovery (Zlotnik 
and Yoshie 2000). 
 
Some chemokine receptors bind multiple chemokines, and vice versa, while 
others have exclusive chemokine receptor/ligand interactions (Table 1.3, Figure 
1.3) (Lazennec and Richmond 2010, Roy, Evans et al. 2014). Most receptors 
generally bind to ligands that are restricted to one class of chemokines, i.e. CC or 
CXC ligands bind to CCR or CXCR respectively. Overall this suggests a high level of 
redundancy and compensatory mechanisms between chemokines. However, it 
has been proposed that the interaction between different chemokines with the 
same receptor may activate different signalling pathways (Murphy, Baggiolini et 
al. 2000). In particular, studies on CXCR3 have shown that there is no redundancy 
of ligand/receptor responses at a molecular level, suggesting a range of 
interactions that confers considerable flexibility to the response (O'Boyle 2012). 
1.3.3 Structure and Signalling  
The chemokine receptors share many structural features: 
 Similar in size (about 350 amino acids) 
 Short acidic N-terminal end 
 Seven helical transmembrane domains with three intracellular and three 
extracellular hydrophilic loops 
 Presence of the canonical sequence DRYLAIV within their second 
intracellular loop, important for G-protein coupling and signalling 
 Intracellular C-terminus containing serine and threonine residues 
important for receptor regulation  
The N-terminal domain of the chemokine receptor is extracellular and determines 
ligand binding specificity, while the C-terminal of the chemokine receptor interacts 
with the G proteins to allow intracellular signalling after receptor activation. (Patel, 
Channon et al. 2013) 
 
The binding between a chemokine and its receptor induces a conformational 
change to the receptor leading to the activation of the coupled G proteins 
(Zweemer, Toraskar et al. 2014). Upon activation the Gβγ heterodimers disconnect 
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from the Gα subunit, allowing both subunits to propagate downstream signal 
transduction pathways. Both the α and the βγ subunits complex mediate 
chemokine-induced signals; however, it is the Gβγ subunits, which are required for 
chemotaxis (Figure 1.4). 
 
 
Figure 1.4 Chemokine-chemokine receptor signalling 
Schematic representation of Chemokines of chemokine-chemokine receptors signalling 
pathways. Chemokines binding to its receptors activates G proteins. The Gα and Gβγ 
subunits dissociate and regulate downstream effector functions such as activation of SRC, 
Cdc42, cAMP, PLC, PAK1 and Pi3K (O'Hayre, Salanga et al. 2008). 
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1.3.4 Atypical chemokine receptors 
Atypical (decoy or silent) chemokine receptors (ACKRs) are a subfamily of 
chemokine receptors that upon chemokine binding are unable to mediate the GPCR 
signalling events of “classical” chemokine receptors which lead to chemotaxis 
(Bachelerie, Graham et al. 2014).  Four atypical chemokine receptors have been 
identified ACKR1/DARC, ACKR2/D6, ACKR3/CXCR7, and ACKR4/CCX-CKR/CCRL1 
(Bachelerie, Graham et al. 2014).  
 
The atypical receptors present, like the “classical chemokine”, seven 
transmembrane domain but in most of them the highly conserved “DRYLAIV” motif 
is missing, preventing the activation of the coupled G protein (Nibbs and Graham 
2013). The main function of the atypical chemokine receptors is to act as 
scavengers in order to remove an excess of chemokines, regulating the innate and 
adaptive immune response (Nomiyama, Osada et al. 2011). Atypical receptors can 
also generate signals through the downstream biochemical cascades of G-protein-
independent signalling of GPCRs for example β-arrestins (Ulvmar, Hub et al. 2011). 
 
1.3.5 Chemokines and chemokine receptors in disease 
Several diseases have been associated with inappropriate activation of the 
chemokine network. In fact, abnormal regulation of both chemokines and their 
receptors has been shown to play a role in autoimmune disorders (inflammatory 
bowel disease, multiple sclerosis, psoriasis, atherosclerosis and rheumatoid 
arthritis), vascular and viral diseases and cancers (Table 1.3) (Gerard and Rollins 
2001, Cheng and Chen 2014).  
 
Atherosclerosis is a chronic inflammatory disease in which the arterial wall 
thickens, forming a plaque, through the damage of endothelial cells, the 
recruitment of leukocytes and the proliferation of vascular smooth muscle cells. 
Chemokines, in particular CCL2 and CX3CL1, have been implicated in the 
recruitment of monocytes inside the arterial lesion where they differentiate into 
macrophages, causing plaque formation and progression (Saederup, Chan et al. 
 47 
2008, Weber 2008).  
 
Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disease of the 
synovia of the joints. It is characterised by the infiltration of inflammatory cells. 
Some chemokines and chemokine receptors have been implicated in leukocyte 
ingress into the inflamed synovium and in synovial angiogenesis. CXCL8, CXCL5 
and CXCL1, secreted by both synovial-lining cells and infiltrating leukocytes, are 
the most abundant chemokines present in the sera and synovial fluids in RA 
patients (Szekanecz, Vegvari et al. 2010, Raman, Sobolik-Delmaire et al. 2011).  
 
Multiple sclerosis (MS) is a chronic neuroinflammatory disease characterised by 
the demyelination of neurons, neurodegeneration and by the recruitment of T 
lymphocytes and macrophages into the central nervous system. High levels of 
CXCL10, CCL3, and CCL5 have been found into MS lesions, which mediate the 
migration of T cells into the central nervous system (Gerard and Rollins 2001, 
Cheng and Chen 2014).  
 
An example of the involvement of chemokine and their receptor in viral diseases 
can be observed during human immunodeficiency virus 1 (HIV-1) infection. The 
chemokine receptors involved during HIV-1 pathogenesis are principally CXCR4 
and CCR5. Several studies have demonstrated that CXCR4 and CCR5 are required 
by the virus to entry into host cells. Moreover, it has been shown that people with 
a polymorphism in the CCR5 gene are resistant to viral infection (Gerard and 











Chemokine receptors Disease 
CCR1 MS, psoriasis, RA and cancer 
CCR2 MS, RA, atherosclerosis and cancer 
CCR4 Asthma 
CCR5 HIV and Cancer 
CCR7 Cancer 
CXCR3 MS, RA and cancer 
CXCR4 HIV and cancer 
CX3CR1  Atherosclerosis and cancer 
Table 1.3 Chemokine receptors implicated in disease processes 
Some chemokine receptors and the diseases in which they are involved. Adaptation from 
(Allen, Crown et al. 2007). 
 
1.4 Chemokines and chemokine receptors in 
cancer 
Chemokines and their receptors, which play an essential role in cellular migration 
and cell-cell interactions, are also involved in the movement of cells in and out of a 
tumour. In addition to their primary role as chemoattractants, chemokines and 
their receptors are also involved in other aspect of tumour development, such as 
tumour cell growth, metastasis formation and angiogenesis (Lazennec and 
Richmond 2010). 
 
In the TME, the chemokines network it is really complex. In fact, both tumour and 
non-tumour cells not only can secrete several types of chemokines; but, at the same 
time, these cells can also express on their membrane a wide range of chemokine 
receptors. This results in the recruitment, activation and/or regulations of 
different cell types mediating the balance between anti- and pro-tumour responses 
(Lazennec and Richmond 2010). Chemokines and their receptors have been found 
expressed in several cancer types (Table 1.4). Interestingly, chemokine receptors 
which have been found on tumour cells, are generally not expressed on their 
normal tissues.  
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CXCR4 is one of the most commonly reported chemokine receptor expressed in 
cancers, present on at least 23 different tumours (Table 1.4) (Lazennec and 
Richmond 2010). This receptor is involved in metastasis formation and invasion 
(Mehrad, Keane et al. 2007, Sarvaiya, Guo et al. 2013). 
 
Table 1.4 Chemokine receptors in cancer 
List of chemokine receptors which are upregulated in cancer. The table also shows the 
ligands for each chemokine receptors, and the tumours in which they are found. 
Adaptation from (Balkwill 2012). 
 
1.4.1 Regulation of chemokines and chemokine receptors in 
cancer 
Many different mechanisms can be involved in the altered expression of 
chemokines and chemokine receptors in cancer. The expression of chemokines and 
their receptors expression is regulated both by genetic and epigenetic mechanisms 
and environmental signals originated from the TME (Nagarsheth, Wicha et al. 
2017). For example, mutations in the RAS gene, one of the most frequently mutated 
oncogene in human cancer, induce the production of tumour-promoting 
Chemokine 
receptor 
Chemokines Tumour expression 
CXCR4 CXCL12 23 different cancers including 
breast, prostate and 
melanoma 
CXCR2 CXCL1, CXCL2, CXCL3, 
CXCL5, CXCL6, CXCL7 
and CXCL8 
Melanoma, pancreas, ovarian, 
prostate and lung 
CCR2 CCL2, CCL7, CCL8 and 
CCL13 
Multiple myeloma, prostate 
and breast 
CCR4 CC17 and CCL22 Breast and T-cell lymphoma 
CCR7 CCL19 and CCL21 Breast, melanoma, gastric, 
cervical, stomach, colorectal, T 
cell lymphoma and CCL 
CCR10 CCL26, CCL27 and 
CCL28 
Melanoma 
CX3CR1 CX3CL1 Pancreas, prostate, breast and 
neuroblastoma 
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inflammatory cytokines and chemokines, including CXCL1 and CXCL8. NF-kB 
(nuclear factor kappa-light-chain-enhancer of activated B cells), a key signalling 
factor often activated in cancer cells, can contribute to the transcription of 
chemokines and chemokines receptors (Richmond 2002, Maxwell, Gallagher et al. 
2007). In breast cancer, the abnormal translocation of β-catenin induces the 
activation of several transcription factors and leads to the transcription and 
expression of CCL2, which has been implicated in the development of metastasis 
and invasion (Mestdagt, Polette et al. 2006).  
 
Genetic mutations in chemokines and their receptors can also induce a pro-tumour 
effect. A study reported that a cancer cell line with a point mutation in the CXCR4 
gene showed a delayed in vivo growth compared to non-mutated CXCR4. 
Importantly, the mutant receptor responds to CXCL12 signals (Ierano, Giuliano et 
al. 2009, Nagarsheth, Wicha et al. 2017).   
 
Conditions present within the tumour, such as hypoxia and a rich cytokine 
environment can induce the transcription of certain chemokine or their receptors. 
For example, hypoxia triggers CXCL12 expression in primary human ovarian 
tumour cells, mechanism mediated by the transcription factor hypoxia-inducible 
factor 1 (HIF-1) (Kryczek, Lange et al. 2005, Nagarsheth, Wicha et al. 2017). HIF-1 
it is also responsible of the expression of CXCR4 in renal cell carcinoma and of 
CXCR7 expression in rhabdomyosarcoma cells (Nagarsheth, Wicha et al. 2017). 
 
1.4.2 The role of chemokines and chemokine receptors in 
malignant cells 
Chemokines and their receptors play several roles during tumour progression, 
such as tumour cell growth, survival, and metastasis formation. The expression of 
chemokine receptors on cancer cells has been associated with their proliferation. 
For example, CXCR4 is involved in the tumour growth of many tumours and its 
inhibition induces apoptosis in ovarian cancer, hepatic cancer and chronic 
lymphocytic leukaemia cells (Sarvaiya, Guo et al. 2013). CXCL12 also plays an 
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important role in promoting the tumour growth of several cancer types, including 
leukaemia, glioma, non- Hodgkin's lymphoma, breast cancer, ovarian cancer, small 
cell lung cancer, and colon cancer (Sarvaiya, Guo et al. 2013). CXCR2 and its ligands 
have been shown to play a role in the growth of pancreatic, head and neck, and non-
small cell lung carcinomas (Table 1.4) (Mukaida, Sasaki et al. 2014).  
 
Moreover, the chemokine network can induce the tumour growth by generation of 
an autocrine loop induced by the secretion of chemokines by tumour cells itself. 
For example, the secretion of CXCL1, CXCL2, CXCL3 and CXCL8 by melanoma cells 
induce an autocrine loop which promotes tumour growth and proliferation. 
Indeed, blocking the corresponding chemokine receptor, CXCR2, to these ligands 
was found to attenuate melanoma cell proliferation (Payne and Cornelius 2002). 
Additionally, CXCL1, CXCL2 and CXCL3 have been associated with the tumour 
growth of pancreatic, cancer and gastric cancer. 
 
The binding of chemokine to their receptors on tumour cells promote the 
proliferation and survival of tumour cells in several ways: inducing the activation 
of the MAPK/Erk signalling pathway, upregulating the expression of Mdm2, 
downregulating Bcl-2 expression or inhibiting the activation of caspase-3 and 
caspase-9. 
 
Several lines of evidence support a role for the chemokine network in the invasion 
and metastasis of cancer (Sarvaiya, Guo et al. 2013). In breast cancer, CXCR4 and 
CCR7 are highly expressed and direct metastases to organs that are rich in their 
respective ligands (Muller, Homey et al. 2001, Sarvaiya, Guo et al. 2013). Moreover, 
CXCR4 promotes metastasis formation also in ovarian, prostate, and lung cancers 
(Raman, Sobolik-Delmaire et al. 2011); while CCR7 play a role in squamous cell, 
colorectal and gastric carcinomas metastatization. Breast cancer cells expressing 
CXCR4 are able to metastasize towards sites where CXCL12 is produced, such as 
the lymph nodes, lungs, liver and bone marrow (Mukherjee and Zhao 2013). The 
expression of CCR7 on tumour cells is associated with metastasis to the lymph 
nodes where its ligands, CCL19 and CCL21, are constitutively produced (Sarvaiya, 
Guo et al. 2013). 
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CXCR3 is another chemokines which induce cancer metastasis. In fact, the 
expression of CXCR3 has been associated with the pulmonary metastases of murine 
breast cancers, as well as the lymph node metastases of murine melanoma and 
colon cancer (Ma, Norsworthy et al. 2009). CCR9 and CCR10 expression on 
melanoma cells are associated with metastasis; CCR9 promote metastasization into 
the intestine while CCR10 into the lymph nodes (Raman, Sobolik-Delmaire et al. 
2011) 
 
1.4.3 Chemokines and chemokine receptors in leukocyte 
recruitment in the TME 
The chemokines secreted into the TME are important in leukocyte trafficking in 
and out of the tumour. Notably, the type and the amount of chemokines and 
chemokines receptors are both important to determine which cell types are 
recruited into the tumour. Indeed, the alterations in the immune infiltration that is 
observed during tumour progression are caused by changing in the amount and 
the composition of chemokines ad their receptors present in the TME (Nagarsheth, 
Wicha et al. 2017). Each chemokine can recruit certain cell populations (Table 1.5). 
For this reason, the subset of immune cells present into the TME is, at least in part, 
determined by the network of chemokines secreted by malignant cells and stromal 
cells. For example, the presence of CC chemokines in the TME has been associated 
with the infiltration of macrophage and lymphocyte in human carcinomas of the 
breast, cervix, pancreas, sarcomas and glioma (Balkwill 2004). 
 
CCL2 and CCL5 are the main attractants of monocytes into the TME (Nagarsheth, 
Wicha et al. 2017). CCL2 and CCL5 are secreted in breast cancer, melanoma, 
esophageal cancer, colon cancer, prostate cancer and pancreatic cancer 
(Mantovani, Savino et al. 2010). The CCL2–CCR2 signalling it is responsible for the 
recruitment of macrophages into the TME of many cancers. CCL2 levels correlate 
with the amount of TAMs in many tumours and are associated with poor patient 
prognosis in some cancers, such as breast cancer (Pollard 2004). The presence of 
macrophages affects tumour progression, angiogenesis, metastasis and 
chemotherapy response (Nagarsheth, Wicha et al. 2017). Moreover, the presence 
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of TAMs in the TME promotes an immune-suppressive environment by the 
production of immunosuppressive molecules, like TGF-β and IL-10, which will lead 
to the suppression of adaptive immunity (Pollard 2004). 
 
The CXCL5/CXCR2 and CXCL12/CXCR4 axes are involved in the recruitment of 
MDSCs into the TME of many cancers, such as breast cancer (Nagarsheth, Wicha et 
al. 2017).  
 
The presence of CXCL9 and CXCL10 in the TME recruit TILs that express CXCR3. 
High levels of CXCL9 and CXCL10 are associated with the infiltration of CD8+ T cells, 
and in patients with ovarian cancer and colon cancer this correlates with a 
decrease in metastasis formation and improved survival (Nagarsheth, Wicha et al. 
2017). The recruitment of TILs can be mediated also by CXCL16, which is found 
over-expressed in neuroblastoma, pancreatic and breast carcinoma (Mantovani, 
Savino et al. 2010). Tregs cells are recruited into the TME by the CCL22-CCR4 
signalling pathway, CCL22 is secreted mainly by tumour cells and macrophages 

















Chemokines Immune cells 
recruited 
Effects on the TME 
CCL2 Monocytes and MDSCs Promotes tumour cell proliferation, 
vascularization and metastasis 
CCL3 Monocytes and 
macrophages 
Promotes cancer extravasation 
CCL5 Monocytes and 
macrophages 
Induces metastasis 
CCL22 Tregs Induces antitumour immunity 
CXCL8 Neutrophils and MDSCs Promotes invasion, migration, 
apoptosis and angiogenesis 
Increase the immunogenecity of the 
tumour  
CXCL12 B cells, pDCs, 
monocytes and  T cells 
Promotes proliferation, survival 
metastasis and angiogenesis 
CXCL14 DCs Promotes invasions 
Inhibits proliferation, metastasis 
and increase apoptosis 
CXCL17 MDSCs Promotes angiogenesis 
CXCL9 and 
CXCL10 
T cells and NK cells Inhibits angiogenesis 
Table 1.5 Chemokine functions and immune cells recruitment  
List of chemokines associated with the immune populations that they recruit into the TME 
and their function during tumour progression. DC, dendritic cell; MDSC: myeloid-derived 
suppressor cell; NK: natural killer; pDC: plasmacytoid dendritic cells; Treg cell: regulatory 
T cell. Modified from (Nagarsheth, Wicha et al. 2017). 
 
1.4.4 Chemokines and chemokine receptors and angiogenesis 
Chemokines have an important role in tumour angiogenesis. Chemokines perform 
their role in angiogenesis by either directly binding their receptors on endothelial 
cells and regulating their functions, or by inducing the expression of pro-
angiogenic factors and promote the recruitment of pro-angiogenic immune cells 
and endothelial progenitors to the TME (Sarvaiya, Guo et al. 2013).  
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The CXC chemokine family plays a critical role in angiogenesis. The presence or 
absence of a three amino acid sequence, glutamic acid-leucine-argenine (referred 
as the ‘ELR’ motif), further subdivided the CXC chemokine family into two groups. 
Studies have established that angiogenic activity of CXC chemokines depends on 
the presence of the ELR motif in the CXC sequence. In fact, CXC chemokines that are 
ELR+ display potent angiogenic activities and stimulate endothelial cell chemotaxis, 
whereas ELR– chemokines are angiostatic (Santoni, Bracarda et al. 2014). ELR+ 
chemokines mediate their pro-angiogenic functions both as autocrine growth 
factors and as potent paracrine mediators of angiogenesis, which required the 
activation of NF-κB pathway (Santoni, Bracarda et al. 2014). CXCL1, CXCL2, CXCL3, 
CXCL5, CXCL6, CXCL8, CXCL12, CCL2, CCL11 and CCL16 belong to the angiogenic 
type of chemokines whereas CXCL4, CXCL9, CXCL10, CXCL11 and CXCL14 are 
angiostatic. Moreover, studies have shown that ELR+ chemokines bind to CXCR1 
and CXCR2, while the ELR– chemokines bind to CXCR3, CXCR4 and CXCR5 (Mehrad, 
Keane et al. 2007, Santoni, Bracarda et al. 2014).  
 
Some of CC chemokines also play a role in angiogenesis, such as CCL2, CCL11, 
CCL16, and CCL21. The first three chemokines have been shown to promote 
angiogenesis while CCL21 has an anti-angiogenic effect on tumours (Santoni, 
Bracarda et al. 2014).    
 
Chemokines and their receptors are involved in several steps of tumour 
progression, and metastasis, therefore they have been considered as a therapeutic 
target (Mukaida, Sasaki et al. 2014, Vela, Aris et al. 2015). Pre-clinical studies 
showed that CXCR4 antagonists significantly reduced the size of primary tumours 
and had anti-metastatic effects in mouse models of melanoma, osteosarcoma, 
breast and prostate tumours (Allavena, Germano et al. 2011, Nagarsheth, Wicha et 
al. 2017). 
 
1.5 CX3CL1 and its receptor 
CX3CL1, also known as fractalkine or neurotactin, is the only member of the CX3C 
chemokine group (Bazan, Bacon et al. 1997). In steady-state conditions, CX3CL1 is 
 56 
expressed in the brain, lungs, kidney, intestines, pancreas, adipose tissue and liver. 
Its expression is upregulated in inflammatory conditions. At cellular level, CX3CL1 
it is expressed by neurons, adypocytes, epithelial, endothelial and smooth muscle 
cells (Jung, Aliberti et al. 2000, Kim, Vallon-Eberhard et al. 2011).  
 
CX3CL1 exists both as a soluble and as a cell membrane protein. Mature membrane 
bound fractalkine is a 371 (mouse) or 373 (human) amino acid peptide. It contains 
four domains: a chemokine domain joined by a mucin-like stalk to a 
transmembrane domain, that is proposed to act as an adhesion molecule, and a 
cytoplasmic domain (Figure 1.5) (Kim, Vallon-Eberhard et al. 2011). The 
extracellular domain is shed from the cell surface by the ADAM10 and ADAM17 
metalloproteases (Figure 1.5) (Hundhausen, Misztela et al. 2003, Kim, Vallon-
Eberhard et al. 2011). The shedding of membrane bound CX3CL1 into a soluble 
form represents a key regulatory mechanism for CX3CL1 signalling. The release of 
soluble CX3CL1 from endothelial and epithelial cells occurs both constitutively and 
in an inducible manner (Hundhausen, Misztela et al. 2003, Kim, Vallon-Eberhard et 
al. 2011).  The constitutive cleavage of CX3CL1 occurs manly by ADAM10. 
Appropriate stimuli, such as lipopolysaccharide (LPS) and interleukin IL-1β, 
accelerate the CX3CL1 shedding by ADAM17 (Liu, Jiang et al. 2016). The shedding 
of CX3CL1 by ADAM17 is increased in several pathological condition such as 
cancer, diabetes, atherosclerosis, ischemia, arthritis, neurological and immune 
diseases (Menghini, Fiorentino et al. 2013).  
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Figure 1.5 Structure of CX3CL1 and its receptor 
Membrane-bound CX3CL1 enables the integrin-independent capture and firm adhesion of 
leukocytes via the G-coupled receptor CX3CR1. Cleavage of cell-surface CX3CL1 by 
metalloproteinases (ADAM 10/17) generates a soluble chemokine, which binds CX3CR1 
on nearby cells, via signalling intermediates, can induce cell chemotaxis and survival. 
Modified from (Kasama, Odai et al. 2008).  
 
CX3CR1 is the sole receptor for CX3CL1 (Imai, Hieshima et al. 1997). This receptor 
is a G-coupled receptor and is expressed on monocytes, macrophages, dendritic 
cells, T cells, NK cells and microglia (Imai, Hieshima et al. 1997, Jung, Aliberti et al. 
2000). Receptor binding by soluble fractalkine induces phosphorylation of Akt and 
ERK in a time- and dose-dependent manner (Lee, Namkoong et al. 2006). .  
 
Both transmembrane and soluble forms of CX3CL1 bind to CX3CR1, but each form 
mediates distinct functions. Transmembrane CX3CL1 serves as an adhesion 
molecule, mediating enhanced leukocyte adhesion to endothelial cells under flow 
conditions, without the activation of integrins (Fong, Robinson et al. 1998, Schulz, 
Schafer et al. 2007). This activity is largely independent of CX3CR1-mediated G-
protein activation but is predominantly a result of the physical interaction of the 
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transmembrane chemokine with its receptor. By contrast, soluble CX3CL1 acts as 
a chemoattractant inducing directional cell migration of monocytes, NK cells, T 
cells and B cells, via CX3CR1 signalling and activation of G -proteins (Gautier, 
Jakubzick et al. 2009, Corcione, Ferretti et al. 2012). CX3CL1/CX3CR1 interactions 
are also vital for many homeostatic processes, including the survival of CX3CR1high 
blood monocytes (Landsman, Bar-On et al. 2009), wound healing (Ishida, Gao et al. 
2008) and trans-endothelial migration for immune surveillance (Auffray, Fogg et 
al. 2007). 
 
The generation, by Jung et al, of the CX3CR1GFP/GFP mouse model, in which the 
CX3CR1 locus has been replaced by GFP reporter gene, allowed investigation of the 
expression and the function of this chemokine receptor. In this model, they 
substituted the first 390 bp of the second CX3CR1 exon with GFP, encoding the N 
terminus of the receptor, which is crucial for interacting with CX3CL1 (Jung, 
Aliberti et al. 2000).  The study revealed that the homozygous mutant 
CX3CR1GFP/GFP mice did not exhibit any developmental defects, were generated in 
normal Mendelian distribution, and were fertile (Jung, Aliberti et al. 2000). 
Moreover, they demonstrated that the CX3CL1-CX3CR1 axis did not play essential 
role in monocyte recruitment in peritonitis, DC differentiation and migration in 
response to microbial antigens or contact sensitizers, and the microglial response 
to nerve injury (Jung, Aliberti et al. 2000). 
 
However, other researches have shown that the CX3CL1/CX3CR1 network is 
known to be involved in various pathological conditions, such as cancer, 
inflammation, infection, diabetes and autoimmunity diseases (Jung, Aliberti et al. 
2000, Kim, Vallon-Eberhard et al. 2011). For instance, CX3CR1 is responsible for 
recruiting dendritic cells and a subset of monocytes in models of atherosclerosis 
(Liu, Yu et al. 2008). CX3CR1 deficiency results in impaired microglia migration in 





1.5.1 CX3CR1 in cancer 
Several studies have reported an upregulation of CX3CR1 in cancers such as 
prostate (Shulby, Dolloff et al. 2004), breast (Andre, Cabioglu et al. 2006) and 
pancreatic (Allavena, Germano et al. 2011) (see Figure 1.6). CX3CR1 expression is 
associated with increased migration and metastasis formation (Marchesi, Piemonti 
et al. 2008, Marchesi, Locatelli et al. 2010). 
 
 
Figure 1.6 CX3CR1 in cancer and metastasis 
Scheme showing in which tumours CX3CR1 is upregulated and the organs or tissue to 
which it mediated the migration and the metastasis formation. CNS: central nervous 
system. Modified from (Marchesi, Locatelli et al. 2010).  
 
There is evidence that CX3CR1 plays a role in different stages of tumour 
progression. In lung tumours, malignant cells recruit macrophages by secreting 
CCL2 and CX3CL1. The CCR2-CCL2 and CX3CR1-CX3CL1 cross talk between cancer 
cells and the recruited macrophages enhances cancer cell proliferation and 
migration (Schmall, Al-Tamari et al. 2015). 
 
The CX3CR1/CX3CL1 axis has been also implicated in B cell malignancies, where it 





its ligand, and the TME (Ferretti, Pistoia et al. 2014). In breast cancer CX3CR1 
expression by tumour cells was associated with metastasis to the brain. Moreover, 
CX3CL1 expression showed a positive correlation with increased TILs but it 
correlated negatively with overall survival (Liu, Jiang et al. 2016). In 
neuroblastoma, soluble CX3CL1 stimulates CX3CR1+ cancer cells to transmigrate 
through human bone marrow endothelium, implying a prometastatic effect. In 
human colon carcinoma the expression of CX3CR1 is correlated with poor 
prognosis. Furthermore, depletion of CX3CR1 resulted in the significant inhibition 
of liver metastasis formation. Metastatic tumours in CX3CR1 KO mice exhibit also 
increase in apoptosis and decrease in vasculature, which seemed to be mediated 
by macrophages. In fact, it has been observed that in hepatic metastases 
macrophages expressed CX3CR1 (Zheng, Yang et al. 2013).  
 
CX3CR1 is highly expressed in both human pancreatic tumour cell lines and in 
primary PDAC tumour tissues, whilst a ‘benign’ epithelial pancreatic duct cell line 
and ‘normal’ exocrine pancreas do not express the receptor (Allavena, Germano et 
al. 2011). Interestingly, CX3CR1 expression is an early feature of pancreatic 
carcinogenesis, being found already in PanIN-1. In addition, expression is 
increased from PanIN-1 to PanIN-3 (Celesti, Di Caro et al. 2013).  
 
Marchesi et al. showed that in pancreatic cancer the CX3CL1-CX3CR1 axis is 
responsible for the neurotropism of tumour cells to peripheral nerves, which is 
known as perineural invasion (PNI). CX3CR1+ tumour cells migrate in response to 
its ligand CX3CL1 (Allavena, Germano et al. 2011). There is also a positive 
correlation between CX3CR1 expression and the grade of PNI; high receptor 
expression was associated with increased neuron invasion by cancer cells 
(Allavena, Germano et al. 2011) (Marchesi, Locatelli et al. 2010). Their work 







1.6 Aim of this thesis 
The aim of this thesis is to investigate the role of CX3CR1 in a murine model of 
pancreatic cancer, the KPC model. I will examine if the lack of CX3CR1 in KPC mice 
has an effect on overall survival of mice, response to chemotherapy and on the 















































2.1 Animal husbandry 
The conditional CX3CR1GFP/+Lox-Stop-Lox-KRASG12D/+LSL-Trp53R172H/+ and the 
CX3CR1GFP/+Pdx1-Cre strains were interbred to obtain CX3CR1GFP/GFPLSL-
KRASG12D/+LSLTrp53R172H/+Pdx1-Cre (CKPC) and LSL-KRASG12D/+ 
LSLTrp53R172H/+Pdx1-Cre (KPC) mutant mice. All mice were genotype at weaning 
and samples sent to Transnetyx, Inc.  
 
The mice were constantly monitored for the appearance of palpable tumours, 
ascites, swollen abdomen, weight loss, inability to move, reduced food ingestion 
and visible symptoms of pain (hunching, piloerection and isolation from other 
mice). The presence of any of these symptoms was considered an endpoint human 
criteria. Thus, mice were culled by neck dislocation. Animal procedures were 
carried out in accordance with the U.K. Home Office Animal and Scientific 
Procedures Act 1986. 
 







Table 2.1 Description of the mice strains 
The table summarises the mutations that characterise the mice strains used in the 
experiments.  
 
2.2 Tissue processing  
Blood, pancreatic tumour, spleen, mesenteric lymph nodes and legs were collected 
from each mouse. The tumour and spleen were cut in half, one half of each organ 
was transferred into a cryovials and snap frozen in liquid nitrogen and stored at -
80°C. The other half as well as the mesenteric lymph nodes and legs, were placed 
in a bijou tube with phosphate buffered saline (PBS) (SIGMA - D8537) and kept on 
ice until further processing for flow cytometry staining.  
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2.2.1 Blood processing  
Mice were anaesthetised by 3% isoflurane/1% 02 anaesthesia. Cardiac puncture 
was performed with a 1 ml syringe (Henke Sass Wolf - cat. No 5010-200V0) 
coupled to a 27G needle (BD Microlance - Cat. No 302200) previously coated with 
Ethylenediaminetetraacetic acid (EDTA) (Invitrogen - Cat. No 9262) to avoid blood 
clots. Typically, 0.5 to 1 ml of blood were obtained. Subsequently, blood was 
centrifuged with three consecutive times to separate the plasma from cells.  
1. 200 relative centrifugal force (rcf) for 10 minutes at 4°C  
2. 2300 rcf for 5 minutes at 4°C  
3. 16100 rcf for 3 minutes at 4°C.  
After the process, plasma was collected in an eppendorf tube and stored at -80°C. 
For blood cell analysis, pellets obtained after centrifugations were transferred into 
a 50 mL falcon tube and incubated with red blood cell lysis buffer (eBioscence - Cat. 
No 00-4300-54) for 10 minutes at room temperature. Lysis reaction was stopped 
by adding 10 ml of FACS buffer [2.0 mM EDTA and 5% of bovine serum albumin 
(BSA) in PBS] and then centrifuged at 320 rcf for 5 minutes at 4°C. The pellet was 
resuspended in 5 ml of FACS buffer.  
 
2.2.2 Pancreatic tumours  
Each tumour was longitudinally cut in half. Half of the tumour was snap frozen in 
liquid nitrogen or dry ice and the other half was placed in ice-cold PBS and kept on 
ice. Using a scalpel the tumour was cut into small pieces and transferred into a 50 
ml falcon containing 5 ml of Dulbecco's Modified Eagle's Medium (DMEM) (Sigma 
– Cat. No P4333) plus 2.0 mg/ml of collagenase IV (sigma – cat. No C9263-1G) and 
10 mg/ml of DNase (sigma - cat. No D4513). Tumour digestion was performed in 
an orbital shaker at 150 rpm for 20 minutes at 37°C. The reaction was stopped by 
adding 10 ml of FACS buffer. The digested tumour was then passed through a 70 
µm cell strainer (Fischer Scientific – Cat. No 11597522) with FACS buffer to obtain 
a single cell suspension and centrifuged at 320 rcf for 5 minutes at 4°C. Finally, the 
pellet was resuspended in 10 ml of FACS buffer.  
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2.2.3 Spleen  
Spleen was collected from each mouse in ice-cold PBS and kept on ice until further 
disruption through a 70 µm cell strainer with FACS buffer. The obtained 
suspension was centrifuged at 320 rcf for 5 minutes at 4°C. The cell pellet was 
resuspended in 10 ml of red blood lysis buffer solution (prepared as in 2.2.1) and 
incubated for 10 minutes at room temperature. Lysis was stopped by adding 10 ml 
of FACS buffer and then centrifuged at 320 rcf for 5 minutes at 4°C. Finally, the 
pellet was resuspended in FACS buffer.  
 
2.2.4 Mesenteric lymph nodes 
1-3 MLN were collected in ice-cold PBS and kept on ice until they were disrupted 
through a 70 µm cell straining with FACS buffer and then centrifuged at 320 rcf for 
5 minutes at 4°C. The pellet was resuspended in 5 ml of FACS buffer.  
 
2.2.5 Bone marrow  
Hind legs of each mouse were collected in ice-cold PBS and kept on ice. The femurs 
and tibias were flushed with FACS buffer using a 27G needle. The obtained cell 
suspension was passed through a 70 µm cell strainer with FACS buffer and then 
centrifuged as explained in 2.2.3. Red blood cell lysis was performed as described 
in 2.2.1.  
 
2.3 Staining for flow cytometry analysis 
For each organ 0.5-3 x 106 of cells were plated into a v-bottom 96-well cell plate 
(Termo Fisher – Cat. No 2605) and centrifuged at 320 rcf for 5 minutes at 4°C. For 
blocking non-specific binding sites, cells were resuspended and incubated for 15 
minutes on ice in 50 µl ice-cold FACS buffer containing anti-mouse CD16/32 
(fragment crystallisable) receptors (eBioscience – 14-0161-86) diluted 1:100 in 
FACS buffer. After, 50 µl of antibody master mix (2X) was added to each sample 
(Table 2.2) and incubated for 30 minutes on ice in the dark. Samples were washed 
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twice in FACS buffer, by centrifugation at 320 rcf for 5 minutes at 4°C. In order to 
visualise dead cells, 50 µl of Fixed Viability Dye (FVD) (eBioscience – Cat. No 65-
0863-18), diluted (1:250) in PBS, was added to each sample and incubated for 30 
minutes on ice in the dark. After 2 washes, samples were resuspended in 100 µl of 
FACS buffer and kept at 4°C until analysis by flow cytometry. Flow cytometry was 
performed using an LSRFortesa cell analyser (BD biosciences). Data were analysed 
using the FLowJo software (Tree Star, Oregon, USA). 
 
Table 2.2 List of the antibodies used for flow cytometry analysis 
Table describes conjugated antibodies, obtained from eBioscience and Biolegend, used for 
flow cytometric analysis listing the coupled fluorochrome, dilution, company and 
catalogue number for each antibody. APC: allophycocyanin, PE: Phycoerythirin, Pe-Cy7: 
Phycoerythirin-cyanine-7 and PerCP-Cy5.5: Peridinin-chlorophyll proteins- Cyanine-5.5. 
 
2.4 Immunofluorescence staining 
Tumour sections, obtained from frozen tumour samples, were air-dried for 30 
minutes. Slides were fixed in 4% PFA for 20 minutes at room temperature, washed 
in PBS and permeabilised with 0.1% Triton-X100 (Sigma-Aldrich T8787) in PBS for 
5 minutes at room temperature. Tumour sections were blocked with mouse 
background blocker (MenaPath MP-961) for 1 hour at room temperature. Sections 
were incubated with primary antibody, isotype control and/or conjugated 
antibody diluted in 5% goat serum and 2.5% BSA in PBS for 1 hour at room 
Marker Fluorochrome Dilution 1X Company Cat. N. 
CD45 Brilliant Violet 785 1:100 Biolegend 103149 
CD11b Brilliant Violet 650 1:100 Biolegend 101239 
Ly6G AlexaFlor700 1:100 eBioscence 56-5931 
Ly6C e-Flour650 1:100 eBioscence 48-5932 
F4/80 PE 1:100 Biolegend 123110 
CD3  Pe-Cy7 1:50 Biolegend 100320 
CD4 Brilliant Violet 605 1:200 Biolegend  100548 
CD8 APC 1:200 eBioscence 17-0081 
CD19 PerCP-Cy5.5 1:200 Biolegend 115534 
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temperature (Table 2.3). Sections were washed with PBS with 0.1% Tween-20 
(Sigma-Aldrich – P7949) (PBS-T) and, when stained with primary antibody, 
incubated with a goat anti-rabbit Alexa-546 secondary antibody (Invitrogen 
A21245) for 1 hour, diluted 1:1000, at room temperature in the absence of light. 
Sections were rinsed three times with PBS-T and once with water. 
 
The slides were mounted using Prolong Gold antifade reagent with 4’6-Diamidino-
2-Phenylindole (DAPI) (Invitrogen P36931). 
 
Table 2.3 List of the primary antibodies used for Immunofluorescence staining 
 Table describes primary antibodies used for immunofluorescence staining, detailing the 
coupled fluorochrome (when present), dilution used, purchaser and catalogue number for 
each antibody.  
 
 
2.5 Tumour protein extraction 
 For protein extraction, 75 mg of frozen tumour was homogenised in 1 ml of lysis 
buffer (150 nM NaCl (Sigma-Aldrich – 71380), 20 mM Tris pH 7.5 (Sigma-Aldrich – 
T1503), 1 mM EDTA, 1 mM EGTA (Invitrogen E4378), 1% Triton X-100 (Sigma-
Aldrich – X100) plus complete mini protease inhibitor cocktail tablet  (Roche                                                                                                                      
– 11836153001) and phosphatase inhibitors II and III (Sigma-Aldrich - P5726 and 
P0044, respectively). Samples were homogenised using a gentleMACS 
homogeniser. The homogenised tissue was centrifuged at 200 rcf for 5 minutes, 
transferred into an eppendorf tube and sonicated using probe solicitor at 40% 
amplitude for 5-15 seconds on ice. After rotating the samples for 30 minutes at 4°C 
on a rotator, tubes were centrifuged at 16100 rcf for 15 minutes at 4°C and 
supernatants collected.  
 
 
Antibody Conjugated Dilution Company Catalogue 
number 
F4/80 NO 1:300 Serotec MCA497R 
CX3CR1   NO 1:50 ABCAM AB8021 





1:1000 Invitrogen A21245 
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2.6 Protein Quantification 
Protein concentration was determined using the BCA protein assay. Working 
reagent was prepared by combining 50 parts of bicinchoninic acid solution (Sigma-
Aldrich – B6943) and 1 part of Copper (II) sulphate solution (Sigma-Aldrich - 
C2284). To create a standard curve, BSA was diluted in PBS to obtain a range of 
protein concentrations between 0 to 2 mg/ml. 10 μl of samples (diluted 1:10 in 
PBS) negative control or BSA standards were plated, in triplicate, in a 96-well plate 
with 200 μl of working reagent and incubated at 37°C for 30 minutes. The optical 
density was measured at 595 nm and the concentration of each sample was 
interpolated from the standard curve.  
 
2.7 Enzyme-linked immunosorbent assay (ELISA) 
ELISA kits from BD biosciences were used to measure the level of IL-12p40 (Cat. 
No 555165), IL-6 (Cat. No 555240), TNF-a (Cat. No 558354) and IL-10 (Cat. No  
555157). The assay was performed in 96-wells microplates from Costar (Cat. No 
3690), according to the manufacturer’s guidelines. Briefly, capture antibody was 
diluted 1:250 in PBS, added to each well and incubated overnight at 4°C. On the 
following day, the plate was washed three times in washing buffer (PBS with 0.05% 
of Tween-20). In order to block any specific binding, the assay diluent (PBS with 
10% FBS) was added to each well and incubated for 1 hour at room temperature.  
Then, standard solutions of each cytokine were prepared by serial dilution to 
obtain the following concentrations 1000, 500, 250, 125, 62.5 31.3 and 15.6 pg/mL. 
After discarding the assay diluent and washing three times the plate, samples and 
standards were added to each well and incubated for 2 hours at room temperature. 
The plate was then washed five times with washing buffer and subsequently the 
working detector solution [detection antibody and horseradish peroxidase (HRP)] 
was added to the plate and incubated for 1 hour at room temperature. At the end 
of the incubation, the plate was washed seven times and then substrate solution, 
tetramethylbenzidine (TMB) and hydrogen peroxide from the TMB substrate 
reagent set (BD Pharmagen, Cat. No 555214) were added and incubated in the 
absence of light until the appropriate colour change was observed. The reaction 
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was stopped by adding 25 ul of 1M of H3PO4 in each well. Plates were analysed on 
a plate reader at 450 nm.  
 
2.7.1 CX3CL1 ELISA 
To determine the presence and concentration of CX3CL1 I used the Mouse 
CX3CL1/Fractalkine Quantikine ELISA Kit (R&D system - MCX310). Briefly, tumour 
protein lysates and plasmas were allowed to thaw on ice. Tumour samples were 
diluted in calibrator diluent RD5-3, to obtain 85 μg of protein/sample, while 
plasma samples were diluted in 1:1 or 1:10. In each well, of a 96 well plate, 50 μl of 
Assay Diluent RD1W were added to 50 μl of standards, control, or samples. After 
two hours of incubation at room temperature, samples were washed 5 times in 
washing buffer. Then, 100 μl of mouse fractalkine conjugate was added to each well 
and incubated for two hours at room temperature. After 5 washes in washing 
buffer, 100 μl of substrate solution was added to each well and incubated for 30 
minutes at room temperature. Finally, 100 μl of stop solution was added to each 
well and the plate was read at 450 nm with wavelength correction, set to 540 nm.  
 
2.8 RNA extraction 
30 mg of tumour samples were homogenised in 600 μl of RLT buffer with 4% b- 
mercaptoethanol using a gentleMACS homogeniser. RNA was obtained using the 
RNeasy microkit (Qiagen - 74004) according to manufacturer guidelines. Briefly, 
each sample was centrifuged for 3 minutes at 13200 rcf, the supernatant was 
collected and pipetted directly into a QIAshredder spin column placed in a 2 ml 
collection tube, and centrifuged for 2 minutes 16100 rcf for 3 minutes at 4°C. After 
collecting the supernatant, equal volume of 70% ethanol was added and sample 
transferred to an RNA binding column placed in a 2 ml collection tube, centrifuged 
20 seconds at 9300 rcf and flow-through discarded. Then, 350 μl of RW1 buffer was 
added, and tubes centrifuged for 20 seconds at 9300 rcf and the flow-through was 
discarded. Next, 80 μl of RDD buffer DNAse solution (70 μl of RDD buffer with 10 
μl of DNase) was added and incubated for 10 minutes. After, 350 μl of RW1 buffer 
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was added and the column centrifuged for 20 seconds at 9300 rcf and flow-through 
was discarded. Then, 500 μl of RPE buffer was added and columns were 
centrifuged for 20 seconds at 9300 rcf and the flow-through discarded. Finally, a 
washing step with 500 μl of 80% EtOH was performed and columns were 
centrifuged for 2 minutes at 9300 rcf, and the flow-through placed in a new 2 ml 
tube and centrifuged for 5 minutes at 16100 rcf.  
RNA was eluted by transferring the column into a 1.5 ml tube and adding 14 μL of 
H2O directly onto the membrane. The flow through was collected after 
centrifugation of 1 minute at 16100 rcf. Total amount and quality of RNA was 
determined for each sample using a Nanodrop D- UB-Vis spectrophotometer 
(Termo Scientific). 
  
2.9 Complementary DNA (cDNA) synthesis 
Single stranded cDNA was synthesised from mRNA using a commercial high-
capacity cDNA reverse transcription kit (Life Sciences Solutions, Cat: 4368813). 
For each sample reaction a 2x reverse transcription (RT) master mix was prepared 
containing 2 µl 10x RT buffer, 0.8 µl 25x dNTP mix (100mM), 2 µl 10x RT random 
primers, 1 µl MultiScribeTM reverse transcriptase, and 4.2 µl nuclease-free H2O. In 
a 96-well reaction plate 12 µl of RNA samples, diluted in nuclease-free H2O to 
contain equal amounts of RNA, were added to wells containing 8 µl of 2X RT master 
mix and mixed by pipetting. The reaction plate was sealed using an adhesive film 
and centrifuged at 1500 rpm for 1 minute to remove air bubbles. qRT-PCRs were 
performed using a thermal cycler (BIO-RAD, Model#: T100, Cat#: 186-1096), 
program conditions below (Table 2.4).  
 
 Step 1 Step 2 Step 3 Step 4 
Temperature (°C) 25 37 85 4 
Time 10 120 5 ∞ 
Table 2.4 cDNA synthesis program 
A table displaying the information used to perform reverse transcription on a thermal 
cycler. For each step of the reaction the temperature and duration is given. 
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2.10 Quantitative reverse transcriptome 
polymerase chain reaction (qRT-PCR) 
 
Synthesised single strand cDNA products were diluted (1:50) with nuclease-free 
H2O. A qRT-PCR reaction master mix was prepared for each gene of interest 
containing 10 µl iTaqTM universal probes supermix (2X qRT-PCR master mix) (BIO-
RAD, Cat: 172-5135), 1 µl 20X target gene FAM labelled TaqMan gene expression 
assay (Life Sciences Solutions, Cat: See Table 4). In a 96-well reaction plate, 11 µl 
of qRT-PCR reaction master mix was added to 9 µl of diluted cDNA. The reaction 
plate was sealed using an adhesive film and centrifuged at 500 rcf for 1 minute to 
remove air bubbles. qRT-PCRs were performed using a Real-Time PCR system (Life 
Sciences Solutions, Model: StepOnePlusTM, Cat: 4376600).  
 
Gene Company Cat number 
Cx3cr1 Applied biosystem Mm00438354_m1 
Cx3cl1 Applied biosystem Mm00436454_m1 
Csf1 Applied biosystem Mm00432686_m1 
Ccl2 Applied biosystem Mm00441242_m1 
Csf1R Applied biosystem Mm01266652_m1 
TNF-α Applied biosystem Mm00443258_m1 
IL-1b Applied biosystem Mm00434228_m1 
3.12IL-6 Applied biosystem Mm00446190_m1 
IFN-γ Applied biosystem Mm99999071_m1 
IL-10 Applied biosystem Mm00439616_m1 
IL-12a Applied biosystem Mm00434169_m1 
Nos2 Applied biosystem Mm01309898_m1 
Mrc1 Applied biosystem Mm01329362_m1 
Arg1 Applied biosystem Mm00475991_m1 
Table 2.5 List of primer for qRT-PCR 
Table describing the primers used for qRT-PCR including company and catalogue number.  
 
 72 
2.11 Gemcitabine treatment 
Mice were recruited when tumours were palpable.  Gemcitabine were obtained 
from Fresenius Kabi and diluted PBS (SIGMA - D8537). Mice were treated with 
gemcitabine, which was injected intra-peritoneal twice a week during two weeks 
at 100mg/kg. Mice where daily monitored and body weighed recorded twice a 
week. After two weeks of treatment with gemcitabine mice were sacrificed and 
pancreatic tumours harvested for analysis.  
  
2.12 RNA sequencing and analysis 
Pancreatic tumour samples from 6 CKPC mice were used for RNA extraction and 
sequencing (RNA-Seq). RNA extraction was performed as described in 2.8 and RNA 
quality assessment was carried out using the Agilent RNA 6000 Nano chip (Agilent 
Technology – Cat. No 5067-1511).  In briefly, the nano dye (1:65) was added to an 
aliquot of filtered gel. The gel/dye mix was spun for 10 minutes at room 
temperature at 13,000 rcf and then allowed to equilibrate at room temperature for 
30 minutes. The gel was then dispensed into the RNA nano chip. 5 µl pico marker, 
1 µl pico ladder and 1 µl of each sample were dispensed into the appropriate wells 
of the chip. After 1 minute the chip was inserted into the Agilent 2100 Bioanalizer. 
The 2100 expert software was used to calculate RNA concentration and RNA 
integrity number (RIN) for each sample.  
 
RNA sequencing was performed by the Wellcome Trust Centre for Human Genetics 
(University of Oxford, UK) on rRNA depleted samples to ~40x mean depth, on the 
Illumina HiSeq4000 platform, generating 150bp paired-end reads. RNA-Seq reads 
were mapped to the mouse genome (mm10, Genome Reference Consortium 
GRCm38) using hisat2 in strand-specific mode. The number of reads aligning to the 
exonic region of each gene were counted using htseq-count based on Ensembl 
annotation.  Only genes that achieved at least one read count per million reads 
(CPM) in at least 25% of the samples were kept. X-Y genes were excluded. 
Conditional quantile normalisation (cqn) was performed counting for gene length 
and gc content and a log2 transformed RPKM expression matrix was generated.  
 73 
 
Differential expression was performed in R using the edgeR package (version 3.8.6) 
(Robinson, McCarthy et al. 2010). The generalised linear model (GLM) approach 
was used for the differential analysis (McCarthy, Chen et al. 2012). Adjusted p-
values were calculated using the Benjamini-Hochberg method. Principal 
component analysis (PCA), volcano plots and heatmaps of differentially expressed 
genes were plotted using R in-built functions and ggplot2 (version 1.0.1) (Wickham 
2009). Conversion of ensemble gene IDs to HUGO gene nomenclature (hgnc) was 
carried out using biomaRt (version 2.22.0) (Durinck, Moreau et al. 2005, Thurber, 
Haynes et al. 2009). Classification of protein-coding genes was performed using the 























To study the role of CX3CR1 in pancreatic cancer I used a mouse model obtained 
by crossing the GFP-CX3CR1 mouse, which expresses GFP under control of the 
endogenous CX3CR1 locus, with the KPC mouse.  The result of the crossing is a 
mouse with the genotype CX3CR1GFP/GFPLSL-KRASG12D/+LSLTrp53R172H/+Pdx1-Cre. 
This was named the CKPC mouse model. In these mice the CX3CR1 protein was 
absent as they expressed eGFP instead of CX3CR1. This allowed the identification 
of cell types that would usually express CX3CR1. 
 
3.2 Characterisation of the CX3CR1GFP/GFP mouse 
model 
The GFP-CX3CR1 mouse model was first established by S Jung (S. Jung et al. 2000). 
In this study, they reported that mice lacking CX3CR1 had no evidence of 
developmental defects. Moreover, they showed that none of the green-fluorescent 
cell populations were impaired in the comparison between CX3CR1+/GFP and 
CX3CR1GFP/GFP mice. Despite these results, I decided to compare the distribution of 
leukocytes in CX3CR1GFP/GFP and wild-type (WT) age-matched littermate control 
mice using the mice that I had generated. 
 
Blood, spleen, bone marrow, pancreas and mesenteric lymph nodes (MLN) were 
analysed by flow cytometry. Single cell suspensions from each tissue were stained 
with fluorescence antibodies against markers able to discriminate between 
myeloid and lymphoid cell populations. These markers are shown in Table 3.1. A 
fixable viability dye (FVD) was added in the antibody pool to eliminate dead cells 









Immune cell subsets Phenotype markers Tissues analysed 
Leukocytes  CD45+ Pancreas, spleen, blood, 
bone marrow and MLN  
Myeloid cells CD45+CD11b+ Spleen, blood, bone 





Spleen, blood, bone 
marrow 
Granulocytes CD45+CD11b+Ly6G+LY6C+ Spleen, blood, bone 
marrow 
Macrophages CD45+Ly6G-LY6C-F4/80+ Spleen and bone 
marrow 
B cells CD45+CD11b-CD3-CD19+ Spleen, blood, bone 
marrow and MLN 
CD4+ T cells CD45+CD11b-CD19-
CD3+CD4+ 
Spleen, blood, bone 
marrow and MLN 
CD8+ T cells  CD45+CD11b-CD19-
CD3+CD8+ 
Spleen, blood, bone 
marrow and MLN 
Table 3.1 Cell surface markers used to identify different cell populations by flow 
cytometry 
Single cell suspensions from each tissue were stained with a pool of antibodies for the 
markers listed in the table and quantified by flow cytometry analysis.  
 
3.2.1 Leukocyte cells in the pancreas of wild type and 
CX3CR1GFP/GFP mice 
The pancreas has both endocrine (islets of Langerhans) and exocrine (acinar and 
ductal cells) functions. The exocrine pancreas is involved in the production and 
secretion of digestive enzymes and pancreatic juice into the small intestine, 
whereas the endocrine pancreas is responsible for producing hormones crucial for 
glucose homeostasis and metabolism (Cleveland, Sawyer et al. 2012). 
 
The presence of immune cells in the pancreas was assessed by flow cytometry 




Figure 3.1 Representative gating strategies for the resident immune cells in the 
pancreas by flow cytometry  
Single cell suspensions from the pancreas were stained with a pool of fluorescence-
conjugated antibodies and analysed by flow cytometry. Acquired cells were gated to 
eliminate (A) debris, (B) doublets and (C) dead cells to obtain (D) CD45+ cells.  
 
Leukocytes, defined as CD45+ cells, represented less than 5% of viable cells in the 
pancreas. There was no significant difference in the leukocytes wild-type and 











Figure 3.2 Frequency of leukocytes populations in the pancreas 
Flow cytometric analysis of leukocytes from the pancreas of wild-type (WT) and 
CX3CR1GFP/GFP (KO) mice. Values for individual mice are shown as dots and a horizontal 
line represents mean of the values. Statistical significance was determined by unpaired t-
test. N = 4 per group. ns: not significant.  
 
3.2.2 Leukocyte subsets in the spleen of wild-type and 
CX3CR1GFP/GFP mice 
The spleen is the largest secondary lymphoid organ; it acts primarily as a blood 
filter. It holds a reserve of blood, which can be valuable in case of hemorrhagic 
shock. The spleen is involved in the immune response by detecting foreign particles 
and pathogens, such as bacteria, and producing white blood cells in response. 
Interestingly the spleen contains about one-fourth of the body’s lymphocytes.  
It also removes old red blood cells and platelets and also recycles iron (Mebius and 
Kraal 2005).  
 























Figure 3.3 Representative gating strategy for leukocyte subsets in the spleen by flow 
cytometry 
Total spleen single cell suspensions were stained with a pool of fluorescence-conjugated 
antibodies and analysed by flow cytometry. Acquired cells were gated to eliminate (A) 
debris, (B) doublets and (C) dead cells to obtain (D) CD45+ cells. CD45+ cells were analysed 
for the expression of (E) F4/80 and CD11b allowing to distinguish between different cell 
populations. CD11b+ cells were analysed in (F) for the expression of Ly6C and Ly6G. 
Lymphoid cells were analysed in (G) for the expression of CD19 and CD3. (H) CD3+ cells 
were further analysed for the expression of CD4 and CD8. 
 
In the spleen, CD45+ cells constituted more than 90% of viable cells (Figure 3.4A), 
of which around 75% consisted of lymphocytes whilst about 15% were myeloid 
cells.  
 
Flow cytometric analysis of splenic myeloid cells revealed no significant difference 
in F4/80+ macrophages (Figure 3.4B), Ly6C+Ly6G+ granulocytes (Figure 3.4C) and 
Ly6chigh monocytes (Figure 3.4D) between wild-type mice and CX3CR1GFP/GFP mice.  
 80 
 
Figure 3.4 Frequency of myeloid cells in the spleen from wild type and CX3CR1GFP/GFP 
mice 
Flow cytometric analysis of leukocytes from spleen of wild-type (WT) and CX3CR1GFP/GFP 
(KO) mice. (A) Percentages of total CD45+ cells (B) F4/80+ macrophages, (C) Ly6C+Ly6G+ 
granulocytes and (D) Ly6Chigh monocytes. Values for individual mice are shown as dots and 
a horizontal line represents mean of the values. Statistical analysis was determined by 
unpaired t-test. N = 4 per group. ns: not significant. 
 
Flow cytometric analysis showed also no significant difference in CD19+ B cells 
between wild-type and CX3CR1GFP/GFP mice (Figure 3.5A). 
 
The percentage of CD3+ T lymphocytes was decreased, but was not significantly 
different; in CX3CR1GFP/GFP mice compared wild-type mice (Figure 3.5B). Analysis 
of CD3+ T cell subsets revealed that the CD4+ T cells (Figure 3.5C) and CD8+ T cells 
distribution (Figure 3.5D) was not significantly different in in CX3CR1GFP/GFP mice 












































































Figure 3.5 Frequency of lymphoid cells in the spleen from wild type and 
CX3CR1GFP/GFP mice 
Flow cytometric analysis of leukocytes from spleen of wild-type (WT) and CX3CR1GFP/GFP 
(KO) mice. (A) Percentages of CD19+ cells, (B) CD3+ cells, (C) CD4+ cells and (D) CD8+ cells. 
Values for individual mice are shown as dots and a horizontal line represents mean of the 
values. Statistical analysis was determined by unpaired t-test. N = 4 per group. ns: not 
significant. 
 
3.2.3 Leukocyte subsets in the blood of wild type and 
CX3CR1GFP/GFP mice 
Immune cells circulate in the blood, through the body, monitoring the presence of 
pathogens and foreign substances.  
 
Figure 3.6 shows the gating strategy used to investigate the leukocyte populations 













































































Figure 3.6 Representative gating strategy for the leukocytes subsets in the blood by 
flow cytometry 
Single cell suspensions of peripheral blood leukocytes were stained with a pool of 
fluorescence-conjugated antibodies and analysed by flow cytometry. Acquired cells were 
gated to eliminate (A) debris, (B) doublets and (C) dead cells to obtain (D) CD45+ cells. 
CD45+ cells were discriminated between myeloid and lymphoid subset by the expression 
of (E) CD11b. Myeloid cells were analysed in (F) for the expression of Ly6C and Ly6G. 
Lymphoid cells were analysed in (G) for the expression of CD19 and CD3. (H) CD3+ cells 
were further analysed for the expression of CD4 and CD8. 
 
 
Flow cytometric analysis showed no difference in the amount of CD45+ cells 
between wild-type and CX3CR1GFP/GFP mice (Figure 3.7A). CD11b+ myeloid cells 
represented approximately 30% of leukocytes in both groups (Figure 3.7B). 
Ly6Chigh monocytes (Figure 3.7D) and Ly6C+Ly6G+ granulocytes (Figure 3.7C) 
showed no difference between groups. 
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Figure 3.7 Frequency of myeloid cells in the blood of wild type and CX3CR1GFP/GFP 
mice 
Flow cytometric analysis of leukocytes from peripheral blood of wild-type (WT) and 
CX3CR1GFP/GFP (KO) mice. (A) Percentages of total CD45+ cells (B) CD11b+ myeloid cells, (C) 
Ly6C+Ly6G+ granulocytes and (D) Ly6Chigh monocytes. Values for individual mice are 
shown as dots and a horizontal line represents mean of the values. Statistical analysis was 
determined by unpaired t-test. N = 4 per group. ns: not significant. 
 
CD19+ B cells were the most abundant cells in the blood, approximately 50% in 
both CX3CR1GFP/GFP and wild type mice (Figure 3.8A). The percentage of CD3+ T 
lymphocytes (Figure 3.8B) and the distribution between CD4+ T cells (Figure 3.8C) 


















































































Figure 3.8 Frequency of lymphoid cells in the peripheral blood of wild type and 
CX3CR1GFP/GFP mice 
Flow cytometric analysis of leukocytes from peripheral blood of wild-type (WT) and 
CX3CR1GFP/GFP (KO) mice. (A) Percentages of CD19+ cells, (B) CD3+ cells, (C) CD4+ cells and 
(D) CD8+ cells. Values for individual mice are shown as dots and a horizontal line 
represents mean of the values. Statistical analysis was determined by unpaired t-test. N = 
4 per group. ns: not significant. 
 
 
3.2.4 Leukocyte subsets in MSL of wild type and CX3CR1GFP/GFP 
mice 
The lymph nodes are small bean shaped secondary lymphoid organs. They are 
present widely throughout the body and linked by lymphatic vessels. Lymph nodes 
act as filters that screen for foreign substances and antigens and are essential for 
the interactions between antigen presenting cells and lymphocytes (Girard, 
Moussion et al. 2012). Mesenteric lymph nodes, MLN, are lymph nodes that are 
located in the walls of the intestines and stomach, between the layers of the 











































































state conditions but quickly enlarges in response to infection with intestinal 
pathogens. 
 
Figure 3.9 Representative gating strategy for the leukocytes in the MLN by flow 
cytometry 
Total MLN single cell suspensions were stained with a pool of fluorescence-conjugated 
antibodies and analysed by flow cytometry. Acquired cells were gated to eliminate (A) 
debris, (B) doublets and (C) dead cells to obtain (D) CD45+ cells. CD45+ cells were analysed 
for the expression of (E) F4/80 and CD11b allowing discrimination between myeloid and 
lymphoid subsets. Lymphoid cells were analysed in (F) for the expression of CD19 and 
CD3. (G) CD3+ cells were further analysed for the expression of CD4 and CD8. 
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Figure 3.10 Frequency of leukocytes cells in the MLN of wild type and CX3CR1GFP/GFP 
mice 
Flow cytometric analysis of leukocytes from MLN of wild-type (WT) and CX3CR1GFP/GFP 
(KO) mice. (A) Percentage of total viable CD45+ cells, (B) CD11b+ myeloid cells, (C) CD19+ 
cells, (D) CD3+ cells, (E) CD4+ cells and (F) CD8+ cells. Values for individual mice are shown 
as dots and a horizontal line represents mean of the values. Statistical analysis was 
determined by unpaired t-test. N = 4 per group. ns: not significant. 
 
MLN analysis by flow cytometry (gating strategy illustrated in Figure 3.9) showed 
no difference in the percentage of CD45+ cells between wild-type and 
CX3CR1GFP/GFP mice (Figure 3.10A). CD11b+ myeloid cells were hardly present in 
lymph nodes, less than 3% in both groups (Figure 3.10B). 
 
Lymphocytes constituted approximately 90% of CD45+ cells, of which 60% were 
CD3+ T cells (Figure 3.10D), and 30% were CD19+ B cells (Figure 3.10C) in both 
wild-type and CX3CR1GFP/GFP mice. Percentages of CD3+ T cell subsets showed no 



















































































































3.2.5 Leukocyte subsets in the bone marrow of wild type and 
CX3CR1GFP/GFP mice 
Bone marrow is a tissue in the interior of bones and it is the site haematopoiesis, 
where all blood cells are generated and differentiated from progenitor cells 
(Gurkan and Akkus 2008). 
 
Figure 3.9 shows the gating strategy used for the flow cytometry analysis of bone 
marrow.  
 
Figure 3.11 Representative gating strategy for the leukocyte subsets in the bone 
marrow by flow cytometry 
Total bone marrow single cell suspensions were stained with a pool of fluorescence-
conjugated antibody antibodies and analysed by flow cytometry. Acquired cells were gate 
to eliminate (A) debris, (B) doublets and (C) dead cells to obtain (D) CD45+ cells. CD45+ 
cells were analysed for the expression of (E) CD11b allowing discrimination between 
myeloid and lymphoid subsets. CD11b+ cells were analysed in (F) for the expression of 
Ly6C and Ly6G and (G) F4/80. CD11b- lymphoid cells were analysed in (H) for the 
expression of CD19 and CD3. (I) CD3+ cells were further analysed for the expression of CD4 
and CD8. 
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CD45+ cells showed no difference between wild-type and CX3CR1GFP/GFP mice 
(Figure 3.12A). Myeloid cells accounted about 37% of CD45+ cells (Figure 3.10B). 
Ly6C+Ly6G+ cells were present in the same proportions in both KPC and CKPC mice, 
comprising approximately 28% of the CD45+ population (Figure 3.12C). These cells 
in the bone marrow identify a subset of immature precursor cells that can give 
origin to monocytes, macrophages, granulocytes and dendritic cells (Kusmartsev, 
Nagaraj et al. 2005). Ly6Chigh monocytes and F4/80+ macrophages were present at 




Figure 3.12 Frequency of myeloid cell subsets in the bone marrow of wild type and 
CX3CR1GFP/GFP mice 
Flow cytometric analysis of leukocytes from peripheral blood of wild-type (WT) and 
CX3CR1GFP/GFP (KO) mice. (A) Percentage of total CD45+ cells (B) CD11b+ myeloid cells, (C) 
Ly6C+Ly6G+ myeloid cells, (D) Ly6Chigh monocytes and (E) F4/80+ macrophages. Values for 
individual mice are shown as dots and a horizontal line represents mean of the values. 
Statistical analysis was determined by unpaired t-test. WT N = 4 KO, N = 3. ns: not 
significant. 
 
Analysis of the lymphocytic subsets revealed no significant difference in CD19+ B 
cells (Figure 3.13A) and CD3+ T cells (Figure 3.13B), between wild-type and 
CX3CR1GFP/GFP mice.  The CD3+, CD4+ T cells (Figure 3.13C) and CD8+ T cells (Figure 











































































































Figure 3.13 Frequency of lymphoid cells in the bone marrow of wild type and 
CX3CR1GFP/GFP mice 
Flow cytometric analysis of lymphocytes from bone marrow of wild-type (WT) and 
CX3CR1GFP/GFP (KO) mice. (A) Percentages of CD19+ cells, (B) CD3+ cells, (C) CD4+ cells and 
(D) CD8+ cells. Values for individual mice are shown as dots and a horizontal line 
represents mean of the values Statistical analysis was determined by unpaired t-test. WT 
N = 4, KO N = 3. ns: not significant. 
 
 
In summary, my analysis of the distribution of leukocytes in CX3CR1GFP/GFP mice 
compared to wild-type control mice showed that the lack of CX3CR1 did not cause 
any significant difference in the myeloid and lymphoid cell subsets analysed. 

















































































3.2.6 GFP expression in leukocyte populations of CX3CR1GFP/GFP 
mice  
As the CX3CR1GFP/GFP mice express GFP instead of functional CX3CR1 protein, I was 
able to identify the cells which would express CX3CR1 in wild-type conditions. I 
quantified the expression of GFP in CX3CR1GFP/GFP mice in different leukocyte 
populations by flow cytometry.  
 
The expression of GFP-CX3CR1 in myeloid and lymphoid cell populations was 
investigated in spleen, blood, mesenchymal lymph nodes and bone marrow. The 
values of geometrical mean intensity of GFP are expressed in Figure 3.14. 
 
Analysis of the level of GFP-CX3CR1 showed that myeloid and lymphoid cells 
differed in its expression. In fact, myeloid cells expressed a higher level of GFP-
CX3CR1 compared to lymphoid cells. 
 
As shown in Figure 3.14, CD19+ B cells had the lowest level of GFP-CX3CR1 in all 
the tissues analysed. CD4+ and CD8+ T cells expressed the same level of GFP-
CX3CR1 in the spleen (Figure 3.14B), MLN (Figure 3.14C) and bone marrow (figure 
3.14D), while in the blood (Figure 3.14A) CD4+ T cells showed higher GFP-CX3CR1 
amount compared CD8+ T cells.  
 
Interestingly, each myeloid cell subset expressed different levels of GFP-CX3CR1 in 
each tissue. In blood (Figure 3.14A) and spleen (Figure 3.14B) the highest levels of 
GFP-CX3CR1 were expressed by Ly6Chigh monocytes followed by F4/80+ 
macrophages. In contrast, in the bone marrow (Figure 3.14D) the highest level of 
GFP-CX3CR1 was expressed by F4/80+ macrophages and then Ly6Chigh monocytes. 
Finally, granulocytes expressed lower levels of GFP-CX3CR1 compared the other 
myeloid cell subsets in all the tissues analysed (Figure 3.14).  
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Figure 3.14 GFP expression in leukocyte populations in the spleen, blood, 
mesenteric lymph nodes and bone marrow  
GFP expression was determined by flow cytometry and quantified as geometrical mean 
intensity of GFP. Leukocytes were gated as described in chapter 3.1.2. GFP intensity were 
analysed in (A) spleen, (B) blood, (C) mesenteric lymph nodes and (D) bone marrow. 
Values for individual mice are shown as dots and a horizontal line represents mean of the 
values. 
 
In summary, the analysis of GFP levels in the CX3CR1GFP/GFP mice showed that it 
was expressed predominantly by myeloid cells. However, not all the myeloid 
subsets expressed GFP at the same amount. In fact, while both Ly6Chigh monocytes 
and F4/80+ macrophages expressed high levels of GFP, Ly6C+Ly6G+ granulocytes 
expressed levels of GFP comparable with the lymphoid cell populations.  
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3.3 Characterization of the CX3CR1GFP/GFP-KPC 
(CKPC) mouse model 
The GFP-CX3CR1 mice were crossed with KPC mice to obtain CX3CR1GFP/GFPLSL-
KRASG12D/+LSLTrp53R172H/+Pdx1-Cre (CKPC) mice. In order to assess if these mice 
expressed GFP in tumour cells, immunofluorescence was performed on malignant 
pancreas tissue. Sections of CKPC (Figure 3.14A) and KPC (Figure 3.14B) pancreas 
were stained for GFP, E-cadherin and DAPI. The GFP expression was observed only in 
the CKPC mice but not in the KPC mice. Moreover, I observed that the E-cadherin 
positive cells co-expressed eGFP, further confirming that the pancreatic tumour cells 
express GFP-CX3CR1, in CKPC as described in Figure 3.14A. 
 
Figure 3.15 Immunofluorescence for GFP in pancreas tissue 
Frozen 7 μm sections of CKPC and KPC pancreatic tissue were stained for GFP and E-
cadherin. DAPI was used as a nuclear marker. Rabbit IgG and rat IgG1 isotype controls 
were stained on CKPC pancreas tissue. Images were taken on a LSM710 microscope at 40X 
magnification. Representative image for N=3 per group and isotype n=1. 
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3.3.1 GFP expression in tumour and leukocyte populations of 
CKPC mice  
The CKPC mice, as the CX3CR1GFP/GFP mice, express GFP instead of a functional 
CX3CR1 protein, allowing the identification of cell populations which would 
express CX3CR1.  
 
CKPC mice were analysed not only to identify which cells express GFP-CX3CR1, but 
also to quantify its level of expression in different leukocyte subsets.  
 
The expression of GFP-CX3CR1 in myeloid and lymphoid cell populations was 
investigated in tumour, blood, spleen, MLN and bone marrow. The values of GFP 
geometrical mean intensity are shown in Figure 3.16. 
 
As in the CX3CR1GFP/GFP mice (Figure 3.14), GFP-CX3CR1 levels were different in 
myeloid and lymphoid cell populations. In particular, myeloid cells expressed 
higher levels of GFP-CX3CR1 as compared to lymphoid cells. 
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Figure 3.16 GFP expression in leukocyte populations in the tumour, spleen, blood, 
mesenchymal lymph nodes and bone marrow of CKPC mice  
GFP expression was determined by flow cytometry and quantified as geometrical mean 
intensity of GFP. Leukocytes were stained as described in chapter 3.1.2. GFP intensity were 
analysed in (A) tumour, (B) spleen, (C) blood, (D) mesenchymal lymph nodes and (E) bone 
marrow. Values for individual mice are shown as dots and a horizontal line represents 






























































































































































































































































































































Figure 3.16 showed that CD19+ B cells had the lowest level of GFP-CX3CR1 in all 
the tissues analysed. 
 
CD4+ and CD8+ T cells expressed the same level of GFP-CX3CR1 in the tumour 
(Figure 3.16A), MLN (Figure 3.16D), while in the blood (Figure 3.16B), spleen 
(Figure 3.16C) and bone marrow (Figure 3.14E) CD4+ T cells showed higher GFP-
CX3CR1 amount compared CD8+ T cells.  
 
Interestingly, as observed in CX3CR1GFP/GFP mice, each myeloid cell subset expressed 
different levels of GFP-CX3CR1. In blood (Figure 3.16B), spleen (Figure 3.14C) and 
bone marrow (Figure 3.16E) the highest levels of GFP-CX3CR1 were expressed by 
Ly6Chigh monocytes, followed by F4/80+ macrophages. In the tumour (Figure 
3.16A) the highest level of GFP-CX3CR1 was expressed by F4/80+ macrophages and 
then Ly6Chigh monocytes. Finally, granulocytes expressed lower level of GFP-
CX3CR1 compared the others myeloid cells subsets in all the tissues analysed 
(Figure 3.16).  
 
The analysis on the GFP levels in the CKPC mice was similar to CX3CR1GFP/GFP mice. 
In fact, in both mice myeloid cells express more GFP in all the organs analysed. 
Moreover, in both models Ly6Chigh monocytes were the cells expressing higher GFP 
level in the blood and spleen, whilst in Ly6C+Ly6G+ granulocytes GFP was 
expressed at low levels in all organs analysed, where the GFP level was comparable 
with what observed in the lymphoid cell subsets. 
 
3.4 Discussion 
Chemokines and their receptors mediate a variety of functional activities in several 
immunological processes, such as chemotaxis and haematopoiesis. In cancer they 
have been implicated in regulation of angiogenesis, metastasis and recruitment of 
immune cells (Raman, Sobolik-Delmaire et al. 2011).  The chemokine receptors 
CX3CR1 and its unique ligand CX3CL1 are known to modulate the migration of 
leukocytes under physiological and pathological conditions. In my study I have 
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investigated the effects of CX3CR1 on immune cell trafficking and tumour cell 
growth in pancreatic cancer.  
 
As mentioned above, chemokine receptors are involve in chemotaxis of immune 
cells also in steady state condition, for this reason I investigated if the lack of 
CX3CR1 has an effect in the immune cells profile of different lymphoid organs. I 
analysed different subset of myeloid and lymphoid cells in blood, spleen, bone 
marrow and MLN and I observed no significant difference when I compared the 
CX3CR1GFP/GFP and wild-type mice. These results are in agreement with the results 
of S. Jung et al. when they established the CX3CR1GFP/GFP mice model (Jung, Aliberti 
et al. 2000).  
 
In some experiments in this chapter the number of mice analysed in each group 
was just three, the minimum sample size to perform statistical analysis. However, 
our results, which showed no difference in the percentages immune cell 
populations between CX3CR1GFP/GFP and WT mice, are consistent with was 
already published by S. Jung (Jung, Aliberti et al. 2000). 
 
After I analysed the leukocyte profiles in the CX3CR1GFP/GFP mice in steady state 
conditions I crossed them with the KPC mice. First, I confirmed that the CKPC mice, 
but not KPC mice, express GFP. Then I looked at the GFP levels in the leukocytes 
populations in the different lymphoid organs. Interestingly, in both CX3CR1GFP/GFP 
and CKPC mice the GFP levels were comparable when looked at the same organ.  
 
3.5 Summary  
 No difference in myeloid and lymphoid population in the pancreas, blood, 
spleen, mesenteric lymph nodes and bone marrow between CX3CR1GFP/GFP 
and CX3CR1+/+ mice 
  Myeloid cells express highest levels of GFP-CX3CR1 compared to lymphoid 
cells in CX3CR1GFP/GFP mice tumours 
 Myeloid cells express highest level of GFP-CX3CR1 compared to lymphoid 
cells in CKPC mice  
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3.6 Conclusion  
In this chapter, I characterised the CX3CR1GFP/GFP mice model looking at the 
leukocyte composition in the pancreas, blood, spleen, mesenchymal lymph nodes 
and bone marrow. I also looked at the level of GFP expression by these cells in both 
the CX3CR1GFP/GFP and CKPC mice. These results will allow a better understanding 
of the role of CX3CR1 in the tumour microenvironment of KPC and CKPC mouse 

















































Several studies have reported an up-regulation of CX3CR1 in different cancers, 
such as prostate (Shulby, Dolloff et al. 2004, Jamieson, Shimizu et al. 2008), breast 
(Andre, Cabioglu et al. 2006, Jamieson-Gladney, Zhang et al. 2011) and pancreatic 
(Marchesi, Piemonti et al. 2008, Celesti, Di Caro et al. 2013). In pancreatic cancer 
CX3CR1 expression is associated with increased migration and metastasis 
formation (Marchesi, Piemonti et al. 2008, Marchesi, Locatelli et al. 2010). CX3CR1 
is highly expressed in both human pancreatic tumour cell lines and in primary 
PDAC tumour tissues, whilst ‘benign’ epithelial pancreatic duct cell lines and 
‘normal’ exocrine pancreas do not express the receptor (Marchesi, Piemonti et al. 
2008). 
 
The chemokine receptor, CX3CR1 forms a high-affinity axis with its unique ligand 
CX3CL1 and is expressed on monocytes, macrophages and T cells. CX3CR1 is also 
present on pancreatic malignant cells, where it has been associated with metastasis 
formation. 
 
The KPC (LoxP-Stop-LoxP-K-rasG12D/+;LSL-Trp53R172H/+;Pdx-1-Cre) mouse model 
is the most commonly used mouse model for pancreatic cancer. The KPC mouse 
recapitulates the pathological, histological, genomic and clinical signatures of 
human pancreatic cancer (Hingorani, Wang et al. 2005) with some of the critical 
genetic mutations involved in human pancreatic cancers (Herreros-Villanueva, 
Hijona et al. 2012, Westphalen and Olive 2012). As described in Chapter 3, the KPC 
genetic mouse model of pancreatic cancer was crossed to the CX3CR1GFP/GFP mice 
to make the CKPC mice to investigate if genetic loss of CX3CR1 affects PDAC 
formation, development and the TME composition.  
 
In this chapter I aim to investigate if genetic loss of CX3CR1 affects PDAC formation 
and progression in the KPC mouse model. In particular, I will examine if loss of 
CX3CR1 expression affects cells of the tumour microenvironment.  
 100 
4.2 Lack of CX3CR1 does not affect mouse survival 
in the KPC model  
In order to evaluate the role played by CX3CR1 in pancreatic cancer, the survival 
rates of KPC mice and CKPC mice were compared. All mice included in the 
experiment developed pancreatic cancer (Figure 4.1A 4.1B). Most of the mice 
showed macro-metastasis in the peritoneum and in the liver (Figure 4.1C).   
 
Figure 4.1 CKPC pancreatic tumour and metastasis 
Representative images from a CKPC mouse at tumour end-point stage. Mice at end point 
stage were scarified and autopsy was performed. Images show the A) peritoneum cavity 
with pancreatic tumour (arrow) B) pancreatic tumour and C) liver metastasizes (arrows).  
 
Overall survival was statistically indistinguishable between KPC and CKPC mice 
(data collection with the help of Dr Juliana Candido). The median lifespan of mice 




























Figure 4.2 Survival of KPC and CKPC mice 
Loss of CX3CR1 did not affect survival of mice which develop pancreatic tumours. Kaplan–
Meier analysis of survival of KPC and CKPC mice monitored until they reached the end 
point.  N=52 KPC mice, N=22 CKPC mice. Statistical significance was determined by Log-
Rank test.  
 
4.3 CX3CR1 and CXC31 expression in KPC and CKPC 
Next, I investigate how the loss of CX3CR1 affects various aspect of the TME. In 
these experiments, tumours were collected when mice reached the end point stage, 
unless otherwise specified. 
 
First of all, I looked at the expression of CX3CR1 at mRNA level and its ligand 
CX3CL1, both at mRNA and protein level, in the tumour and in the blood of KPC and 
CKPC mice.  
 
4.3.1 mRNA levels of Cx3cr1 and Cx3cl1 in KPC and CKPC tumours 
To confirm that Cx3cr1 was not expressed at the mRNA level in the pancreatic 
tumours of CKPC mice I used qRT-PCR. Figure 4.3A shows that in the pancreas of 
CKPC mice the expression of Cx3cr1 was absent.  






















Moreover, I evaluated if loss of the chemokine receptor Cx3cr1 had an effect on the 
expression of its only known ligand Cx3cl1. There was no significant difference in 
Cx3cl1 mRNA expression in KPC tumours compared to the CKPC (Figure 4.3B). 
 
Figure 4.3 Cx3cr1 and Cx3cl1 mRNA expression level  
RNA was extracted from frozen pancreas tumours of KPC and CKPC mice and qRT-PCR was 
performed. A) Cx3cr1 and B) Cx3cl1 mRNA expression level relative to β2 microglobulin 
(B2m) were plotted. Values for individual mice are shown as dots and a horizontal line 
represents mean of the values. Statistical significance was determined by unpaired t-test. 
N=5 per group. ns: not significant. 
 
4.3.2 CX3CL1 protein in tumour and plasma of KPC and CKPC mice 
After observing no significant changes at the mRNA level for Cx3cl1 in the tumours 
of CKPC mice compared to KPC, the protein level of CX3CL1 was assessed. CX3CL1 
levels were measured by ELISA in tumour protein lysates and in the plasma of KPC 
and CKPC mice, as described in Methods. 
 
Both in the tumours and plasma of KPC mice I found low expression of CX3CL1. 
However, it was highly expressed in the CKPC mice in both tumour lysates (Figure 
4.4A) and plasma (Figure 4.4B) and the differences were statistically significant. I 
observed that CKPC mice express 10 times more CX3CL1 compared KPC mice (p = 







































































Figure 4.4 CX3CL1 protein levels in tumour and plasma of KPC and CKPC mice 
The levels of CX3CL1 in KPC and CKPC mice were determined by ELISA. A) 85 μg of protein 
lysate from frozen tumours was tested and values are shown as ng of CX3CL1/μg of total 
protein. B) 50 μl of plasma (diluted 1:1 with water) was analysed and values are shown as 
ng of CX3CL1/1 ml of plasma. Values for individual mice are shown as dots and a horizontal 
line represents mean of the values. Statistical significance was determined by unpaired t-
test. N = 5 in Figure A) N=4 in Figure B. P-values are shown on the graphs. 
 
4.4 Immune infiltration in pancreatic tumours 
I next assessed whether CX3CR1 has a role in regulating immune infiltration into 
PDAC tumours. Infiltration of both myeloid and lymphoid cells in KPC and CKPC 
pancreatic tumours was analysed by flow cytometry. Single cell suspensions from 
each pancreatic tumour were stained with fluorescence-labelled antibodies against 
a panel of markers able to discriminate between myeloid and lymphoid cell 
populations as described in Methods. The different immune cells were identified 






































































Figure 4.5 Representative gating strategy for the leukocyte subsets in the tumour by 
flow cytometry 
Total pancreatic tumour single cell suspensions were stained with a pool of fluorescence-
conjugated antibody antibodies and analysed by flow cytometry. Acquired cells were gate 
to eliminate (A) debris, (B) doublets and (C) dead cells to obtain (D) CD45+ cells. CD45+ 
cells were analysed for the expression of (E) CD11b and (H) CD3+ allowing discrimination 
between myeloid and lymphoid subsets. CD11b+ cells were analysed in (F) for the 
expression of Ly6C and Ly6G and (G) F4/80. (I) CD3+ cells were further analysed for the 
expression of CD4 and CD8 
 
Infiltration of CD45+ cells was not significantly different between KPC and CKPC 
tumours (Figure 4.6A). The frequency of myeloid cells, based on CD11b expression, 
was not statistically increased in the CKPC compared to the KPC mice, (mean value 
of 40% and 20% respectively) (Figure 4.6B). Ly6C+Ly6G+ granulocytes and Ly6Chigh 
monocytes were slightly increase in CKPC compared to KPC mice (Figure 4.6C and 
D, respectively). F4/80+ macrophages, accounted for ~ 20% of the CD45+ cells and 
showed no major difference between KPC and CKPC (figure 4.6E).  
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Figure 4.6 Percentage of myeloid cell subsets in KPC and CKPC tumours 
Flow cytometric analysis of myeloid cells from KPC and CKPC tumours. Cells were gated 
as shown in Figure 3.9. Value for individual mice are shown as dots and a horizontal line 
represents mean of the values. Statistical significance was determined by unpaired t-test. 
N = 4 per group. ns: not significant. 
 
Interestingly, CD3+ T lymphocytes were significantly decreased in CKPC mice 
compared to KPC mice. There were 12% and 4% of CD3+ T cells in KPC and CKPC 
respectively (p value =0.494) (Figure 4. 7A). However, I observed no significant 
difference in the proportion of CD4+ T cells (Figure 4.7B) and CD8+ T cells (Figure 













































































































Figure 4.7 Percentage of myeloid cell subsets in KPC and CKPC tumours 
Flow cytometric analysis of lymphoid cells from KPC and CKPC tumours. Cells were gated 
as shown in Figure 3.9. Value for individual mice are shown as dots and a horizontal line 
represents mean of the values. Statistical significance was determined by unpaired t-test. 
N = 4 per group. ns: not significant. 
 
4.5 CCL2, CSF1 and CSF1R expression in KPC and 
CKPC tumours 
After observing the changes in the levels of CX3CL1 in the plasma and tumours of 
CKPC mice along with the subtle alterations in myeloid cell frequencies, I next 
assessed the expression of CCL2, mediator of myeloid cells chemotaxis, as well as 
CSF1 and CSF1R, involved in myeloid cells proliferation and differentiation.  
CCL2 is a chemokine that leads to the recruitment of monocytes, memory T cells, 
and NK cells to the sites of inflammation (Deshmane, Kremlev et al. 2009). CSF1 is 
a cytokine involved in the proliferation, differentiation, and survival of monocytes 
into macrophages (Stanley and Chitu 2014). CSF1R is a membrane protein receptor 
for CSF1 and IL-34; it is expressed on monocytes and macrophages and it plays a 
role in their differentiation and function (Hamilton 2008). 
I found no statistical difference in the expression of Csf1 and Ccl2 and Csf1R at 

































































Figure 4.8 Csf1, Ccl2 and Csf1r expression in KPC and CKPC tumours 
RNA from frozen pancreas tumours from KPC and CKPC mice was extracted and qRT-PCR 
was performed. A) Csf1, B) Ccl2 and C) Csf1r mRNA expression level relative to B2m were 
plotted. Values for individual tumours are shown as dots and a horizontal line represents 
mean of the values. Statistical significance was determined by unpaired t-test. N=5 
tumours per group. ns: not significant. 
 
4.6 The inflammatory environment in KPC and 
CKPC mice 
The binding of chemokines to their respective receptors initiates a series of cellular 
events: changes in cell shape leading to enhanced locomotion; secretion of 
lysosomal enzymes, and production of cytokines (Griffith, Sokol et al. 2014). 
Therefore, the KPC mice might have a different inflammatory microenvironment 
compared to CKPC mice. In particular, the levels of inflammatory cytokine 
expression were analysed to verify if there were any difference between KPC and 











































































































inflammatory cytokines TNF-α, IL-1β and IL-6 as well as the anti-inflammatory IL-
10.  These were assessed in pancreatic tumour lysates from KPC and CKPC mice at 
gene (Il6, Il12a, Il10 and Tnf) and protein level (TNF-α, IL-1β, IL-6 and IL-12) by 
qRT-PCR and ELISA. 
 
 
There were no significant differences at the mRNA expression levels of Il10, Tnf, 
Il1b and Il6, in tumour lysates from KPC and CKPC mice (Figure 4.9 A-D).  
 
 
Figure 4.9 mRNA expression of Il10, Tnf, Il6 and Il1b expression in KPC and CKPC 
tumours  
RNA from frozen pancreatic tumours of KPC and CKPC mice were extracted and qRT-PCR was 
performed for A) Il10, B) Tnf, C) Il1b and D) Il6 mRNA expression level relative to B2m were plotted. 
Values for individual mice are shown as dots and a horizontal line represents mean of the values. 
Statistical significance was determined by unpaired t-test. N=5 per group. ns: not significant. 
 
IL-10, TNF-α, IL-6 and IL12p40 were measured at protein level by ELISA. IL-10 
levels were significantly higher in CKPC compared to KPC mice, p = 0.0460 (Figure 






































































































































mouse tumours (Figure 4.10B and C, respectively). IL-12 subunit beta (IL-2p40) 
levels were comparable between KPC and CKPC mice (Figure 4.10D). 
  
 
Figure 4.10 Protein expression of IL-10, TNF-, IL-6 and IL-12p40 in KPC and CKPC 
tumours  
Protein levels of inflammatory cytokines in the tumours were determined by ELISA. 85 μg 
of protein lysates from frozen tumours were tested and value are shown as ng of 
cytokines/μg of total protein. A) IL-10, B) TNF-, C) IL-6 and D) IL-12p40. Values for 
individual mice are shown as dots and a horizontal line represents mean of the values. 
Statistical significance was determined by unpaired t-test. N = 5 per group (KPC IL12p40 
= 3). ns: not significant. 
 
 
4.7 mRNA profiles of FACS-sorted tumour-
infiltrating cells from KPC and CKPC mice 
CKPC tumours showed some subtle changes in the TME compared to KPC, 
primarily a reduction in the frequency of CD3+ T cells and an increase in IL-10 



























































































profiles of inflammatory on FACS-sorted tumour infiltrated immune cells namely 
F4/80+ macrophages, Ly6C+Ly6G+ granulocytes and CD3+ T cells. I chose to analyse 
F4/80+ macrophages because those are the cells have the highest levels of CX3CR1, 
CD3+ T cells because they were significantly decreased in CKPC mice compared to 
KPC mice, and Ly6C+Ly6G+ granulocytes because those are the myeloid cells at 
highest density after the F4/80+ macrophages in the tumour microenvironment of 
KPC and CKPC mice.  
 
4.7.1 F4/80+ macrophages 
Figure 4.11 shows mRNA levels Cx3cr1, Tnf, Il6, Il12a, Il1b, Il10, Nos2 and Arg1 in 
sorted F4/80+ macrophages from KPC and CKPC mice. The expression of CX3CR1 
was measured to confirm its KO in CKPC-tumour macrophages (Figure 4.9A). Tnf, 
Il6, IL12a, IL1b and Il10 cytokines were analysed but no significant difference was 
found between macrophages from KPC and CKPC mice (Figure 4.11B, C, D, E and F, 
respectively).   
 
Additionally, two macrophage activation markers nitric oxide synthases-2 (NOS2) 
and Argenase-1 (Arg1) were analysed. NOS2 and Arg1 are classic M1 and M2 
markers, respectively (Jablonski, Amici et al. 2015).  Nos2 and Arg1 mRNA showed 




Figure 4.11 mRNA expression Cx3cr1, Tnf, Il6, Il12a, Il1b, Il10, Nos2 and Arg1 in 
F4/80+ macrophages from KPC and CKPC tumours  
RNA from F4/80+ macrophages FACS-sorted from tumour of KPC and CKPC mice was 
extracted and qRT-PCR was performed for A) Cx3cr1, B) Tnf, C) Il6, D) Il12a, E) Il1b, F) Il10, 
G) Nos2 and H) Arg1 mRNA expression levels relative to B2m were plotted. Values for 
individual mice are shown as dots and a horizontal line represents mean of the values. 
Statistical significance was determined by unpaired t-test. N=4 per group. ns: not 
significant. 
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4.7.2 Ly6c+Ly6G+ granulocytes 
Figure 4.11 shows the mRNA levels of sorted Ly6C+Ly6G+ granulocytes from KPC 
and CKPC mice. The KO of CX3CR1 was confirmed also in CKPC Ly6c+Ly6G+ 
granulocytes, (Figure 4.12A).  In 3 out of 4 KPC Ly6C+Ly6G+ granulocytes Cx3cr1 
expression was not detected, due to the fact that this cell population express low 
level of CX3CR1 (Figure 3.16A). 
 
As with F4/80+ macrophages, I observed no significant difference in the expression 
of cytokines and activation markers in Ly6c+Ly6G+ granulocytes between KPC and 
CKPC mice (Figure 4.12D and E respectively). Tnf, Il6, IL12a, IL1b and Il10 and 
mRNA levels were equal in granulocytes from KPC and CKPC tumours (Figure 
4.12B, C, D, E and F, respectively). Moreover, Ly6c+Ly6G+ granulocytes from CKPC 
tumours expressed the same amount of Nos2 and Arg1 in KPC and CKPC tumours 
(Figure 4.12G and H, respectively). 
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Figure 4.12 mRNA expression Cx3cr1, Tnf, Il6, Il12a, Il1b, Il10, Nos2 and Arg1 in 
Ly6c+Ly6G+ granulocytes from KPC and CKPC tumours 
RNA from frozen Ly6C+Ly6G+ granulocytes sorted from tumours of KPC and CKPC mice 
were extracted and qRT-PCR was performed for A) Cx3cr1, B) Tnf, C) Il6, D) Il12a, E) Il1b, 
F) Il10, G) Nos2 and H) Arg1 mRNA expression levels relative to B2m were plotted. Values 
for individual mice are shown as dots and a horizontal line represents mean of the values. 
Statistical significance was determined by unpaired t-test. N=4 per group. ns: not 
significant. 
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4.7.3 CD3+ T cells 
FACS-sorted CD3+ T cells from KPC and CKPC mice were analysed for expression of 
Cx3cr1, Tnf, Il6, Il12a, Il1b and Il10 as shown in Figure 4.13.  The absence of CX3CR1 
mRNA expression was observed also in CD3+ T cells from CKPC mice (Figure 
4.13A).  There was no significant difference in the mRNA expression of any of 
inflammatory cytokines analysed. However, in CD3+ T cells sorted from CKPC I 
observed slightly more Tnf, (Figure 4.13B).  
 
CD3+ T cells from KPC and CKPC tumours showed equal mRNA levels of Il6, Il12a, 



























Figure 4.13 mRNA expression Cx3cr1, Tnf, Il6, Il12a, Il1b and Il10 in CD3+ T cells from 
KPC and CKPC tumours 
RNA from CD3+ T cells sorted from tumours of KPC and CKPC mice was extracted and qRT-
PCR was performed for A) Cx3cr1, B) Tnf, C) Il6, D) Il12a, E) Il1b and F) Il10, mRNA 
expression levels relative to B2m were plotted. Values for individual mice are shown as 
dots and a horizontal line represents mean of the values. Statistical significance was 












4.8 The effects of chemotherapy on KPC and CKPC 
tumours 
The experiments above showed that absence of CX3CR1 appeared to have no 
impact on tumour development in the KPC mouse model and also that there were 
only a few quite subtle differences in the TME. It is known that chemotherapy not 
only affects tumour cells but can also alter the TME. For example, chemotherapy 
can modify both the composition and functions of immune cells in circulation and 
into the tumour (Galluzzi, Buque et al. 2015, Tsuchikawa, Takeuchi et al. 2016); as 
showed in a study by Soeda et al, where patients treated for three weeks with 
gemcitabine exhibited an increase in circulating CD11c+ DC and CD14+ monocytes 
(Soeda, Morita-Hoshi et al. 2009). Moreover, the effect of chemotherapy on the 
function of the immune cells can be either immuno-suppressive or immuno-
stimulatory (Galluzzi, Zitvogel et al. 2016).  
 
I questioned if administration of chemotherapy in CKPC mice would have an effect 
on tumour growth or could influence the tumour-infiltration of immune cells 
differently to KPC. I chose to treat the animals with gemcitabine, since it is a 
chemotherapy frequently used in clinic to treat patients with pancreatic tumours 
(Kim 2008). Gemcitabine is a cytosine nucleoside analog, which is incorporated in 
DNA during its replication, inducing apoptosis (Noble and Goa 1997). Mice were 
used when their tumours were palpable and then treated twice a week for two 
weeks with gemcitabine administered intra-peritoneally at a dose of 100mg/kg of 
mouse. After two weeks of treatment with gemcitabine mice were sacrificed and 
pancreatic tumours were harvested for analysis.  
 
Firstly, the collected tumours were weighed. As showed in Figure 4.14 pancreatic 
tumours from KPC and CKPC mice did not show any significant differences. 
Notably, the mice at the end of the experiment were not at end-point stage and did 
not show any sign of discomfort and sickness.  
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Figure 4.14 Tumour weight of KPC and CKPC mice treated with gemcitabine  
Pancreatic tumours were collected from KPC and CKPC mice after being treated with 
gemcitabine and weighed. Mice were treated twice a week for two weeks with 
gemcitabine administered intra-peritoneally at a dose of 100mg/kg of mouse. Values for 
individual mice are shown as dots and a horizontal line represents mean of the values. 
Statistical significance was determined by unpaired t-test. KPC N=6 for and CKPC N=5. ns: 
not significant. 
 
Pancreatic tumours were then analysed by flow cytometry. Single cell suspensions 
from each tissue were stained with fluorescent antibodies against markers able to 
discriminate between myeloid and lymphoid cell populations. The gating strategy 
is shown in Figure 4.5. 
 
Overall, the infiltration of CD45+ cells was not significantly different between KPC 
and CKPC mice (Figure 4.15A). The percentages of myeloid cells, based on CD11b 
expression, were decreased in the CKPC compared to the KPC mice, 43% versus 
70% respectively (Figure 4.15B). However, the difference was again not 
statistically significant. When I looked into the myeloid subsets I observed that 
Ly6C+Ly6G+ granulocytes and Ly6Chigh monocytes were equal between KPC and 
CKPC mice (Figure 4.15 and 4.15D, respectively). F4/80+ macrophages were 




























Figure 4.15 Percentage of myeloid cell subsets in the tumour of KPC and CKPC mice 
treated with gemcitabine  
Flow cytometric analysis of myeloid cells from the tumour of KPC and CKPC mice treated 
with gemcitabine. Cells were gated as outline in Figure 3.9. Value for individual mice are 
shown as dots and a horizontal line represents mean of the values. Statistical significance 
was determined by unpaired t-test. KPC N=6 for and CKPC N=5. ns: not significant. 
 
 
CD3+ T lymphocytes were slightly increased in CKPC mice compared to KPC mice, 
40% and 25% of CD45+ cells, respectively (Figure 4.16A). There was no difference 
in the proportion of CD4+ T lymphocytes (Figure 4.16B) and CD8+ T lymphocytes 





















































































































Figure 4.16 Percentage of lymphoid cell subsets in the tumour of KPC and CKPC mice 
treated with gemcitabine  
Flow cytometric analysis of lymphoid cells from the tumour of KPC and CKPC mice treated 
with gemcitabine. Cells were gated as outline in Figure 3.9. Value for individual mice are 
shown as dots and a horizontal line represents mean of the values. Statistical significance 
was determined by unpaired t-test. KPC N=6 for and CKPC N=5. ns: not significant. 
 
4.9 Discussion  
In the previous chapter I have showed that the immune cells infiltrated into 
pancreatic tumours, and expressed CX3CR1 to different extent. Next, I wanted to 
examine if the lack of the CX3CR1 receptor had an effect in the tumour 
microenvironment within the pancreas tumours.  
 
First, I compared the survival of KPC and CKPC mice and I found that the lack of 
CX3CR1 had no effect on the survival of mice with pancreatic tumours (Figure 4.2). 
In PDAC patients, the correlation between CX3CR1 and overall survival was 
investigated by Merchesi et al. In their study they showed that the tumour 
expression of CX3CR1 has no effect on overall survival in relapsed PDAC patients 
(Marchesi, Piemonti et al. 2008).  At this stage, the pancreas of all the mice showed 
no healthy tissue, becoming a large malignant mass. The vast majority of mice 
exhibited metastasis in the peritoneum and liver. I also observed metastasis in the 
diaphragm, spleen, lungs and kidneys. Some mice developed ascites in the 
peritoneum.  
  
CX3CL1 is the only known ligand for CX3CR1, so I expected that the absence of 
CX3CR1 in the CKPC mice might have an effect on the levels of CX3CL1. In fact, it 
has been already observed by Shah et al. that in CX3CR1 KO mice exhibited higher 


































































al. 2015). Our results confirmed this hypothesis showing that in CKPC mice the 
amount of CX3CL1 was much higher compared KPC mice both in tumour lysates 
and plasma (Figure 4.3). In the KPC mice, I barely found any expression of CX3CL1. 
However, when I looked at the mRNA level of CX3CL1 I observed its expression in 
KPC tumours, but there was no difference compared to CKPC mice. This may 
suggest, that KPC and CKPC produced similar amount of CX3CL1, but in the CKPC 
mouse CX3CL1 could have accumulated over time because there was no receptor 
to bind to.  
 
Then I compared infiltration of myeloid and lymphoid cells in KPC and CKPC 
tumours. Our result showed no difference in the overall amount of leukocytes 
infiltrated into the tumour (Figure 4.6). The percentage of T cells within the tumour 
was significantly lower in CKPC mice compared KPC mice (Figure 4.7). However, 
the proportion of CD4+ cells and CD8+ T cells was comparable between CKPC and 
KPC mice. The decrease of CD3+ T cells could be caused by a direct lack of CX3CR1 
on T cells, which impair their recruitment in the tumour microenvironment or 
induced their death. Otherwise, the decrease in the percentages of CD3+ T cells 
could be caused indirectly. Changes in one or more populations of the TME, might 
be the responsible for blocking the recruitment of CD3+ T cells or for promoting 
their death. CX3CR1 is expressed by a subset of cytotoxic T cells (Nishimura, 
Umehara et al. 2002) and by a small subset of CD3+ T cells, CD8+ memory T cells 
with cytotoxic but not proliferative capability (Bottcher, Beyer et al. 2015). 
Therefore, considering that these populations constitute a small proportion of the 
total of CD3+ T cells, it seems unlikely that their decrease in CKPC mice is caused 
by the direct lack of CX3CR1.  
 
CX3CR1 is mostly involved in monocyte survival and differentiation into 
macrophages (Landsman, Bar-On et al. 2009). I wanted to verify if the lack of 
CX3CR1 induced compensatory mechanisms changing levels of other 
chemokines/chemokine receptors. CSF1 and CCL2 are critical for the recruitment 
of macrophages. I looked at the mRNA levels of Csf1 and Ccl2 and I observed that 
CKPC expressed a not significant higher amount of both chemokines. This result 
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may support our hypothesis of a compensatory mechanism mediated by CCL2 and 
CSF1 to explain the comparable levels of macrophages in CKPC and KPC mice.  
There is a growing appreciation that inflammation is the root cause of many 
cancers.  
 
I looked to see if CKPC mice had a different inflammatory microenvironment 
compared to KPC mice. I analysed several inflammatory cytokines, both at mRNA 
and protein levels. Interestingly, I did not observe any significant differences 
between KPC and CKPC mice when I look at the mRNA levels but I observed 
difference at protein levels. In particular, I observed a significant increase in IL-10 
and no significant changes in TNF-α and IL-6 in CKPC mice compared to KPC mice.  
 
I was interested to identify which cells were responsible for the production of these 
cytokines. To assess this I isolated F4/80+ macrophages, Ly6C+Ly6G+ granulocytes 
and CD3+ T cells and measured the mRNA levels of these inflammatory cytokine. 
Our results showed a slight not significant increase in the mRNA levels of Il0, Il6 
and TNF-α produced by F4/80+ macrophages and CD3+ T cells. These results 
indicated that the increase in Il10 in CKPC tumours was produced by other cell 
subsets in the tumour microenvironment. In fact, IL-10 can be produced by tumour 
cells, tumour suppressive myeloid cells and B cells. Otherwise, it is also possible 
that the increase in IL-10 in CKPC tumours it is caused by its production by two or 
more cell subsets. 
 
Chemotherapy can modify the TME by altering the cytokine and chemokine milieu 
as well as frequencies of immune cell populations and their effector function 
(Tsuchikawa, Takeuchi et al. 2016). For this reason I analysed the effects of a two-
week gemcitabine treatment on immune infiltration in KPC and CKPC tumours. 
There was no difference in tumour weight between KPC and CKPC mice at the end 
of the treatment. After two week of gemcitabine treatment I observed a not 
significant decrease in the frequency of CD11b+ cells and an increase in CD3+ T 
cells, both CD4+ and CD8+ T cells, in CKPC compared to KPC. Increase in CTL after 
treatment with gemcitabine was already been observed by Pei et al. and it is 
mediated by DCs (Pei, Pan et al. 2014).  
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Moreover, I observed difference in the immune infiltration, in both KPC and CKPC 
mice, between tumours at end point stages (Figure 4.6 and 7 and tumours after 
gemcitabine treatment (Figure 4.15 and 16). These differences could be caused 
either by the gemcitabine treatment itself or by the different stage of the tumours. 
Several studies have reported that chemotherapy treatment, such as gemcitabine, 
induce immune-modulatory effects (Pei, Pan et al. 2014, Chang, Jiang et al. 2016). 
This might support that gemcitabine was indeed responsible in the changes I 
observed in the in the TME. For example, increase in CTL activity after treatment 
with gemcitabine was already been observed by Pei et al. In this study pancreatic 
tumour cells treated with gemcitabine stimulated DC maturation, which in turn 
promoted T cells proliferation and a CTL antitumor immune response (Pei, Pan et 
al. 2014). 
 
As in chapter 3, the results described here were obtained from analysis of small 
numbers of mice in each experimental group.  This could explain why, even if some 
of my results showed several fold differences between the experimental groups, 
they were not statistically significant. Moreover, the experiments used both male 
and female mice. The use of same-sex mice in the experiments could have given 
more consistent results, in particular when chemokine and chemokine receptors 
levels were analysed. In fact, some chemokines are expressed at different levels in 




 No difference in the survival of CKPC compared to KPC mice 
 Significant decrease in CD3+ T cells in CKPC mice compared to KPC mice 
 Significant increase in the amount of CX3CL1 in the tumour and in the 
plasma of CKPC mice 
 Significant increase in the amount of IL-10 in CKPC mice compared to KPC 
mice 
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 KPC and CKPC mice treated for two weeks with gemcitabine have no 
difference in immune infiltration. 
 
4.11 Conclusion 
Briefly, this chapter compares the TME between KPC and CKPC mice. In particular, 
I looked at the survival, the immune infiltration and the production of cytokines 
and chemokines in both KPC and CKPC mice. The results obtained showed that the 
lack of CX3CR1 caused subtle in the TME. Finally, I analysed the effects of 
chemotherapy on immune infiltration into the TME. In order to better understand 
these results RNA sequencing of KPC and CKPC mice was performed and it will be 




























































In Chapter 4, I compared different aspects of the TME of KPC and CKPC mice. My 
results showed that the lack of CX3CR1 caused a significant decrease of CD3+ T cells 
and increase of IL-10 in the TME. To further understand what caused these changes 
I decided to perform RNA sequencing on KPC and CKPC tumour samples. I chose to 
use RNA sequencing because it is a method that would allow analysis of the entire 
transcriptome, enabling the identification of pathways or genes that were altered 
when CX3CR1 was not expressed in the TME.  
 
In the RNA sequencing experiment, I compared six CKPC tumour samples with 
seven KPC tumour samples. The RNA transcriptome from KPC samples was 
previously obtained by postdoc Dr Juliana Candido. I performed the RNA extraction 
from the CKPC tumour samples. All tumours were processed at end point and the 
same analysis pipeline was applied to all sequencing data. 
 
5.2 RNA quality 
RNA was extracted from 6 CKPC frozen tumours, collected from end point mice and 
kept at -80°C until RNA extraction was performed. Table 5.1 summarises the 
characteristics of each mouse from which the tumour was harvested. 
 
Mouse  Sex Age (days) 
CX3CR1 _K01 Female 98 
CX3CR1 _K02 Female 193 
CX3CR1 _K03 Female 116 
CX3CR1 _K04 Female 165 
CX3CR1 _K05 Female 143 
CX3CR1 _K06 Male 134 
Table 5.1 Characteristics of mice used for RNA sequencing 
Table showing the sex and age of each mouse used for the RNA sequencing experiment. 
Mice were sacrificed at end point. Harvested tumours were snap frozen and kept at -80°C 
until RNA extraction performed.  
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RNA integrity was measured using an Agilent RA 6000 nano kit on the Agilent RNA 
2100 Bioanalyzer.  The software analyses integrity and quality of the RNA in the 
samples, giving an RNA integrity number (RIN).  RIN values range from 1 to 10, 
reflecting complete RNA degradation (RIN = 1) to high quality, intact RNA (RIN = 
10). Figure 5.1 illustrates the results of Agilent analysis on CKPC samples. The 
quality of RNA was acceptable for further analysis. RIN numbers for the control 
KPC samples were > 7 and these samples were also taken at end point (data from 




Figure 5.1 RNA quality 
RNA profiles using an Agilent RA 6000 nano kit for the six CKPC tumour samples which 
were sent for RNA sequencing. Each peak represents one of the ribosomal subunits, 18S 
28S, respectively. RIN is calculated as the ratio of 18S to 28S subunits. The RIN is shown 




5.3 Analysis of gene expression composition  
All the bioinformatics analysis was performed by Dr Eleni Maniati, a senior 
postdoctoral fellow in our laboratory, and Dr Ai Nagano from our Bioinformatics 
Core. The KPC samples were named KPC1-7, while the CKPC samples were named 
CX3CR1 _KO1-6. 
 
In total 16,388 genes were sufficiently quantified. Among these, 13,817 were 
protein-coding genes, accounting for the 84% of the transcriptome (Figure 5.2). 
Pseudogenes, segments of DNA related to real genes that have lost functionality in 
cellular gene expression or protein-coding ability, represented 5% of total genes 
(Figure 5.2).  
4% of genes were predicted genes with no experimental validation up to date. 
These genes are transcribed genomic regions potentially representing novel genes, 
but which need to be confirmed in the laboratory. 2% of total genes were long 
intergenic non-coding RNA (LincRNA). Linc RNA are a subset of long non-coding 
RNAs (lncRNAs), containing more than 200 nucleotides with no coding potential, 
which do not overlap with any known protein-coding genes.  
 
Antisense RNA, processed transcript and immunoglobulin/T cell receptor (IG/TR) 
genes each accounted for 1% of total genes. Antisense RNAs are single-stranded 
RNA species, complementary to messenger RNAs (mRNAs). Processed transcripts 
are non-coding RNA that does not contain an open reading frame (ORF). IG genes 
codify for B cell receptor or antibody while TC genes codify for the T cell receptors. 
Finally, the remaining 2% of genes grouped other non-coding RNA species, such as 




Figure 5.2 Gene species in the dataset 
Pie chart showing the distribution of mapped reads to different transcript types and gene 
regions. IG=immunoglobulin, TR= T cell receptor.  
 
Next, I looked at the classification of protein-coding genes generated by Panther 
tool. As shown in Figure 5.3 more than 1500 genes belonged to the nucleic acid 
binding subgroup. I also observed that protein-coding genes codifying for receptor, 
signalling molecule, cytoskeletal and defence/immune protein were highly present 




Figure 5.3 Classification of protein coding genes 
Bar chart showing the protein class ontology enrichments of protein-coding genes using 
the Panther tool.  The graph displays also the number of proteins (count) identified for 






5.4 Principal component analysis   
Principal component analysis (PCA) is a dimensionality reduction and 
unsupervised clustering method.  PCA allows identification of the relative 
relationship between each sample in 2 or 3-dimensional coordinate space in order 
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to visualize sample-to-sample distances. PCA uses linear combinations of the 
original data to define a new set of unrelated variables (principal components). 
 
The results obtained performing PCA confirmed that our samples clustered in 
two separated groups, representing the KPC and CX3CR1_KO (CKPC) genotype 
(Figure 5.4).  
 
 
Figure 5.4 Principal component analysis 
The graph shows how our 13 samples from KPC and CKPC tumours cluster using principal 
component analysis (PCA). The x-axis is the direction that separates the data points the 
most (PC1) and accounts for 30.9% of the variance in the data. The y-axis is a second 




5.5 Differential expression analysis  
Differential expression analysis allows identification of genes significantly 
different between two or more conditions. Using a threshold of adjusted p-value < 






























identified, of which 368 genes were downregulated, while 239 genes were 
upregulated in CKPC tumour samples compared to KPC (Figure 5.5).  
 
Figure 5.5 Differential expression analyses of KPC and CKPC tumour samples 
Visualization of the comparison of transcript expression profiles between KPC and CKPC 
tumour samples to identify differentially expressed genes. Scattered dot plot illustrating 
average expression (log counts per million, CPM) vs log2 fold change. Blue line illustrates 
log2FC = 1 and -1.  
 
Next, to visualise the differentially expressed (DE) genes within each sample a 
heat-map graph was generated. A heat-map is a graphical representation of the 
gene expression values for each of the 607 genes. Expression values are 
represented by colours, upregulated genes in CKPC tumour samples were 
represented in red while green indicated downregulated genes in CKPC tumour 

















Figure 5.6 Heat-map of the differential expressed genes 
Hierarchical clustering heat-map of the 607 differentially expressed (DE) genes with 
log2FC > |1| and adj. p-value < 0.05. Each column represents one tumour sample, each row 
represents a single gene. Red represents upregulated genes while green indicates 
downregulated genes in CKPC compared KPC tumour samples. WTCHG = CKPC samples, 
MJ = KPC samples.  
 
Of the 607 DE genes only 212 were protein-coding genes, of which 75 were 
downregulated while 137 were upregulated in CKPC compared KPC tumour 














































































































Figure 5.7 Volcano plot of protein-coding genes 
Visualization of the comparison of transcript expression profiles between KPC and CKPC 
tumour samples to identify differentially expressed genes. Volcano plot illustrating log2 
fold change vs –log10 adj. P-value. Coloured in red are differentially expressed genes (adj. 
p-value < 0.05 and log2FC > |1|) 
 
5.5.1 Analysis of DE protein coding genes 
I next examined the classification of the DE protein-coding genes. Genes coding for 
nucleic acid binding proteins represented the majority of differentially expressed 
genes (Figure 5.8), in line with the abundance in the entire transcriptome (Figure 
5.3).  
 
Approximately 50 DE genes encoded enzymes such as oxidoreductase, hydrolase, 
transferase, ligase and lyase. Interestingly, although defence/immunity proteins 
accounted for just eleven genes, six of them were in the top 20 down- and 
upregulated genes and will be further discussed below.  
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Figure 5.8 Classification of DE protein-coding genes  
Bar chart showing the protein class of DE genes using the Panther bioinformatics tool.  The 
graph displays also the number of proteins (count) identified for each protein class. 
 
Subsequently, I also examined which gene ontology biological processes are 
associated with the DE protein coding genes. Figure 5.9 lists the biological 
processes of the DE genes. As expected the most common set of genes identified by 
gene ontology were those involved in cellular process (112 genes). Also of interest, 
98 genes were metabolic genes and five DE genes were related to locomotion. 
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Figure 5.9 Classification of DE protein-coding genes in Gene Ontology biological 
process 
Bar chart showing the gene ontology biological process classification of DE genes using the 
Panther bioinformatics tool. The graph displays also the number of proteins (count) 
identified for each biological process. 
 
5.5.2 Top differentially expressed genes 
Figure 5.10 shows the top 20 genes downregulated in CKPC compared to KPC 
tumours, with fold-change illustrated on a log2 scale. Cx3cr1 was one of the most 
downregulated genes, confirming the targeted genetic disruption of Cx3cr1 in 
CKPC mice (Figure 5.10 and 5.11A).   
 
The top downregulated gene was Aldoart1 with approximately a 10-fold change in 
expression. This gene encodes for an enzyme of the glycolysis pathway illustrating 
a potential link of Cx3cr1 with metabolism (Vemuganti, Bell et al. 2007). 
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Interestingly, some of the most downregulated genes such as Nlrp10 and Cd300ld3, 
play a role in the regulation of innate immunity. Nlrp10 is a member of the NLR 
protein family, a class of pattern recognition receptor. It plays a regulatory role in 
the innate immune system, being part of the inflammasome.  It is expressed by 
monocytes, macrophages, DCs, neutrophils, CD4+ T and B cells (Damm, Lautz et al. 
2013). Cd300ld3 encodes for the CMRF35-like molecule 3 protein belonging to the 
Ig superfamily. It is an activating receptor and it is expressed on macrophages and 
mast cells and plays a role in cytokine production by regulating TLR9 signalling 
(Wu, Zhu et al. 2011).  
Figure 5.10 Top downregulated genes in CKPC vs KPC tumours 
Bar chart showing the top 20 genes that were downregulated in CKPC tumours vs KPC 
tumours. Values shown as Log2 fold changes. 
 
 
Furthermore, among the top downregulated genes I found S100a4, a calcium 
binding protein (Figure 5.10 and 5.11B). S100a4 shows no enzymatic activity but 
exerts its biological function via the interaction with the target proteins. It is 
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expressed by fibroblasts, immune cells, and cancer cells and is released into the 
extracellular space in response to various stimuli. S100a4 regulates several cellular 
processes, such as proliferation, motility, invasion, and tubulin polymerization. 
Over-expression of S100a4 has been associated with several malignancies, among 
which pancreatic, breast and lung cancers (Fei, Qu et al. 2017).  
 
 
Figure 5.11 Gene expression of Cx3cr1 and S100a4 
Boxplots illustrating Cx3cr1 and S100a4 gene expression in KPC and CKPC tumours.  Values 
shown as Log2 fold changes and adj. p-value < 0.05. 
 
Using the same criteria, I identified the top 20 up-regulated genes in CKPC 
compared to KPC tumours, shown in Figure 5.12. The top up-regulated gene was 
Mest coding for Mesoderm-specific transcript homolog protein, a hydrolase 
associated to the endoplasmic reticulum expressed in foetal tissues and also in 
lymphocytes (Kosaki, Kosaki et al. 2000).  
 
Igf2, Insulin like growth factor 2, is upregulated more than six-fold in CKPC 
compared KPC tumours. It is a member of the insulin family of polypeptide growth 
factors; it has growth-promoting activity and has been associated with cancer 
(Brouwer-Visser and Huang 2015).  
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Again, I found that several upregulated genes play a role in the regulation of the 
immune system, such as Il1r1, Clec9a, SiglecH and CD5l. Il1r1, Interleukin 1 
Receptor Like 1, is a member of the interleukin 1 receptor family and is a mediator 
involved in inflammatory responses (Schett, Dayer et al. 2016). Clec9a is a C-type 
lectin-like receptor expressed on DCs, involved in the cross-presentation of 
antigens from dead cells (Macri, Dumont et al. 2016). Cd5l, CD5 antigen-like, it is a 
soluble protein belonging to the SRCR superfamily. It is mostly expressed by 
macrophages and regulates mechanisms in inflammatory responses (Sanjurjo, 
Aran et al. 2015). SiglecH is a member of the Siglec family which are cell surface 
immunoglobulin-like lectins that bind sialic acid. It is expressed by pDCs and 
mediates endocytosis and cross-presentation of antigens (Crocker, Paulson et al. 
2007). 
 
Among the most upregulated genes, three were pseudogenes, Rpl10-ps3, Rps2-ps6 












Figure 5.12 Top upregulated genes in CKPC vs KP tumours 
Top 20 genes that were upregulated in CKPC tumours vs KPC tumours. Values shown as 
Log2 fold changes and adj. P-value <0.05. 
 
 
5.5.3 Immune system related genes 
As illustrated in Chapter 4, the differences I observed between the TMEs from KPC 
and CKPC mice were related to the immune system. For this reason, I looked into 
the DE genes in order to find changes able to explain the differences between KPC 
and CKPC mice.  
 
First of all, I found that the lack of CX3CR1 in pancreatic tumours led to the 
differential expression of two chemokines. The chemokines that were differentially 
expressed were Cxcl10 and Cxcl12, both upregulated in CKPC mice compared to 
KPC mice (Figure 5.13). CXCL10 is secreted by monocytes, endothelial cells and 
fibroblasts and is involved in the recruitment of monocytes, T cells and NK cells 
(Figure 5.13A) (Liu, Guo et al. 2011). CXCL12, also known as stromal cell-derived 
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factor 1 (SDF-1), is produced in response to proinflammatory stimuli, such as TNF 
and IL-1. It plays a role in the migration of T lymphocytes and monocytes (Figure 
5.13B) (Karin 2010). 
 
 
Figure 5.13 Differentially expressed chemokines 
Boxplots illustrating Cxcl10 and Cxcl12 gene expression in KPC and CKPC tumour.  Values 
shown as Log2 fold changes and adj. p-value < 0.05. 
 
I also observed DE genes that are part of the transcription factor family, Gata3 and 
Cebpb (Figure 5.14). Both these transcription factors are expressed by immune 
cells and are downregulated in CKPC mice compared to KPC mice. Gata-3 (GATA 
Binding Protein 3) regulates T cell development and induces the differentiation 
towards T helper 2 (Th2) cells during inflammatory responses (Figure 5.14A) 
(Wan 2014). C/ebp-β (CCAAT/enhancer-binding protein beta) it is important for 
macrophage activation and function, regulating M2-associated genes (Figure 
5.14B) (Huber, Pietsch et al. 2012). 
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Figure 5.14 Differentially expressed transcription factors 
Boxplots illustrating Gata3 and Cebpb gene expression in KPC and CKPC tumour.  Values 
shown as Log2 fold changes and adj. p-value < 0.05. 
 
5.6 Tumour content of the samples 
I next examined epithelial malignancy-associated genes Pdx1, Epcam and Cdh1 in 
KPC and CKPC samples and I found no difference (Figure 5.15). This indicated that 
in KPC and CKPC tumours the malignant component is equal and agrees with the 
data shown in Chapter 4.  
 
Pdx1 (Pancreatic and duodenal homeobox 1) is a transcription factors that plays an 
important role in pancreatic development and is expressed by epithelial cells and 
β-cells, as well in PDAC cells (Figure 5.15A). Epcam (Epithelial cell adhesion 
molecule) is a transmembrane glycoprotein mediating cell–cell adhesion in 
epithelial cells. It is expressed on most normal epithelial cells and gastrointestinal 
carcinomas, such as PDAC (Figure 5.15B). Cdh1 (E-cadherin) is a classical member 
of the cadherin superfamily and it is involved in cell-cell adhesion.  It is expressed 




Figure 5.15 Tumour content level 
Boxplots illustrating Pdx1, Epcam and Cdh1 gene expression in KPC and CKPC tumours.  
Values shown as Log2 fold changes. ns: not significant.  
 
5.7 Discussion 
The lack of CX3CR1 in pancreatic cancer induced subtle changes in the TME, as 
shown in Chapter 4, but did not affect overall survival of mice or response to 
gemcitabine. Likewise, the analysis of the RNA sequencing experiment revealed 
only 607 differentially expressed genes, of which 368 genes were downregulated 
and 239 genes were upregulated, between KPC and CKPC tumours.  
 
In order to exclude potential batch effects in the data arising from sequencing the 
samples on two separate RNAseq runs I examined expression of the tumour-
associated genes, Pdx1, Epcam and Cdh1 (Figure 5.15). As expected, there was no 
significant difference in their expression in KPC and CKPC tumours, which 
confirmed same tumour content and discounted the presence of batch effects in 
the data. On the other hand, there was a significant reduction in expression of 
Cx3cr1 in CKPC mice (Figure 5.11A), which confirmed the genetic disruption of the 
Cx3cr1 locus.  
 
The analysis of KPC and CKPC tumour samples identified 16,388 filtered genes, 
among which, 13,817 were protein-coding genes. I identified 212 differentially 
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expressed protein–coding genes, of which 75 were downregulated while 137 were 
upregulated in CKPC compared KPC tumour samples. 
 
The analysis of the DE protein-coding genes using either Panther protein 
classification or gene ontology biological process indicated that several DE genes 
encoded for immune system and chemotactic proteins (Figure 5.7 and 5.8, 
respectively).  In particular, using the Panther protein classification, I observed 
that the lack of CX3CR1 induced the differential expression of receptors, signalling 
molecules, defense/immunity protein, cell adhesion and cytoskeletal proteins 
(Figure 5.8). Similarly, among the gene ontology biological process, I identified: 
response to stimulus, immune system process, biological adhesion and locomotion 
(Figure 5.9).  
 
Data presented in Chapter 4 indicated a decrease in the frequency of CD3+ T cells 
in CKPC compared to KPC mice (Figure 4.7). Interestingly, I observed several DE 
genes involved in T cell regulation and chemotaxis, among which Gata-3, S100a4, 
were downregulated, Cxcl10 and Cxcl12, were upregulated. Gata-3 is a 
transcription factor that regulates T cell differentiation, being the master regulator 
of Th2 (Ho, Tai et al. 2009). Our results revealed that Gata3 is downregulated in 
CKPC compared KPC tumours (Figure 5.14A). Gata-3 is necessary for CD8+ T cell 
growth and proliferation upon activation. Lack of Gata-3 not only impairs Th2 
differentiation, but also impairs CD4+ (Ho, Tai et al. 2009, Wan 2014) and CD8+ T 
cell proliferation upon TCR and cytokine stimulation (Wang, Misumi et al. 2013, 
Wan 2014). The lack of proliferative T cells might explain the decrease of T cells in 
CKPC mice.  
 
I also observed a decrease in S100a4, which is a member of the S100 family of Ca2+-
binding proteins. S100a4 is expressed by various normal cell populations, 
including fibroblasts, monocytes, macrophages, granulocytes, T and endothelial 
cells and it is localized in the nucleus, cytoplasm, and the extracellular space (Boye 
and Maelandsmo 2010). Moreover, S100a4 is expressed in many human cancers, 
and is correlated with poor prognosis and increased metastasis formation (Fei, Qu 
et al. 2017). Interestingly, S100a4 plays a role not only in inducing metastasis but 
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also in T cells migration into the tumour (Grum-Schwensen, Klingelhofer et al. 
2010, Klingelhofer, Grum-Schwensen et al. 2012). They found that the lack of 
S100a4 impaired the migration of CD3+ T cells into the tumour (Grum-Schwensen, 
Klingelhofer et al. 2010). They also found that, in vitro, S100a4 promotes CD3+ T 
cell migration which is blocked by the treatment with an anti-S100a4 antibody 
(Grum-Schwensen, Klingelhofer et al. 2010). In vivo the anti-S100a4 treatment 
blocked the recruitment of T cells into the tumour (Klingelhofer, Grum-Schwensen 
et al. 2012). These data propose the role of S100a4 as an attractant of CD3+ T cells 
into the tumour, which could explain the decrease in CD3+ T cells I observed in KPC 
mice. 
 
CXCL12 is expressed constitutively by various cell populations, such as fibroblasts 
and endothelial cells, and tissues, among which bone marrow and cardiac tissue. It 
binds to two different receptors, CXCR4 and CXCR7, which mediate different 
functions (Karin 2010). CXCR4 is expressed on most hematopoietic cell types, 
including macrophages, monocytes, T and B lymphocytes, neutrophils and DCs, 
regulating their trafficking in and out peripheral tissues. The role of the CXCL12-
CXCR4 axis in tumour progression has been studied and has been associated with 
enhanced tumour cell survival, proliferation, and metastasis, as well as with 
immune cell chemotaxis. (Sun, Cheng et al. 2010). Of interest is the role of CXCL12 
in regulating the CD3+ T cell infiltrates into the TME. In fact, a study by Feig et al. 
showed that in pancreatic tumours the binding of CXCL12 to cancer cells inhibited 
the migration of T cells into tumour area of the TME (Feig, Jones et al. 2013). 
Moreover, the administration of a CXCR4 inhibitor induced the accumulation of T 
cells into the tumours and reduced cancer cells (Feig, Jones et al. 2013, Guo, Wang 
et al. 2016). Therefore, the increase in Cxcl12 expression (Figure 5.13B) could 
represent another possible mechanism responsible for the decrease in CD3+ T cells.  
 
On the other hand, I also observed the upregulation of Cxcl10 (Figure 5.13A). 
CXCL10, like CXCL12, mediates chemotaxis of T cells and other immune 
populations into inflamed site. CXCL10 is expressed under proinflammatory 
condition by neutrophils, eosinophils, monocytes, epithelial, endothelial and 
stromal cells. Its receptor CXCR3 is expressed on macrophages, DCs, NK cells and 
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activated CD4+ and CD8+ T lymphocytes. The CXCL10-CXCR3 axis mediates several 
functions, such as chemotaxis, apoptosis, cell growth and proliferation (Liu, Guo et 
al. 2011). Notably, CXCR3 is absent on naïve T cells, but is upregulated following 
DC-induced T-cell activation (Groom and Luster 2011).  
 
Nlrp10, member of the NLRs family of cytosolic proteins, is expressed by several 
immune cells, among which T cells, macrophages and DCs and is involved in 
regulating the immune system and inflammation (Damm, Lautz et al. 2013). 
Interestingly, a study by Eisenbarth et al. demonstrated that lack of Nlrp10 
prevents the migration of DCs from the site of the infection to the draining lymph 
nodes, preventing the priming and activation naive CD4+ T cells (Eisenbarth, 
Williams et al. 2012). I observed downregulation of Nlrp10 in CKPC mice which 
could indicate that DC-mediated T cell activation is impaired. Notably, CXCR3 
upregulation, the CXCL10 receptor, occurs following DC-induced T cell activation. 
Therefore, if CD4+ cells are not activated by DC cells, they are unable to respond to 
the CXCL10 gradient present into the tumour.  
 
The infiltration of each immune cell population into the TME is mediated primarily 
the binding of cytokines and chemokines to their receptors, and subsequent 
activation or inhibition of signalling pathways or transcription factors. As 
mentioned above, I observed a decrease in CD3+ T cells into the TME of CKPC mice 
(Figure 4.7). The results obtained by the RNA sequencing analysis indicated some 
factors which could be responsible for it. The changing in the expression of Cxcl12, 
Gata3, S100a4 and Cxcl10 together with Nlrp10, either individually or combined, 
could promote changes in T lymphocytes or in the TME which prevented CD3+ T 
cells access into the tumour.  
 
I further observed that Cebpb was downregulated in CKPC mice compared KPC 
mice (Figure 5.14B). C/ebp-β is a transcription factor, which plays a role in the 
regulation of innate immunity, inflammation, metabolism and adipogenesis 
(Huber, Pietsch et al. 2012). In addition, C/ebp-β, has important roles in myeloid 
development and activation of macrophages, the most abundant cell population in 
PDAC. A study by Ruffell et al. showed that C/ebp-β was involved in the regulation 
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of M2-associated genes, such as Arg1, Il10 and Mrc1. Notably, to promote M2-
associated genes C/ebp-β has to be induced by another bZIP family transcription 
factor, the cAMP-responsive element-binding protein (Creb) (Ruffell, Mourkioti et 
al. 2009, Lawrence and Natoli 2011). However, Creb, as well as the M2 genes Arg1 
and Mrc1, were not among the DE genes. Moreover, sorted F4/80+ macrophages 
from KPC and CKPC tumours showed no difference in the amount of Arg1 and Il10 
mRNA (Figure 4.11), suggesting that the lack of CX3CR1 does not promote a M2 
phenotype in macrophages.  
 
Ccl2, Ccr2, Csf1 and Csf1r are major regulators of macrophage survival and 
chemotaxis. There was no difference in expression of the genes encoding for these 
proteins in KPC and CKPC tumours. This result confirmed qRT-PCR data presented 
in Chapter 4 (Figure 4.8) whereby expression of Ccl2, Csf1 and Csf1r again showed 
no difference between KPC and CKPC tumours. Furthermore, there was no 
difference in the frequency of tumour infiltrating F4/80+ cells (Figure 4.6). 
Together these data suggest that CX3CR1 deletion does not impact the recruitment 
of these cells in pancreatic cancer. 
 
Almost half of DE genes belonged to the GO term that refers to metabolic processes 
(Figure 5.8). Interestingly, a link between CX3CR1 and metabolism has already 
been reported in literature (Ren, Zhao et al. 2013, Polyak, Ferenczi et al. 2014, Shah, 
O'Neill et al. 2015). In particular, Ren et al. found that CX3CL1/CX3CR1 axis 
reprograms glucose metabolism in PDAC. In their study, CX3CL1 induced glucose 
uptake and lactate secretion in pancreatic cancer cell lines, which was mediated by 
Hif-1 expression (Ren, Zhao et al. 2013). However, I did not observe a change in the 
expression of Hif1 between KPC and CKPC tumours possibly because in our 
samples mRNA was extracted from whole tumour masses and not only from 
tumour cells. My results also revealed the downregulation of genes involved in 
glucose metabolism. For example, Aldoart1 (AldoA retrogene 1) was the most 
downregulated gene in CKPC compared KPC tumours. It encodes for the fructose-
bisphosphate aldolase enzyme, which is involved in glucose metabolism 
(Vemuganti, Bell et al. 2007). I also observed downregulation in genes involved in 
the electron transport chain, Ndufa2, mt-Co3, Etfa and Etfb. The latter two genes 
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are also involved in fatty acid oxidation. Together these results suggest that the 
lack of CX3CR1 in PDAC impaired the mitochondrial tricarboxylic acid cycle. PDAC 
metabolism is known to be highly deregulated, due to the poor vascularization, 
hypoxic and nutrient deprived TME. In fact, pancreatic tumours are characterized 
by the glycolytic switch (Warburg effect), upregulation of the hexosamine 
biosynthetic pathway, activation of lipid metabolism, autophagy and pinocytosis 
(Cohen, Neuzillet et al. 2015). Therefore, the lack of CX3CR1 seems to further 
deregulate metabolism in TME of pancreatic cancer.  
 
As mentioned in the introduction to this chapter, the results described were 
obtained from different two RNA sequencing experiments. Although, the RNA 
extractions were not performed by the same person nor at the same time, the data 
showed in this chapter were obtained by analysing the RNA sequencing raw data 
following the same protocol. In fact, the same expression of tumour content 
markers together with the lack of expression of Cx3cr1 in CKPC mice (Figure 
5.11A), excludes the presence of batch effects. Moreover, as in Chapter 4, both 
female and male mice were used in this experiment to obtain the tumour samples. 
 
5.8 Summary 
 Identification of 16,388 filtered genes, among which 13,817 were protein 
coding genes 
 607 DE genes were identified, 368 genes were downregulated in CKPC mice 
while 239 genes were upregulated in KPC mice 
 Identification of 212 DE protein-coding genes; genes that included 
receptors, signalling molecules, defense/immunity, cell adhesion and 
cytoskeletal organization. 
 Upregulation of Cxcl10 and Cxcl12 chemokines in CKPC mice 
 Downregulation of S100a4, calcium binding protein, and Gata3 and Cebpb, 
transcription factors, in CKPC mice 




In this chapter, I described the results of the RNA sequencing of KPC and CKPC 
tumours. The results obtained revealed some possible mechanisms which could 



































































Pancreatic cancer is responsible for 6% of cancer deaths and its incidence is 
expected to increase in the next years. Despite the improvements in the survival 
rate of several cancers, there has been little progress in the treatment of pancreatic 
malignancy. For this reason, research in PDAC has been focusing in the 
identification of new therapeutic targets.  
 
In recent years, the role of the chemokine-chemokine receptor axis in cancer has 
been increasingly investigated (Balkwill 2004, O'Hayre, Salanga et al. 2008, 
Lazennec and Richmond 2010, Mantovani, Savino et al. 2010, Allavena, Germano et 
al. 2011, Balkwill 2012, Sarvaiya, Guo et al. 2013, Mukaida, Sasaki et al. 2014, 
Nagarsheth, Wicha et al. 2017). The role of this axis in tumour progression is 
complex; besides their role in the recruitment of immune cells, chemokines and 
their receptors are also involved in tumour cell survival and proliferation, 
angiogenesis and metastasis formation. For these reasons, chemokine receptors 
have been considered has potential therapeutic targets. 
 
CX3CL1 and its receptor CX3CR1 are the only members of the CX3C chemokine 
family. The upregulation of CX3CR1 has been reported in many cancers, prostate 
(Shulby, Dolloff et al. 2004), breast (Andre, Cabioglu et al. 2006) and pancreatic 
(Allavena, Germano et al. 2011) (see Figure 1.6). In PDAC, CX3CR1 expression is 
associated with increased migration and metastasis formation to peripheral 
nerves, which is known as perineural invasion (PNI) (Marchesi, Piemonti et al. 
2008, Marchesi, Locatelli et al. 2010).  
 
In my study I investigated the impact of deletion of CX3CR1 in the tumour 
microenvironment, focusing on the amount and functions of infiltrating immune 
cells, inflammation, response to chemotherapy and survival. To do so I used a 
genetically engineered mouse model of PDAC, the CX3CR1GFP/GFPLSL-
KRASG12D/+LSL-Trp53R172H/+Pdx1-Cre (CKPC) mouse. In these mice, the CX3CR1 
protein is not functional and they express GFP instead.  
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In my study I showed that CX3CR1 has a subtle effect on the shaping of the TME in 
a mouse model of pancreatic cancer, the KPC model. At a cellular level there was a 
significant decrease in CD3+ T cells (Figure 4.7) and a possible increase in CD11b+ 
myeloid cells (Figure 4.6) in the TME. In terms of cytokines and chemokines, there 
was a significant increase in IL-10 and a possible non-significant increase in TNF-
α, and IL-6 (Figure 4.10). Of interest in relation to these cell and protein changes, 
the RNA-seq analysis showed significant downregulation of S100a4, Nlrp10, Gata3 
and Cebpb (Figure 5.11 and 5.14) and significant upregulation of Cxcl10 and Cxcl12 
(Figure 5.13).  
 
However, even though the TME showed these differences, there was no overall 
survival difference between KPC and CKPC mice. In both mouse models tumours 
where palpable from three months of age and the mice had a median lifespan of 
was 119.5 days and 110.6 days (Figure 4.2). On contrast to our results, Celesti et al. 
found that human PDAC patients with CX3CR1+ tumours had a longer survival 
compared to CX3CR1- tumours (Celesti, Di Caro et al. 2013). This discrepancy might 
be due by the mouse model I used. In fact, in the CKPC mouse model the CX3CR1 
expression is altered not only in tumour cells, but in all CX3CR1-expressing cells. 
They also showed that CX3CR1 expression is an early event during carcinogenesis, 
being already upregulated in PanIN-1, and it is maintained through tumour 
progression. They also hypothesise that the association between the better 
survival and CX3CR1 tumour expression might be only the reflection of an earlier 
disease stage (Celesti, Di Caro et al. 2013). 
  
The response to chemotherapy was also examined in KPC and CKPC mice. The 
tumour weight after two weeks of treatment with gemcitabine was comparable 
between KPC and CKPC mice (Figure 4.14). However, when I looked at the immune 
cell infiltration into the tumour I found some potential differences. CD11b+ myeloid 
cells were slightly decreased (Figure 4.15) in CKPC mice while CD3+ cells were 
increased (Figure 4.16), though not significantly. This might suggest that two 
weeks treatment was not sufficient to see a difference in tumour growth between 
chemotherapy-treated KPC and CKPC tumours.  
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Briefly, my results support that the lack of CX3CR1 is involved in the regulation of 
the TME in a mouse model of pancreatic cancer. These subtle changes in the TME 
were anyway not sufficient to alter, neither the lifespan nor response to 
chemotherapy treatment in mice with pancreatic tumour. These results gain 
importance considering that CX3CR1 targeting has been postulated for cancer 
treatment (Zhao, Gao et al. 2012, Ferretti, Pistoia et al. 2014). However, my study 
suggests that targeting CX3CR1 alone is not sufficient to improve tumour outcome, 
it does show that the lack of CX3CR1 altered various aspects of the tumour 
microenvironment, at cell, protein and RNA levels. However, in this work was used 
a mouse model where CX3CR1 deletion was global, whilst the use of CX3CR1 
inhibitor might show different results. In fact, the compensatory mechanisms that 
might have been induced by the global deletion of CX3CR1 would be avoided by the 
transit use of an inhibitor.  
 
6.2 Summary of results of this thesis 
 KPC mice express CX3CR1 both on tumour cells and on immune cells 
infiltrating the tumour.   
 Plasma and tumour CX3CL1 levels are increased in the absence of CX3CR1  
 KPC and CKPC mice have comparable overall survival 
 There was a decrease in CD3+ T cells and an increase in IL-10 in tumours 
from CKPC compared to KPC mice 
 The lack of CX3CR1 leads to differences in the transcriptome of CKPC mice 
compared to KPC mice 
 Differentially expressed genes encode for proteins involved in metabolism, 




6.3 Future work 
The findings of my thesis give rise to other questions on the role of CX3CR1 in 
pancreatic cancer, in particular related to the mechanisms involved in the 
regulation of the immune system and response to chemotherapy.  
 
First of all, I would like to investigate the mechanisms involved in the changes in 
the decrease in CD3+ T cells into the tumour. In particular, I would like to establish 
if the lack of CX3CR1 produces CD3+ T cells unable to migrate into the tumour or if 
the lack of CX3CR1 in tumour cells impairs the recruitment of CD3+ T cells. To 
answer to this question, I could use an orthotopic model of pancreatic cancer. I 
would generate malignant cell lines from KPC or CKPC tumours, inject into wild-
type mice or CKPC mice and assess the immune infiltration into the tumour. The 
same profile of immune infiltration between the two groups would exclude the role 
of CX3CR1 expression on tumour cells in the recruitment of immune cells. 
Otherwise, differences in the immune cells infiltrated into the tumour would 
suggest that the lack of CX3CR1 on tumour cells impairs the recruitment of immune 
cells into pancreatic tumour.  
 
The RNA sequencing results suggest some hypotheses that could explain the 
changes affecting the immune infiltration into the TME. The decrease in CD3+ T 
cells in CKPC mice could be caused by upregulation of other chemokines (Cxcl10 
and Cxcl12), changes in transcription factor (Gata3) or in other intracellular 
proteins (S100a4 and Nlrp10). I would like to validate these findings by looking at 
protein levels of these in the tumours. Next, I would verify in vitro using transwell 
migration assays to see if CXCL10 or CXCL12 induced or inhibited the migration of 
CX3CR1GFP-GFP CD3+ T cells towards tumour cells.  
  
Finally, I would like to assess if increasing the duration of treatment with 
chemotherapy in KPC and CKPC mice would alter tumour progression. For this 
reason, I would not only measure the tumour weight at the end of experiment, but 
I would like also to compare the tumour volume at the start and end of the 
experiment. This would be determined by ultrasound. 
 154 
Bibliography  
Allavena, P., G. Germano, F. Marchesi and A. Mantovani (2011). "Chemokines in 
cancer related inflammation." Exp Cell Res 317(5): 664-673. 
Allen, S. J., S. E. Crown and T. M. Handel (2007). "Chemokine: receptor structure, 
interactions, and antagonism." Annu Rev Immunol 25: 787-820. 
Anders, H. J., P. Romagnani and A. Mantovani (2014). "Pathomechanisms: 
homeostatic chemokines in health, tissue regeneration, and progressive diseases." 
Trends Mol Med 20(3): 154-165. 
Andre, F., N. Cabioglu, H. Assi, J. C. Sabourin, S. Delaloge, A. Sahin, K. Broglio, J. P. 
Spano, C. Combadiere, C. Bucana, J. C. Soria and M. Cristofanilli (2006). "Expression 
of chemokine receptors predicts the site of metastatic relapse in patients with 
axillary node positive primary breast cancer." Ann Oncol 17(6): 945-951. 
Apte, M. V., R. C. Pirola and J. S. Wilson (2012). "Pancreatic stellate cells: a starring 
role in normal and diseased pancreas." Front Physiol 3: 344. 
Auffray, C., D. Fogg, M. Garfa, G. Elain, O. Join-Lambert, S. Kayal, S. Sarnacki, A. 
Cumano, G. Lauvau and F. Geissmann (2007). "Monitoring of blood vessels and 
tissues by a population of monocytes with patrolling behavior." Science 
317(5838): 666-670. 
Bachelerie, F., G. J. Graham, M. Locati, A. Mantovani, P. M. Murphy, R. Nibbs, A. Rot, 
S. Sozzani and M. Thelen (2014). "New nomenclature for atypical chemokine 
receptors." Nat Immunol 15(3): 207-208. 
Bachem, M. G., S. Zhou, K. Buck, W. Schneiderhan and M. Siech (2008). "Pancreatic 
stellate cells--role in pancreas cancer." Langenbecks Arch Surg 393(6): 891-900. 
Bailey, K. M., J. W. Wojtkowiak, A. I. Hashim and R. J. Gillies (2012). "Targeting the 
metabolic microenvironment of tumors." Adv Pharmacol 65: 63-107. 
Bailey, P., D. K. Chang, K. Nones, A. L. Johns, A. M. Patch, M. C. Gingras, D. K. Miller, 
A. N. Christ, T. J. Bruxner, M. C. Quinn, C. Nourse, L. C. Murtaugh, I. Harliwong, S. 
Idrisoglu, S. Manning, E. Nourbakhsh, S. Wani, L. Fink, O. Holmes, V. Chin, M. J. 
Anderson, S. Kazakoff, C. Leonard, F. Newell, N. Waddell, S. Wood, Q. Xu, P. J. Wilson, 
N. Cloonan, K. S. Kassahn, D. Taylor, K. Quek, A. Robertson, L. Pantano, L. Mincarelli, 
L. N. Sanchez, L. Evers, J. Wu, M. Pinese, M. J. Cowley, M. D. Jones, E. K. Colvin, A. M. 
Nagrial, E. S. Humphrey, L. A. Chantrill, A. Mawson, J. Humphris, A. Chou, M. Pajic, 
C. J. Scarlett, A. V. Pinho, M. Giry-Laterriere, I. Rooman, J. S. Samra, J. G. Kench, J. A. 
Lovell, N. D. Merrett, C. W. Toon, K. Epari, N. Q. Nguyen, A. Barbour, N. Zeps, K. 
Moran-Jones, N. B. Jamieson, J. S. Graham, F. Duthie, K. Oien, J. Hair, R. Grutzmann, 
A. Maitra, C. A. Iacobuzio-Donahue, C. L. Wolfgang, R. A. Morgan, R. T. Lawlor, V. 
Corbo, C. Bassi, B. Rusev, P. Capelli, R. Salvia, G. Tortora, D. Mukhopadhyay, G. M. 
Petersen, I. Australian Pancreatic Cancer Genome, D. M. Munzy, W. E. Fisher, S. A. 
 155 
Karim, J. R. Eshleman, R. H. Hruban, C. Pilarsky, J. P. Morton, O. J. Sansom, A. Scarpa, 
E. A. Musgrove, U. M. Bailey, O. Hofmann, R. L. Sutherland, D. A. Wheeler, A. J. Gill, 
R. A. Gibbs, J. V. Pearson, N. Waddell, A. V. Biankin and S. M. Grimmond (2016). 
"Genomic analyses identify molecular subtypes of pancreatic cancer." Nature 
531(7592): 47-52. 
Balkwill, F. (2004). "Cancer and the chemokine network." Nat Rev Cancer 4(7): 
540-550. 
Balkwill, F. (2009). "Tumour necrosis factor and cancer." Nat Rev Cancer 9(5): 361-
371. 
Balkwill, F. R. (2012). "The chemokine system and cancer." J Pathol 226(2): 148-
157. 
Bardeesy, N. and R. A. DePinho (2002). "Pancreatic cancer biology and genetics." 
Nat Rev Cancer 2(12): 897-909. 
Bayne, L. J., G. L. Beatty, N. Jhala, C. E. Clark, A. D. Rhim, B. Z. Stanger and R. H. 
Vonderheide (2012). "Tumor-derived granulocyte-macrophage colony-
stimulating factor regulates myeloid inflammation and T cell immunity in 
pancreatic cancer." Cancer Cell 21(6): 822-835. 
Bazan, J. F., K. B. Bacon, G. Hardiman, W. Wang, K. Soo, D. Rossi, D. R. Greaves, A. 
Zlotnik and T. J. Schall (1997). "A new class of membrane-bound chemokine with a 
CX3C motif." Nature 385(6617): 640-644. 
Bolm, L., S. Cigolla, U. A. Wittel, U. T. Hopt, T. Keck, D. Rades, P. Bronsert and U. F. 
Wellner (2017). "The Role of Fibroblasts in Pancreatic Cancer: Extracellular Matrix 
Versus Paracrine Factors." Transl Oncol 10(4): 578-588. 
Bottcher, J. P., M. Beyer, F. Meissner, Z. Abdullah, J. Sander, B. Hochst, S. Eickhoff, J. 
C. Rieckmann, C. Russo, T. Bauer, T. Flecken, D. Giesen, D. Engel, S. Jung, D. H. Busch, 
U. Protzer, R. Thimme, M. Mann, C. Kurts, J. L. Schultze, W. Kastenmuller and P. A. 
Knolle (2015). "Functional classification of memory CD8(+) T cells by CX3CR1 
expression." Nat Commun 6: 8306. 
Boye, K. and G. M. Maelandsmo (2010). "S100A4 and metastasis: a small actor 
playing many roles." Am J Pathol 176(2): 528-535. 
Brouwer-Visser, J. and G. S. Huang (2015). "IGF2 signaling and regulation in 
cancer." Cytokine Growth Factor Rev 26(3): 371-377. 
Burns, W. R. and B. H. Edil (2012). "Neuroendocrine pancreatic tumors: guidelines 
for management and update." Curr Treat Options Oncol 13(1): 24-34. 




Carr, R. M. and M. E. Fernandez-Zapico (2016). "Pancreatic cancer 
microenvironment, to target or not to target?" EMBO Mol Med 8(2): 80-82. 
Celesti, G., G. Di Caro, P. Bianchi, F. Grizzi, F. Marchesi, G. Basso, D. Rahal, G. 
Delconte, M. Catalano, P. Cappello, M. Roncalli, A. Zerbi, M. Montorsi, F. Novelli, A. 
Mantovani, P. Allavena, A. Malesci and L. Laghi (2013). "Early expression of the 
fractalkine receptor CX3CR1 in pancreatic carcinogenesis." Br J Cancer 109(9): 
2424-2433. 
Chang, A. I., A. H. Schwertschkow, J. A. Nolta and J. Wu (2015). "Involvement of 
mesenchymal stem cells in cancer progression and metastases." Curr Cancer Drug 
Targets 15(2): 88-98. 
Chang, J. H., Y. Jiang and V. G. Pillarisetty (2016). "Role of immune cells in pancreatic 
cancer from bench to clinical application: An updated review." Medicine 
(Baltimore) 95(49): e5541. 
Cheng, W. and G. Chen (2014). "Chemokines and chemokine receptors in multiple 
sclerosis." Mediators Inflamm 2014: 659206. 
Cid-Arregui, A. and V. Juarez (2015). "Perspectives in the treatment of pancreatic 
adenocarcinoma." World J Gastroenterol 21(31): 9297-9316. 
Clark, C. E., S. R. Hingorani, R. Mick, C. Combs, D. A. Tuveson and R. H. Vonderheide 
(2007). "Dynamics of the immune reaction to pancreatic cancer from inception to 
invasion." Cancer Res 67(19): 9518-9527. 
Cleveland, M. H., J. M. Sawyer, S. Afelik, J. Jensen and S. D. Leach (2012). "Exocrine 
ontogenies: on the development of pancreatic acinar, ductal and centroacinar 
cells." Semin Cell Dev Biol 23(6): 711-719. 
Cohen, R., C. Neuzillet, A. Tijeras-Raballand, S. Faivre, A. de Gramont and E. 
Raymond (2015). "Targeting cancer cell metabolism in pancreatic 
adenocarcinoma." Oncotarget 6(19): 16832-16847. 
Collisson, E. A., A. Sadanandam, P. Olson, W. J. Gibb, M. Truitt, S. Gu, J. Cooc, J. 
Weinkle, G. E. Kim, L. Jakkula, H. S. Feiler, A. H. Ko, A. B. Olshen, K. L. Danenberg, M. 
A. Tempero, P. T. Spellman, D. Hanahan and J. W. Gray (2011). "Subtypes of 
pancreatic ductal adenocarcinoma and their differing responses to therapy." Nat 
Med 17(4): 500-503. 
Colotta, F., P. Allavena, A. Sica, C. Garlanda and A. Mantovani (2009). "Cancer-
related inflammation, the seventh hallmark of cancer: links to genetic instability." 
Carcinogenesis 30(7): 1073-1081. 
Combadiere, C., C. Feumi, W. Raoul, N. Keller, M. Rodero, A. Pezard, S. Lavalette, M. 
Houssier, L. Jonet, E. Picard, P. Debre, M. Sirinyan, P. Deterre, T. Ferroukhi, S. Y. 
Cohen, D. Chauvaud, J. C. Jeanny, S. Chemtob, F. Behar-Cohen and F. Sennlaub 
(2007). "CX3CR1-dependent subretinal microglia cell accumulation is associated 
with cardinal features of age-related macular degeneration." J Clin Invest 117(10): 
2920-2928. 
 157 
Conroy, T., F. Desseigne, M. Ychou, O. Bouche, R. Guimbaud, Y. Becouarn, A. Adenis, 
J. L. Raoul, S. Gourgou-Bourgade, C. de la Fouchardiere, J. Bennouna, J. B. Bachet, F. 
Khemissa-Akouz, D. Pere-Verge, C. Delbaldo, E. Assenat, B. Chauffert, P. Michel, C. 
Montoto-Grillot, M. Ducreux, U. Groupe Tumeurs Digestives of and P. Intergroup 
(2011). "FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer." N Engl 
J Med 364(19): 1817-1825. 
Corbo, V., G. Tortora and A. Scarpa (2012). "Molecular pathology of pancreatic 
cancer: from bench-to-bedside translation." Curr Drug Targets 13(6): 744-752. 
Corcione, A., E. Ferretti and V. Pistoia (2012). "CX3CL1/fractalkine is a novel 
regulator of normal and malignant human B cell function." J Leukoc Biol 92(1): 51-
58. 
Cox, A. D. and K. P. Olive (2012). "Silencing the killers: paracrine immune 
suppression in pancreatic cancer." Cancer Cell 21(6): 715-716. 
Crocker, P. R., J. C. Paulson and A. Varki (2007). "Siglecs and their roles in the 
immune system." Nat Rev Immunol 7(4): 255-266. 
Damm, A., K. Lautz and T. A. Kufer (2013). "Roles of NLRP10 in innate and adaptive 
immunity." Microbes Infect 15(6-7): 516-523. 
de Sousa Cavalcante, L. and G. Monteiro (2014). "Gemcitabine: metabolism and 
molecular mechanisms of action, sensitivity and chemoresistance in pancreatic 
cancer." Eur J Pharmacol 741: 8-16. 
Deshmane, S. L., S. Kremlev, S. Amini and B. E. Sawaya (2009). "Monocyte 
chemoattractant protein-1 (MCP-1): an overview." J Interferon Cytokine Res 29(6): 
313-326. 
Durinck, S., Y. Moreau, A. Kasprzyk, S. Davis, B. De Moor, A. Brazma and W. Huber 
(2005). "BioMart and Bioconductor: a powerful link between biological databases 
and microarray data analysis." Bioinformatics 21(16): 3439-3440. 
Eales, K. L., K. E. Hollinshead and D. A. Tennant (2016). "Hypoxia and metabolic 
adaptation of cancer cells." Oncogenesis 5: e190. 
Eisenbarth, S. C., A. Williams, O. R. Colegio, H. Meng, T. Strowig, A. Rongvaux, J. 
Henao-Mejia, C. A. Thaiss, S. Joly, D. G. Gonzalez, L. Xu, L. A. Zenewicz, A. M. 
Haberman, E. Elinav, S. H. Kleinstein, F. S. Sutterwala and R. A. Flavell (2012). 
"NLRP10 is a NOD-like receptor essential to initiate adaptive immunity by 
dendritic cells." Nature 484(7395): 510-513. 
Erkan, M., C. Reiser-Erkan, C. W. Michalski, S. Deucker, D. Sauliunaite, S. Streit, I. 
Esposito, H. Friess and J. Kleeff (2009). "Cancer-stellate cell interactions perpetuate 
the hypoxia-fibrosis cycle in pancreatic ductal adenocarcinoma." Neoplasia 11(5): 
497-508. 
Evans, A. and E. Costello (2012). "The role of inflammatory cells in fostering 
pancreatic cancer cell growth and invasion." Front Physiol 3: 270. 
 158 
Farrow, B. and B. M. Evers (2002). "Inflammation and the development of 
pancreatic cancer." Surg Oncol 10(4): 153-169. 
Fei, F., J. Qu, M. Zhang, Y. Li and S. Zhang (2017). "S100A4 in cancer progression 
and metastasis: A systematic review." Oncotarget. 
Feig, C., A. Gopinathan, A. Neesse, D. S. Chan, N. Cook and D. A. Tuveson (2012). "The 
pancreas cancer microenvironment." Clin Cancer Res 18(16): 4266-4276. 
Feig, C., J. O. Jones, M. Kraman, R. J. Wells, A. Deonarine, D. S. Chan, C. M. Connell, E. 
W. Roberts, Q. Zhao, O. L. Caballero, S. A. Teichmann, T. Janowitz, D. I. Jodrell, D. A. 
Tuveson and D. T. Fearon (2013). "Targeting CXCL12 from FAP-expressing 
carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in 
pancreatic cancer." Proc Natl Acad Sci U S A 110(50): 20212-20217. 
Ferretti, E., V. Pistoia and A. Corcione (2014). "Role of fractalkine/CX3CL1 and its 
receptor in the pathogenesis of inflammatory and malignant diseases with 
emphasis on B cell malignancies." Mediators Inflamm 2014: 480941. 
Fong, A. M., L. A. Robinson, D. A. Steeber, T. F. Tedder, O. Yoshie, T. Imai and D. D. 
Patel (1998). "Fractalkine and CX3CR1 mediate a novel mechanism of leukocyte 
capture, firm adhesion, and activation under physiologic flow." J Exp Med 188(8): 
1413-1419. 
Galluzzi, L., A. Buque, O. Kepp, L. Zitvogel and G. Kroemer (2015). "Immunological 
Effects of Conventional Chemotherapy and Targeted Anticancer Agents." Cancer 
Cell 28(6): 690-714. 
Galluzzi, L., L. Zitvogel and G. Kroemer (2016). "Immunological Mechanisms 
Underneath the Efficacy of Cancer Therapy." Cancer Immunol Res 4(11): 895-902. 
Gautier, E. L., C. Jakubzick and G. J. Randolph (2009). "Regulation of the migration 
and survival of monocyte subsets by chemokine receptors and its relevance to 
atherosclerosis." Arterioscler Thromb Vasc Biol 29(10): 1412-1418. 
Gerard, C. and B. J. Rollins (2001). "Chemokines and disease." Nat Immunol 2(2): 
108-115. 
Girard, J. P., C. Moussion and R. Forster (2012). "HEVs, lymphatics and homeostatic 
immune cell trafficking in lymph nodes." Nat Rev Immunol 12(11): 762-773. 
Griffith, J. W., C. L. Sokol and A. D. Luster (2014). "Chemokines and chemokine 
receptors: positioning cells for host defense and immunity." Annu Rev Immunol 
32: 659-702. 
Groom, J. R. and A. D. Luster (2011). "CXCR3 ligands: redundant, collaborative and 
antagonistic functions." Immunol Cell Biol 89(2): 207-215. 
Grum-Schwensen, B., J. Klingelhofer, M. Grigorian, K. Almholt, B. S. Nielsen, E. 
Lukanidin and N. Ambartsumian (2010). "Lung metastasis fails in MMTV-PyMT 
 159 
oncomice lacking S100A4 due to a T-cell deficiency in primary tumors." Cancer Res 
70(3): 936-947. 
Guerra, C. and M. Barbacid (2013). "Genetically engineered mouse models of 
pancreatic adenocarcinoma." Mol Oncol 7(2): 232-247. 
Guo, F., Y. Wang, J. Liu, S. C. Mok, F. Xue and W. Zhang (2016). "CXCL12/CXCR4: a 
symbiotic bridge linking cancer cells and their stromal neighbors in oncogenic 
communication networks." Oncogene 35(7): 816-826. 
Gurkan, U. A. and O. Akkus (2008). "The mechanical environment of bone marrow: 
a review." Ann Biomed Eng 36(12): 1978-1991. 
H Chen, J. T., LWeinberg, M Nikfarjam (2015). "Diffuse Pancreatic Mucinous Cystic 
Neoplasm Treated by Total Pancreatectomy." JOP. Journal of the Pancreas. 
Hamilton, J. A. (2008). "Colony-stimulating factors in inflammation and 
autoimmunity." Nat Rev Immunol 8(7): 533-544. 
Heinemann, V., M. Reni, M. Ychou, D. J. Richel, T. Macarulla and M. Ducreux (2014). 
"Tumour-stroma interactions in pancreatic ductal adenocarcinoma: rationale and 
current evidence for new therapeutic strategies." Cancer Treat Rev 40(1): 118-
128. 
Herreros-Villanueva, M., E. Hijona, A. Cosme and L. Bujanda (2012). "Mouse models 
of pancreatic cancer." World J Gastroenterol 18(12): 1286-1294. 
Hezel, A. F., A. C. Kimmelman, B. Z. Stanger, N. Bardeesy and R. A. Depinho (2006). 
"Genetics and biology of pancreatic ductal adenocarcinoma." Genes Dev 20(10): 
1218-1249. 
Hingorani, S. R., L. Wang, A. S. Multani, C. Combs, T. B. Deramaudt, R. H. Hruban, A. 
K. Rustgi, S. Chang and D. A. Tuveson (2005). "Trp53R172H and KrasG12D 
cooperate to promote chromosomal instability and widely metastatic pancreatic 
ductal adenocarcinoma in mice." Cancer Cell 7(5): 469-483. 
Ho, I. C., T. S. Tai and S. Y. Pai (2009). "GATA3 and the T-cell lineage: essential 
functions before and after T-helper-2-cell differentiation." Nat Rev Immunol 9(2): 
125-135. 
Hruban, R. H., A. Maitra and M. Goggins (2008). "Update on pancreatic 
intraepithelial neoplasia." Int J Clin Exp Pathol 1(4): 306-316. 
Hruban, R. H., R. E. Wilentz and S. E. Kern (2000). "Genetic progression in the 
pancreatic ducts." Am J Pathol 156(6): 1821-1825. 
Huber, R., D. Pietsch, T. Panterodt and K. Brand (2012). "Regulation of C/EBPbeta 
and resulting functions in cells of the monocytic lineage." Cell Signal 24(6): 1287-
1296. 
 160 
Hundhausen, C., D. Misztela, T. A. Berkhout, N. Broadway, P. Saftig, K. Reiss, D. 
Hartmann, F. Fahrenholz, R. Postina, V. Matthews, K. J. Kallen, S. Rose-John and A. 
Ludwig (2003). "The disintegrin-like metalloproteinase ADAM10 is involved in 
constitutive cleavage of CX3CL1 (fractalkine) and regulates CX3CL1-mediated cell-
cell adhesion." Blood 102(4): 1186-1195. 
Ierano, C., P. Giuliano, C. D'Alterio, M. Cioffi, V. Mettivier, L. Portella, M. Napolitano, 
A. Barbieri, C. Arra, G. Liguori, R. Franco, G. Palmieri, C. Rozzo, R. Pacelli, G. Castello 
and S. Scala (2009). "A point mutation (G574A) in the chemokine receptor CXCR4 
detected in human cancer cells enhances migration." Cell Cycle 8(8): 1228-1237. 
Imai, T., K. Hieshima, C. Haskell, M. Baba, M. Nagira, M. Nishimura, M. Kakizaki, S. 
Takagi, H. Nomiyama, T. J. Schall and O. Yoshie (1997). "Identification and 
molecular characterization of fractalkine receptor CX3CR1, which mediates both 
leukocyte migration and adhesion." Cell 91(4): 521-530. 
Iodice, S., S. Gandini, P. Maisonneuve and A. B. Lowenfels (2008). "Tobacco and the 
risk of pancreatic cancer: a review and meta-analysis." Langenbecks Arch Surg 
393(4): 535-545. 
Ishida, Y., J. L. Gao and P. M. Murphy (2008). "Chemokine receptor CX3CR1 
mediates skin wound healing by promoting macrophage and fibroblast 
accumulation and function." J Immunol 180(1): 569-579. 
Jablonski, K. A., S. A. Amici, L. M. Webb, D. Ruiz-Rosado Jde, P. G. Popovich, S. 
Partida-Sanchez and M. Guerau-de-Arellano (2015). "Novel Markers to Delineate 
Murine M1 and M2 Macrophages." PLoS One 10(12): e0145342. 
Jamieson-Gladney, W. L., Y. Zhang, A. M. Fong, O. Meucci and A. Fatatis (2011). "The 
chemokine receptor CX(3)CR1 is directly involved in the arrest of breast cancer 
cells to the skeleton." Breast Cancer Res 13(5): R91. 
Jamieson, W. L., S. Shimizu, J. A. D'Ambrosio, O. Meucci and A. Fatatis (2008). 
"CX3CR1 is expressed by prostate epithelial cells and androgens regulate the levels 
of CX3CL1/fractalkine in the bone marrow: potential role in prostate cancer bone 
tropism." Cancer Res 68(6): 1715-1722. 
Jung, S., J. Aliberti, P. Graemmel, M. J. Sunshine, G. W. Kreutzberg, A. Sher and D. R. 
Littman (2000). "Analysis of fractalkine receptor CX(3)CR1 function by targeted 
deletion and green fluorescent protein reporter gene insertion." Mol Cell Biol 
20(11): 4106-4114. 
Kamisawa, T., L. D. Wood, T. Itoi and K. Takaori (2016). "Pancreatic cancer." Lancet 
388(10039): 73-85. 
Karin, N. (2010). "The multiple faces of CXCL12 (SDF-1alpha) in the regulation of 
immunity during health and disease." J Leukoc Biol 88(3): 463-473. 
Kasama, T., T. Odai, K. Wakabayashi, N. Yajima and Y. Miwa (2008). "Chemokines 
in systemic lupus erythematosus involving the central nervous system." Front 
Biosci 13: 2527-2536. 
 161 
Keane, M. G., L. Horsfall, G. Rait and S. P. Pereira (2014). "A case-control study 
comparing the incidence of early symptoms in pancreatic and biliary tract cancer." 
BMJ Open 4(11): e005720. 
Kim, K. W., A. Vallon-Eberhard, E. Zigmond, J. Farache, E. Shezen, G. Shakhar, A. 
Ludwig, S. A. Lira and S. Jung (2011). "In vivo structure/function and expression 
analysis of the CX3C chemokine fractalkine." Blood 118(22): e156-167. 
Kim, Y. T. (2008). "[Chemotherapy for pancreatic cancer]." Korean J Gastroenterol 
51(2): 111-118. 
Klimczak, A. and U. Kozlowska (2016). "Mesenchymal Stromal Cells and Tissue-
Specific Progenitor Cells: Their Role in Tissue Homeostasis." Stem Cells Int 2016: 
4285215. 
Klingelhofer, J., B. Grum-Schwensen, M. K. Beck, R. S. Knudsen, M. Grigorian, E. 
Lukanidin and N. Ambartsumian (2012). "Anti-S100A4 antibody suppresses 
metastasis formation by blocking stroma cell invasion." Neoplasia 14(12): 1260-
1268. 
Kosaki, K., R. Kosaki, W. J. Craigen and N. Matsuo (2000). "Isoform-specific 
imprinting of the human PEG1/MEST gene." Am J Hum Genet 66(1): 309-312. 
Kryczek, I., A. Lange, P. Mottram, X. Alvarez, P. Cheng, M. Hogan, L. Moons, S. Wei, L. 
Zou, V. Machelon, D. Emilie, M. Terrassa, A. Lackner, T. J. Curiel, P. Carmeliet and W. 
Zou (2005). "CXCL12 and vascular endothelial growth factor synergistically induce 
neoangiogenesis in human ovarian cancers." Cancer Res 65(2): 465-472. 
Kumari, N., B. S. Dwarakanath, A. Das and A. N. Bhatt (2016). "Role of interleukin-6 
in cancer progression and therapeutic resistance." Tumour Biol 37(9): 11553-
11572. 
Kusmartsev, S., S. Nagaraj and D. I. Gabrilovich (2005). "Tumor-associated CD8+ T 
cell tolerance induced by bone marrow-derived immature myeloid cells." J 
Immunol 175(7): 4583-4592. 
La Rosa, S., F. Sessa and C. Capella (2015). "Acinar Cell Carcinoma of the Pancreas: 
Overview of Clinicopathologic Features and Insights into the Molecular Pathology." 
Front Med (Lausanne) 2: 41. 
Landsman, L., L. Bar-On, A. Zernecke, K. W. Kim, R. Krauthgamer, E. Shagdarsuren, 
S. A. Lira, I. L. Weissman, C. Weber and S. Jung (2009). "CX3CR1 is required for 
monocyte homeostasis and atherogenesis by promoting cell survival." Blood 
113(4): 963-972. 
Lawrence, T. and G. Natoli (2011). "Transcriptional regulation of macrophage 
polarization: enabling diversity with identity." Nat Rev Immunol 11(11): 750-761. 
Lazennec, G. and A. Richmond (2010). "Chemokines and chemokine receptors: new 
insights into cancer-related inflammation." Trends Mol Med 16(3): 133-144. 
 162 
Lee, S. J., S. Namkoong, Y. M. Kim, C. K. Kim, H. Lee, K. S. Ha, H. T. Chung, Y. G. Kwon 
and Y. M. Kim (2006). "Fractalkine stimulates angiogenesis by activating the Raf-
1/MEK/ERK- and PI3K/Akt/eNOS-dependent signal pathways." Am J Physiol 
Heart Circ Physiol 291(6): H2836-2846. 
Lesina, M., M. U. Kurkowski, K. Ludes, S. Rose-John, M. Treiber, G. Kloppel, A. 
Yoshimura, W. Reindl, B. Sipos, S. Akira, R. M. Schmid and H. Algul (2011). 
"Stat3/Socs3 activation by IL-6 transsignaling promotes progression of pancreatic 
intraepithelial neoplasia and development of pancreatic cancer." Cancer Cell 19(4): 
456-469. 
Lewis, A. M., S. Varghese, H. Xu and H. R. Alexander (2006). "Interleukin-1 and 
cancer progression: the emerging role of interleukin-1 receptor antagonist as a 
novel therapeutic agent in cancer treatment." J Transl Med 4: 48. 
Liu, M., S. Guo, J. M. Hibbert, V. Jain, N. Singh, N. O. Wilson and J. K. Stiles (2011). 
"CXCL10/IP-10 in infectious diseases pathogenesis and potential therapeutic 
implications." Cytokine Growth Factor Rev 22(3): 121-130. 
Liu, M., S. Guo and J. K. Stiles (2011). "The emerging role of CXCL10 in cancer 
(Review)." Oncol Lett 2(4): 583-589. 
Liu, P., Y. R. Yu, J. A. Spencer, A. E. Johnson, C. T. Vallanat, A. M. Fong, C. Patterson 
and D. D. Patel (2008). "CX3CR1 deficiency impairs dendritic cell accumulation in 
arterial intima and reduces atherosclerotic burden." Arterioscler Thromb Vasc Biol 
28(2): 243-250. 
Liu, W., L. Jiang, C. Bian, Y. Liang, R. Xing, M. Yishakea and J. Dong (2016). "Role of 
CX3CL1 in Diseases." Arch Immunol Ther Exp (Warsz) 64(5): 371-383. 
Longley, D. B., D. P. Harkin and P. G. Johnston (2003). "5-fluorouracil: mechanisms 
of action and clinical strategies." Nat Rev Cancer 3(5): 330-338. 
Longo, V., O. Brunetti, A. Gnoni, S. Cascinu, G. Gasparini, V. Lorusso, D. Ribatti and 
N. Silvestris (2016). "Angiogenesis in pancreatic ductal adenocarcinoma: A 
controversial issue." Oncotarget 7(36): 58649-58658. 
Lunardi, S., R. J. Muschel and T. B. Brunner (2014). "The stromal compartments in 
pancreatic cancer: are there any therapeutic targets?" Cancer Lett 343(2): 147-
155. 
Ma, X., K. Norsworthy, N. Kundu, W. H. Rodgers, P. A. Gimotty, O. Goloubeva, M. 
Lipsky, Y. Li, D. Holt and A. Fulton (2009). "CXCR3 expression is associated with 
poor survival in breast cancer and promotes metastasis in a murine model." Mol 
Cancer Ther 8(3): 490-498. 
Macri, C., C. Dumont, A. P. Johnston and J. D. Mintern (2016). "Targeting dendritic 
cells: a promising strategy to improve vaccine effectiveness." Clin Transl 
Immunology 5(3): e66. 
 163 
Madalli, S., M. Beyrau, J. Whiteford, J. Duchene, I. Singh Nandhra, N. S. Patel, M. P. 
Motwani, D. W. Gilroy, C. Thiemermann, S. Nourshargh and R. S. Scotland (2015). 
"Sex-specific regulation of chemokine Cxcl5/6 controls neutrophil recruitment and 
tissue injury in acute inflammatory states." Biol Sex Differ 6: 27. 
Mahadevan, D. and D. D. Von Hoff (2007). "Tumor-stroma interactions in 
pancreatic ductal adenocarcinoma." Mol Cancer Ther 6(4): 1186-1197. 
Mannino, M. H., Z. Zhu, H. Xiao, Q. Bai, M. R. Wakefield and Y. Fang (2015). "The 
paradoxical role of IL-10 in immunity and cancer." Cancer Lett 367(2): 103-107. 
Mantovani, A., B. Savino, M. Locati, L. Zammataro, P. Allavena and R. Bonecchi 
(2010). "The chemokine system in cancer biology and therapy." Cytokine Growth 
Factor Rev 21(1): 27-39. 
Marchesi, F., M. Locatelli, G. Solinas, M. Erreni, P. Allavena and A. Mantovani (2010). 
"Role of CX3CR1/CX3CL1 axis in primary and secondary involvement of the 
nervous system by cancer." J Neuroimmunol 224(1-2): 39-44. 
Marchesi, F., L. Piemonti, G. Fedele, A. Destro, M. Roncalli, L. Albarello, C. Doglioni, 
A. Anselmo, A. Doni, P. Bianchi, L. Laghi, A. Malesci, L. Cervo, M. Malosio, M. Reni, A. 
Zerbi, V. Di Carlo, A. Mantovani and P. Allavena (2008). "The chemokine receptor 
CX3CR1 is involved in the neural tropism and malignant behavior of pancreatic 
ductal adenocarcinoma." Cancer Res 68(21): 9060-9069. 
Marsh Rde, W., M. S. Talamonti, M. H. Katz and J. M. Herman (2015). "Pancreatic 
cancer and FOLFIRINOX: a new era and new questions." Cancer Med 4(6): 853-863. 
Mastracci, T. L. and L. Sussel (2012). "The Endocrine Pancreas: insights into 
development, differentiation and diabetes." Wiley Interdiscip Rev Membr Transp 
Signal 1(5): 609-628. 
Maxwell, P. J., R. Gallagher, A. Seaton, C. Wilson, P. Scullin, J. Pettigrew, I. J. Stratford, 
K. J. Williams, P. G. Johnston and D. J. Waugh (2007). "HIF-1 and NF-kappaB-
mediated upregulation of CXCR1 and CXCR2 expression promotes cell survival in 
hypoxic prostate cancer cells." Oncogene 26(52): 7333-7345. 
McCarthy, D. J., Y. Chen and G. K. Smyth (2012). "Differential expression analysis of 
multifactor RNA-Seq experiments with respect to biological variation." Nucleic 
Acids Res 40(10): 4288-4297. 
McKenna, L. R. and B. H. Edil (2014). "Update on pancreatic neuroendocrine 
tumors." Gland Surg 3(4): 258-275. 
Mebius, R. E. and G. Kraal (2005). "Structure and function of the spleen." Nat Rev 
Immunol 5(8): 606-616. 
Mehrad, B., M. P. Keane and R. M. Strieter (2007). "Chemokines as mediators of 
angiogenesis." Thromb Haemost 97(5): 755-762. 
 164 
Menghini, R., L. Fiorentino, V. Casagrande, R. Lauro and M. Federici (2013). "The 
role of ADAM17 in metabolic inflammation." Atherosclerosis 228(1): 12-17. 
Mestdagt, M., M. Polette, G. Buttice, A. Noel, A. Ueda, J. M. Foidart and C. Gilles 
(2006). "Transactivation of MCP-1/CCL2 by beta-catenin/TCF-4 in human breast 
cancer cells." Int J Cancer 118(1): 35-42. 
Mi, H., A. Muruganujan and P. D. Thomas (2013). "PANTHER in 2013: modeling the 
evolution of gene function, and other gene attributes, in the context of phylogenetic 
trees." Nucleic Acids Res 41(Database issue): D377-386. 
Mielgo, A. and M. C. Schmid (2013). "Impact of tumour associated macrophages in 
pancreatic cancer." BMB Rep 46(3): 131-138. 
Mukaida, N., S. Sasaki and T. Baba (2014). "Chemokines in cancer development and 
progression and their potential as targeting molecules for cancer treatment." 
Mediators Inflamm 2014: 170381. 
Mukherjee, D. and J. Zhao (2013). "The Role of chemokine receptor CXCR4 in breast 
cancer metastasis." Am J Cancer Res 3(1): 46-57. 
Muller, A., B. Homey, H. Soto, N. Ge, D. Catron, M. E. Buchanan, T. McClanahan, E. 
Murphy, W. Yuan, S. N. Wagner, J. L. Barrera, A. Mohar, E. Verastegui and A. Zlotnik 
(2001). "Involvement of chemokine receptors in breast cancer metastasis." Nature 
410(6824): 50-56. 
Murphy, P. M., M. Baggiolini, I. F. Charo, C. A. Hebert, R. Horuk, K. Matsushima, L. H. 
Miller, J. J. Oppenheim and C. A. Power (2000). "International union of 
pharmacology. XXII. Nomenclature for chemokine receptors." Pharmacol Rev 
52(1): 145-176. 
Nagarsheth, N., M. S. Wicha and W. Zou (2017). "Chemokines in the cancer 
microenvironment and their relevance in cancer immunotherapy." Nat Rev 
Immunol. 
Neesse, A., P. Michl, K. K. Frese, C. Feig, N. Cook, M. A. Jacobetz, M. P. Lolkema, M. 
Buchholz, K. P. Olive, T. M. Gress and D. A. Tuveson (2011). "Stromal biology and 
therapy in pancreatic cancer." Gut 60(6): 861-868. 
Nibbs, R. J. and G. J. Graham (2013). "Immune regulation by atypical chemokine 
receptors." Nat Rev Immunol 13(11): 815-829. 
Nishimura, M., H. Umehara, T. Nakayama, O. Yoneda, K. Hieshima, M. Kakizaki, N. 
Dohmae, O. Yoshie and T. Imai (2002). "Dual functions of fractalkine/CX3C ligand 
1 in trafficking of perforin+/granzyme B+ cytotoxic effector lymphocytes that are 
defined by CX3CR1 expression." J Immunol 168(12): 6173-6180. 
Noble, S. and K. L. Goa (1997). "Gemcitabine. A review of its pharmacology and 
clinical potential in non-small cell lung cancer and pancreatic cancer." Drugs 54(3): 
447-472. 
 165 
Nomiyama, H., N. Osada and O. Yoshie (2011). "A family tree of vertebrate 
chemokine receptors for a unified nomenclature." Dev Comp Immunol 35(7): 705-
715. 
O'Boyle, G. (2012). "The yin and yang of chemokine receptor activation." Br J 
Pharmacol 166(3): 895-897. 
O'Hayre, M., C. L. Salanga, T. M. Handel and S. J. Allen (2008). "Chemokines and 
cancer: migration, intracellular signalling and intercellular communication in the 
microenvironment." Biochem J 409(3): 635-649. 
Ocana, A., C. Nieto-Jimenez, A. Pandiella and A. J. Templeton (2017). "Neutrophils 
in cancer: prognostic role and therapeutic strategies." Mol Cancer 16(1): 137. 
Ottenhof, N. A., R. F. de Wilde, A. Maitra, R. H. Hruban and G. J. Offerhaus (2011). 
"Molecular characteristics of pancreatic ductal adenocarcinoma." Patholog Res Int 
2011: 620601. 
Ozdemir, B. C., T. Pentcheva-Hoang, J. L. Carstens, X. Zheng, C. C. Wu, T. R. Simpson, 
H. Laklai, H. Sugimoto, C. Kahlert, S. V. Novitskiy, A. De Jesus-Acosta, P. Sharma, P. 
Heidari, U. Mahmood, L. Chin, H. L. Moses, V. M. Weaver, A. Maitra, J. P. Allison, V. S. 
LeBleu and R. Kalluri (2014). "Depletion of carcinoma-associated fibroblasts and 
fibrosis induces immunosuppression and accelerates pancreas cancer with 
reduced survival." Cancer Cell 25(6): 719-734. 
Pancreatic-Cancer-UK. (2016). "Types of pancreatic cancer." from 
https://www.pancreaticcancer.org.uk/types. 
Pandol, S., M. Edderkaoui, I. Gukovsky, A. Lugea and A. Gukovskaya (2009). 
"Desmoplasia of pancreatic ductal adenocarcinoma." Clin Gastroenterol Hepatol 
7(11 Suppl): S44-47. 
Patel, J., K. M. Channon and E. McNeill (2013). "The downstream regulation of 
chemokine receptor signalling: implications for atherosclerosis." Mediators 
Inflamm 2013: 459520. 
Payne, A. S. and L. A. Cornelius (2002). "The role of chemokines in melanoma tumor 
growth and metastasis." J Invest Dermatol 118(6): 915-922. 
Pei, Q., J. Pan, H. Zhu, X. Ding, W. Liu, Y. Lv, X. Zou and H. Luo (2014). "Gemcitabine-
treated pancreatic cancer cell medium induces the specific CTL antitumor activity 
by stimulating the maturation of dendritic cells." Int Immunopharmacol 19(1): 10-
16. 
Phillips, P. (2012). Pancreatic stellate cells and fibrosis. Pancreatic Cancer and 
Tumor Microenvironment. P. J. Grippo and H. G. Munshi. Trivandrum (India). 
Pollard, J. W. (2004). "Tumour-educated macrophages promote tumour 
progression and metastasis." Nat Rev Cancer 4(1): 71-78. 
 166 
Polyak, A., S. Ferenczi, A. Denes, Z. Winkler, R. Kriszt, B. Pinter-Kubler and K. J. 
Kovacs (2014). "The fractalkine/Cx3CR1 system is implicated in the development 
of metabolic visceral adipose tissue inflammation in obesity." Brain Behav Immun 
38: 25-35. 
Provenzano, P. P., C. Cuevas, A. E. Chang, V. K. Goel, D. D. Von Hoff and S. R. Hingorani 
(2012). "Enzymatic targeting of the stroma ablates physical barriers to treatment 
of pancreatic ductal adenocarcinoma." Cancer Cell 21(3): 418-429. 
Quail, D. F. and J. A. Joyce (2013). "Microenvironmental regulation of tumor 
progression and metastasis." Nat Med 19(11): 1423-1437. 
Raman, D., T. Sobolik-Delmaire and A. Richmond (2011). "Chemokines in health 
and disease." Exp Cell Res 317(5): 575-589. 
Rasheed, Z. A., W. Matsui and A. Maitra (2012). Pathology of pancreatic stroma in 
PDAC. Pancreatic Cancer and Tumor Microenvironment. P. J. Grippo and H. G. 
Munshi. Trivandrum (India). 
Ren, H., T. Zhao, J. Sun, X. Wang, J. Liu, S. Gao, M. Yu and J. Hao (2013). "The 
CX3CL1/CX3CR1 reprograms glucose metabolism through HIF-1 pathway in 
pancreatic adenocarcinoma." J Cell Biochem 114(11): 2603-2611. 
Reznik, R., A. E. Hendifar and R. Tuli (2014). "Genetic determinants and potential 
therapeutic targets for pancreatic adenocarcinoma." Front Physiol 5: 87. 
Richmond, A. (2002). "Nf-kappa B, chemokine gene transcription and tumour 
growth." Nat Rev Immunol 2(9): 664-674. 
Robinson, M. D., D. J. McCarthy and G. K. Smyth (2010). "edgeR: a Bioconductor 
package for differential expression analysis of digital gene expression data." 
Bioinformatics 26(1): 139-140. 
Roy, I., D. B. Evans and M. B. Dwinell (2014). "Chemokines and chemokine 
receptors: update on utility and challenges for the clinician." Surgery 155(6): 961-
973. 
Ruffell, B., N. I. Affara and L. M. Coussens (2012). "Differential macrophage 
programming in the tumor microenvironment." Trends Immunol 33(3): 119-126. 
Ruffell, D., F. Mourkioti, A. Gambardella, P. Kirstetter, R. G. Lopez, N. Rosenthal and 
C. Nerlov (2009). "A CREB-C/EBPbeta cascade induces M2 macrophage-specific 
gene expression and promotes muscle injury repair." Proc Natl Acad Sci U S A 
106(41): 17475-17480. 
Ryan, D. P., T. S. Hong and N. Bardeesy (2014). "Pancreatic adenocarcinoma." N 
Engl J Med 371(11): 1039-1049. 
Saederup, N., L. Chan, S. A. Lira and I. F. Charo (2008). "Fractalkine deficiency 
markedly reduces macrophage accumulation and atherosclerotic lesion formation 
 167 
in CCR2-/- mice: evidence for independent chemokine functions in atherogenesis." 
Circulation 117(13): 1642-1648. 
Sanjurjo, L., G. Aran, N. Roher, A. F. Valledor and M. R. Sarrias (2015). "AIM/CD5L: 
a key protein in the control of immune homeostasis and inflammatory disease." J 
Leukoc Biol 98(2): 173-184. 
Santoni, M., S. Bracarda, M. Nabissi, F. Massari, A. Conti, E. Bria, G. Tortora, G. 
Santoni and S. Cascinu (2014). "CXC and CC chemokines as angiogenic modulators 
in nonhaematological tumors." Biomed Res Int 2014: 768758. 
Sarvaiya, P. J., D. Guo, I. Ulasov, P. Gabikian and M. S. Lesniak (2013). "Chemokines 
in tumor progression and metastasis." Oncotarget 4(12): 2171-2185. 
Schett, G., J. M. Dayer and B. Manger (2016). "Interleukin-1 function and role in 
rheumatic disease." Nat Rev Rheumatol 12(1): 14-24. 
Schmall, A., H. M. Al-Tamari, S. Herold, M. Kampschulte, A. Weigert, A. Wietelmann, 
N. Vipotnik, F. Grimminger, W. Seeger, S. S. Pullamsetti and R. Savai (2015). 
"Macrophage and cancer cell cross-talk via CCR2 and CX3CR1 is a fundamental 
mechanism driving lung cancer." Am J Respir Crit Care Med 191(4): 437-447. 
Schober, M., R. Jesenofsky, R. Faissner, C. Weidenauer, W. Hagmann, P. Michl, R. L. 
Heuchel, S. L. Haas and J. M. Lohr (2014). "Desmoplasia and chemoresistance in 
pancreatic cancer." Cancers (Basel) 6(4): 2137-2154. 
Schulz, C., A. Schafer, M. Stolla, S. Kerstan, M. Lorenz, M. L. von Bruhl, M. Schiemann, 
J. Bauersachs, T. Gloe, D. H. Busch, M. Gawaz and S. Massberg (2007). "Chemokine 
fractalkine mediates leukocyte recruitment to inflammatory endothelial cells in 
flowing whole blood: a critical role for P-selectin expressed on activated platelets." 
Circulation 116(7): 764-773. 
Shah, R., S. M. O'Neill, C. Hinkle, J. Caughey, S. Stephan, E. Lynch, K. Bermingham, G. 
Lynch, R. S. Ahima and M. P. Reilly (2015). "Metabolic Effects of CX3CR1 Deficiency 
in Diet-Induced Obese Mice." PLoS One 10(9): e0138317. 
Shulby, S. A., N. G. Dolloff, M. E. Stearns, O. Meucci and A. Fatatis (2004). "CX3CR1-
fractalkine expression regulates cellular mechanisms involved in adhesion, 
migration, and survival of human prostate cancer cells." Cancer Res 64(14): 4693-
4698. 
Sica, A. and A. Mantovani (2012). "Macrophage plasticity and polarization: in vivo 
veritas." J Clin Invest 122(3): 787-795. 
Sideras, K., H. Braat, J. Kwekkeboom, C. H. van Eijck, M. P. Peppelenbosch, S. Sleijfer 
and M. Bruno (2014). "Role of the immune system in pancreatic cancer progression 
and immune modulating treatment strategies." Cancer Treat Rev 40(4): 513-522. 
Sionov, R. V., Z. G. Fridlender and Z. Granot (2015). "The Multifaceted Roles 
Neutrophils Play in the Tumor Microenvironment." Cancer Microenviron 8(3): 
125-158. 
 168 
Smyth, M. J., E. Cretney, M. H. Kershaw and Y. Hayakawa (2004). "Cytokines in 
cancer immunity and immunotherapy." Immunol Rev 202: 275-293. 
Snady, H., H. Bruckner, A. Cooperman, J. Paradiso and L. Kiefer (2000). "Survival 
advantage of combined chemoradiotherapy compared with resection as the initial 
treatment of patients with regional pancreatic carcinoma. An outcomes trial." 
Cancer 89(2): 314-327. 
Soeda, A., Y. Morita-Hoshi, H. Makiyama, C. Morizane, H. Ueno, M. Ikeda, T. Okusaka, 
S. Yamagata, N. Takahashi, I. Hyodo, Y. Takaue and Y. Heike (2009). "Regular dose 
of gemcitabine induces an increase in CD14+ monocytes and CD11c+ dendritic cells 
in patients with advanced pancreatic cancer." Jpn J Clin Oncol 39(12): 797-806. 
Stanley, E. R. and V. Chitu (2014). "CSF-1 receptor signaling in myeloid cells." Cold 
Spring Harb Perspect Biol 6(6). 
Steele, C. W., N. B. Jamieson, T. R. Evans, C. J. McKay, O. J. Sansom, J. P. Morton and 
C. R. Carter (2013). "Exploiting inflammation for therapeutic gain in pancreatic 
cancer." Br J Cancer 108(5): 997-1003. 
Sun, X., G. Cheng, M. Hao, J. Zheng, X. Zhou, J. Zhang, R. S. Taichman, K. J. Pienta and 
J. Wang (2010). "CXCL12 / CXCR4 / CXCR7 chemokine axis and cancer 
progression." Cancer Metastasis Rev 29(4): 709-722. 
Suresh, P. and A. Wanchu (2006). "Chemokines and chemokine receptors in HIV 
infection: role in pathogenesis and therapeutics." J Postgrad Med 52(3): 210-217. 
Szekanecz, Z., A. Vegvari, Z. Szabo and A. E. Koch (2010). "Chemokines and 
chemokine receptors in arthritis." Front Biosci (Schol Ed) 2: 153-167. 
Tan, M. C., P. S. Goedegebuure, B. A. Belt, B. Flaherty, N. Sankpal, W. E. Gillanders, T. 
J. Eberlein, C. S. Hsieh and D. C. Linehan (2009). "Disruption of CCR5-dependent 
homing of regulatory T cells inhibits tumor growth in a murine model of pancreatic 
cancer." J Immunol 182(3): 1746-1755. 
Tao, L., G. Huang, H. Song, Y. Chen and L. Chen (2017). "Cancer associated 
fibroblasts: An essential role in the tumor microenvironment." Oncol Lett 14(3): 
2611-2620. 
Teague, A., K. H. Lim and A. Wang-Gillam (2015). "Advanced pancreatic 
adenocarcinoma: a review of current treatment strategies and developing 
therapies." Ther Adv Med Oncol 7(2): 68-84. 
Thurber, R. V., M. Haynes, M. Breitbart, L. Wegley and F. Rohwer (2009). 
"Laboratory procedures to generate viral metagenomes." Nat Protoc 4(4): 470-
483. 
Tsuchikawa, T., S. Takeuchi, T. Nakamura, T. Shichinohe and S. Hirano (2016). 
"Clinical impact of chemotherapy to improve tumor microenvironment of 
pancreatic cancer." World J Gastrointest Oncol 8(11): 786-792. 
 169 
Turley, S. J., V. Cremasco and J. L. Astarita (2015). "Immunological hallmarks of 
stromal cells in the tumour microenvironment." Nat Rev Immunol 15(11): 669-
682. 
Turner, M. D., B. Nedjai, T. Hurst and D. J. Pennington (2014). "Cytokines and 
chemokines: At the crossroads of cell signalling and inflammatory disease." 
Biochim Biophys Acta 1843(11): 2563-2582. 
Ulvmar, M. H., E. Hub and A. Rot (2011). "Atypical chemokine receptors." Exp Cell 
Res 317(5): 556-568. 
Vela, M., M. Aris, M. Llorente, J. A. Garcia-Sanz and L. Kremer (2015). "Chemokine 
receptor-specific antibodies in cancer immunotherapy: achievements and 
challenges." Front Immunol 6: 12. 
Vemuganti, S. A., T. A. Bell, C. O. Scarlett, C. E. Parker, F. P. de Villena and D. A. 
O'Brien (2007). "Three male germline-specific aldolase A isozymes are generated 
by alternative splicing and retrotransposition." Dev Biol 309(1): 18-31. 
Viehl, C. T., T. T. Moore, U. K. Liyanage, D. M. Frey, J. P. Ehlers, T. J. Eberlein, P. S. 
Goedegebuure and D. C. Linehan (2006). "Depletion of CD4+CD25+ regulatory T 
cells promotes a tumor-specific immune response in pancreas cancer-bearing 
mice." Ann Surg Oncol 13(9): 1252-1258. 
Vincent, A., J. Herman, R. Schulick, R. H. Hruban and M. Goggins (2011). "Pancreatic 
cancer." Lancet 378(9791): 607-620. 
Von Hoff, D. D., T. Ervin, F. P. Arena, E. G. Chiorean, J. Infante, M. Moore, T. Seay, S. 
A. Tjulandin, W. W. Ma, M. N. Saleh, M. Harris, M. Reni, S. Dowden, D. Laheru, N. 
Bahary, R. K. Ramanathan, J. Tabernero, M. Hidalgo, D. Goldstein, E. Van Cutsem, X. 
Wei, J. Iglesias and M. F. Renschler (2013). "Increased survival in pancreatic cancer 
with nab-paclitaxel plus gemcitabine." N Engl J Med 369(18): 1691-1703. 
Vonlaufen, A., S. Joshi, C. Qu, P. A. Phillips, Z. Xu, N. R. Parker, C. S. Toi, R. C. Pirola, J. 
S. Wilson, D. Goldstein and M. V. Apte (2008). "Pancreatic stellate cells: partners in 
crime with pancreatic cancer cells." Cancer Res 68(7): 2085-2093. 
Vonlaufen, A., P. A. Phillips, Z. Xu, D. Goldstein, R. C. Pirola, J. S. Wilson and M. V. 
Apte (2008). "Pancreatic stellate cells and pancreatic cancer cells: an unholy 
alliance." Cancer Res 68(19): 7707-7710. 
Wachsmann, M. B., L. M. Pop and E. S. Vitetta (2012). "Pancreatic ductal 
adenocarcinoma: a review of immunologic aspects." J Investig Med 60(4): 643-663. 
Waddell, N., M. Pajic, A. M. Patch, D. K. Chang, K. S. Kassahn, P. Bailey, A. L. Johns, D. 
Miller, K. Nones, K. Quek, M. C. Quinn, A. J. Robertson, M. Z. Fadlullah, T. J. Bruxner, 
A. N. Christ, I. Harliwong, S. Idrisoglu, S. Manning, C. Nourse, E. Nourbakhsh, S. Wani, 
P. J. Wilson, E. Markham, N. Cloonan, M. J. Anderson, J. L. Fink, O. Holmes, S. H. 
Kazakoff, C. Leonard, F. Newell, B. Poudel, S. Song, D. Taylor, N. Waddell, S. Wood, 
Q. Xu, J. Wu, M. Pinese, M. J. Cowley, H. C. Lee, M. D. Jones, A. M. Nagrial, J. Humphris, 
L. A. Chantrill, V. Chin, A. M. Steinmann, A. Mawson, E. S. Humphrey, E. K. Colvin, A. 
 170 
Chou, C. J. Scarlett, A. V. Pinho, M. Giry-Laterriere, I. Rooman, J. S. Samra, J. G. Kench, 
J. A. Pettitt, N. D. Merrett, C. Toon, K. Epari, N. Q. Nguyen, A. Barbour, N. Zeps, N. B. 
Jamieson, J. S. Graham, S. P. Niclou, R. Bjerkvig, R. Grutzmann, D. Aust, R. H. Hruban, 
A. Maitra, C. A. Iacobuzio-Donahue, C. L. Wolfgang, R. A. Morgan, R. T. Lawlor, V. 
Corbo, C. Bassi, M. Falconi, G. Zamboni, G. Tortora, M. A. Tempero, I. Australian 
Pancreatic Cancer Genome, A. J. Gill, J. R. Eshleman, C. Pilarsky, A. Scarpa, E. A. 
Musgrove, J. V. Pearson, A. V. Biankin and S. M. Grimmond (2015). "Whole genomes 
redefine the mutational landscape of pancreatic cancer." Nature 518(7540): 495-
501. 
Wan, Y. Y. (2014). "GATA3: a master of many trades in immune regulation." Trends 
Immunol 35(6): 233-242. 
Wang, X. and Y. Lin (2008). "Tumor necrosis factor and cancer, buddies or foes?" 
Acta Pharmacol Sin 29(11): 1275-1288. 
Wang, Y., I. Misumi, A. D. Gu, T. A. Curtis, L. Su, J. K. Whitmire and Y. Y. Wan (2013). 
"GATA-3 controls the maintenance and proliferation of T cells downstream of TCR 
and cytokine signaling." Nat Immunol 14(7): 714-722. 
Weber, C. (2008). "Chemokines in atherosclerosis, thrombosis, and vascular 
biology." Arterioscler Thromb Vasc Biol 28(11): 1896. 
Westphalen, C. B. and K. P. Olive (2012). "Genetically engineered mouse models of 
pancreatic cancer." Cancer J 18(6): 502-510. 
Whatcott, C. J., R. G. Posner, D. D. Von Hoff and H. Han (2012). Desmoplasia and 
chemoresistance in pancreatic cancer. Pancreatic Cancer and Tumor 
Microenvironment. P. J. Grippo and H. G. Munshi. Trivandrum (India). 
Whipple, C. and M. Korc (2008). "Targeting angiogenesis in pancreatic cancer: 
rationale and pitfalls." Langenbecks Arch Surg 393(6): 901-910. 
White, G. E., A. J. Iqbal and D. R. Greaves (2013). "CC chemokine receptors and 
chronic inflammation--therapeutic opportunities and pharmacological 
challenges." Pharmacol Rev 65(1): 47-89. 
Wickham, H. (2009). ggplot2, Springer-Verlag New York. 
Wood, L. D. and R. H. Hruban (2012). "Pathology and molecular genetics of 
pancreatic neoplasms." Cancer J 18(6): 492-501. 
Wood, L. D. and R. H. Hruban (2015). "Genomic landscapes of pancreatic neoplasia." 
J Pathol Transl Med 49(1): 13-22. 
Wormann, S. M., K. N. Diakopoulos, M. Lesina and H. Algul (2014). "The immune 
network in pancreatic cancer development and progression." Oncogene 33(23): 
2956-2967. 
Wu, Y., X. Zhu, N. Li, T. Chen, M. Yang, M. Yao, X. Liu, B. Jin, X. Wang and X. Cao (2011). 
"CMRF-35-like molecule 3 preferentially promotes TLR9-triggered 
 171 
proinflammatory cytokine production in macrophages by enhancing TNF receptor-
associated factor 6 ubiquitination." J Immunol 187(9): 4881-4889. 
Yuen, A. and B. Diaz (2014). "The impact of hypoxia in pancreatic cancer invasion 
and metastasis." Hypoxia (Auckl) 2: 91-106. 
Zhao, T., S. Gao, X. Wang, J. Liu, Y. Duan, Z. Yuan, J. Sheng, S. Li, F. Wang, M. Yu, H. 
Ren and J. Hao (2012). "Hypoxia-inducible factor-1alpha regulates chemotactic 
migration of pancreatic ductal adenocarcinoma cells through directly 
transactivating the CX3CR1 gene." PLoS One 7(8): e43399. 
Zhao, X., W. Fan, Z. Xu, H. Chen, Y. He, G. Yang, G. Yang, H. Hu, S. Tang, P. Wang, Z. 
Zhang, P. Xu and M. Yu (2016). "Inhibiting tumor necrosis factor-alpha diminishes 
desmoplasia and inflammation to overcome chemoresistance in pancreatic ductal 
adenocarcinoma." Oncotarget 7(49): 81110-81122. 
Zheng, J., M. Yang, J. Shao, Y. Miao, J. Han and J. Du (2013). "Chemokine receptor 
CX3CR1 contributes to macrophage survival in tumor metastasis." Mol Cancer 
12(1): 141. 
Zhou, C., J. Zhang, Y. Zheng and Z. Zhu (2012). "Pancreatic neuroendocrine tumors: 
a comprehensive review." Int J Cancer 131(5): 1013-1022. 
Zlotnik, A. and O. Yoshie (2000). "Chemokines: a new classification system and 
their role in immunity." Immunity 12(2): 121-127. 
Zlotnik, A. and O. Yoshie (2012). "The chemokine superfamily revisited." Immunity 
36(5): 705-716. 
Zweemer, A. J., J. Toraskar, L. H. Heitman and I. J. AP (2014). "Bias in chemokine 
receptor signalling." Trends Immunol 35(6): 243-252. 
 
 
 
 
